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Abstract  
 
Cell-based regenerative medicine therapies (RMTs) have great potential to treat 
chronic diseases and the diseases that are currently difficult to be cured, via the use of 
stem cells, progenitor cells or stromal cells. However, before they can be translated into 
the clinic, the safety and efficacy of RMTs needs to be evaluated in animal models. An 
important part of this evaluation is to monitor the viability and biodistribution of the 
cells after they have been implanted.  Non-invasive in vivo imaging techniques, mainly 
including optical imaging modalities and non-optical imaging modalities, are powerful 
tools for evaluating viability and biodistribution as they enable the cells to be 
monitored longitudinally in each individual animal. Among these modalities, an 
emerging technology known as multispectral optoacoustic tomography (MSOT) is 
well-suited for this purpose because it combines high spatial resolution and high 
temporal resolution with high sensitivity.  Another advantage of MSOT is that its 
multispectral capabilities means that multiple photoabsorbers can be imaged 
simultaneously.  A major aim of this project was to develop non-toxic, stable organic 
nanoparticles that can be taken up by cells with high efficiency, enabling the cells to be 
monitored in vivo using MSOT.  
 A perylene diimide (PDI) compound was synthesized, which showed strong 
light absorbance in the near infrared (NIR) region in organic solution. Due to its high 
hydrophobicity, in order to use it as a probe for cell imaging, aqueous PDI nanoparticle 
suspensions were developed by nanoprecipitation and emulsion freeze-drying, with 
poly (vinyl alcohol) (PVA), tocopherol polyethylene glycol succinate (TPEG), and an 
in-house synthesized block copolymer as stabilizer. The PDI nanoparticle suspensions 
showed maximum NIR absorbance at 700 nm. Both PVA and block copolymer-
stabilized PDI nanoparticles showed low cytotoxicity under standard concentration 
ranges, as tested with mouse mesenchymal stem/stromal cells (MSCs). However, 
unlike PVA-stabilized PDI nanoparticles, block copolymer-PDI nanoparticles showed 
strong uptake by the MSCs and could produce strong signals as tested by UV-Vis and 
flow cytometry. The MSCs labelled with block copolymer-PDI nanoparticles were 
injected subcutaneously into mice to evaluate their effectiveness as fluorescence and 
MSOT imaging probes. The results showed that with fluorescence imaging, the signals 
generated by MSCs labelled with PDI particles were not much stronger than the 
	 ix	
fluorescence signals generated from the background. In contrast, the MSCs labelled 
with PDI nanoparticles could be easily visualised with MSOT for at least 11 days 
(study end point).  
Another problem with cell-based RMTs is that a large proportion of the injected 
population usually dies within 24-48 hours, which could possibly render the cells less 
effective. This problem could potentially be overcome by implanting the cells in a 
hydrogel, as previous studies have indicated that this tends to improve viability. A 
second main aim of this study was therefore to develop a hydrogel to encapsulate cells 
for implantation, and to functionalise the hydrogel so that its stability can be monitored 
in vivo with MSOT. The results showed that MSCs encapsulated in injectable 
thermosetting chitosan hydrogel survived, and the presence of PDI nanoparticles in the 
hydrogel enabled the gel system to be imaged using MSOT.  
 To summarise, this project has demonstrated the use of PDI nanoparticles as 
NIR probes for MSOT imaging. Because chemical synthesis methods are available to 
prepare a series of PDI compounds with tunable NIR absorption wavelength and 
hydrophilicity, this method can be a powerful route to synthesize desired PDI 
nanoparticles (and the mixture of them for multimodal imaging) as well as PDI-based 
hydrogels. In turn, this can offer effective in vivo live cell imaging longitudinally and 
help to better understand the safety and efficacy of RMTs. 
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Chapter 1 Introduction and review on relevant research 
topics 
 
1.1 Cell-based Regenerative Medicine Therapies (RMTs) 
By definition, regenerative medicine is used to replace or regenerate human 
cells, tissue or organs, to restore or establish normal function [1]. RMTs have great 
potential for a variety of difficult-to-cure diseases, regenerating organ and tissue loss 
due to disease and injury, and reducing reliance on transplantation [2-4]. Stem cells are 
mainly involved in RMTs although stromal cells and macrophages are also used [2]. 
Stem cells have two distinct properties: the capacity to self-renew and the ability to 
differentiate into specialized cells [5]. They are typically defined in terms of their fate 
of differentiation, with unipotent stem cells giving rise to just one type of specialized 
cell; multipotent stem cells giving rise to a range of different specialized cells; and 
pluripotent stem cells generating all cell types within the mature organism. Progenitor 
cells, which are usually derived from stem cells, can also differentiate to generate 
different types of specialized cells but have a limited capacity to self-renew [5].  
 The stem cells that are used in RMTs mainly include embryonic stem cells 
(ESCs), induced pluripotent stem cells (iPSCs), and somatic stem cells (SSCs), also 
known as adult stem cells [6]. SSCs can be found and isolated from a range of different 
tissues, with examples including mesenchymal stem/stromal cells (MSCs), 
haematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs) [6]. Figure 
1-1 illustrates how stem cells can be used for RMTs and in drug discovery. ESCs and 
iPSCs are particularly advantageous because they can generate any cell type, and 
because they do not become senescent, they can easily be expanded. However, there 
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are ethical issues relating to the use of ESCs, and for both cell types there are some 
safety concerns because it is known that undifferentiated ESCs and iPSCs can generate 
tumours. The risk of tumourigenicity seems proportional to the length of time that the 
cells are cultured [6,7].  
 
Figure 1-1. Diagram showing how stem cells can be used to generate patient-specific 
cells of a desired type for regenerative medicine or drug discovery.  Reprinted from ref 
4. 
 
SSCs, on the other hand, are less tumourigenic, but have some disadvantages. 
For instance, they can be difficult to source, and because they tend to become senescent 
in culture, they can be difficult to expand.  However, MSCs have quite a good scale-up 
potential as they can be cultured for a number of weeks before becoming senescent [7]. 
Furthermore, MSCs can be sourced from a number of tissues, including bone marrow, 
	
	
	
	
3	
adipose tissue and the umbilical cord. Indeed, MSCs have been the mostly used cell 
type in regenerative medicine [8-10], and for this reason, are the main focus of this 
project. 
 
1.1.1 The differentiation and fate of stem cells 
Before describing MSCs, the factors and pathways that regulate the 
differentiation and the fate of the stems are explained here. The same principles (or 
factors) may be applied for all types of stem cells although the specific details may be 
different for MSCs. 
The differentiation of stem cells is regulated by soluble factors such as growth 
factors, cytokines, small molecules (chemical cues), cell-cell interactions and the extra-
cellular matrix, which all together comprise the stem cell niches [4, 11, 12]. Families of 
protein signaling molecules include the TGFβ	 (transforming growth factor beta) 
superfamily (33 in mammals, including activators such as Activin A, BMP4, TGFβ3, 
TGFβ1 and inhibitors such as Noggin, LeftyA, Ceberus); the FGF (fibroblast growth 
factors) family (23, e.g., activators such as FGF2, FGF8); the WNT family (19, 
activators such as WNT3A, inhibitors such as DKK1, Frizzled 8); and the Hedgehog 
family (3, e.g., activators such as sonic hedgehog (SHH)) [11]. These protein factors 
can act either to promote or inhibit differentiation towards a specific cell type. 
Examples of small molecules that can promote cell differentiation include ascorbic acid, 
nicotinamide, retinoic acid, indolactam V, etc. [11]. The combination of protein factors 
and small molecules may be used to direct cell differentiation efficiently.   
Niches are the 3D local tissue microenvironments that maintain and regulate the 
fate of stem cells. Identifying and characterizing niches are crucial to maintain healthy 
growth/renewal of stem cells and regulate their self-renewal and differentiations. There 
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are different ways in which stem cells can divide: asymmetric (generates one identical 
daughter stem cell and one committed progenitor cell) and symmetric (either generates 
two identical daughter stem cells, or two committed progenitor cells) [12,13]. The 
balance between asymmetric and symmetric divisions determines the size of the stem 
cell population, as illustrated in Figure 1-2 [13]. Asymmetric division maintains the 
size of the stem cell population; symmetric division that generates  two committed cells, 
leads to the size of the stem cell population becoming exhausted; symmetric division 
that generates two  stem cells leads to expansion of the stem cell population. When 
stem cell populations are being expanded in vitro, culture conditions that facilitate 
symmetric division to generate two identical daughter stem cells are typically used. 
 
 
Figure 1-2. Schematic showing the division patterns of stem cells. Reprinted from ref 
13.  
 
1.1.2 MSCs 
MSCs were first isolated from bone marrow. It was found that bone marrow 
contained a population of HSCs and a rare population of plastic-adherent stromal cells. 
These stromal cells displayed multipotency [14] and were named as MSCs because 
they were thought to reside in the stromal compartment of various tissues.  There are 
no specific surface markers to unequivocally identify MSCs, but a set of criteria has 
been proposed: (i) adherence to plastic when cultured in vitro; (ii) expression of typical 
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surface markers, which may be different for different species (Table 1-1); (iii) capacity 
to differentiate to osteoblasts, adipocytes, and chondroblasts in vitro. These criteria are 
for human MSCs but may not be completely applicable to other species [9]. MSCs can 
now be isolated from various tissues including umbilical cord, adipose tissue, placenta, 
lung, liver, skin, and synovial tissue [9,15]. These MSCs are heterogeneous with 
different growth potential but exhibit similar surface markers and mesodermal 
differentiation potential [9].  
 
Table 1-1. Surface markers used to characterise MSCs. (Adapted from refs 9 and 18). 
Positive Markers Negative Markers 
Mouse Human Mouse Human 
Sca-1 Sca-1 CD45 CD45 
CD44 CD44 CD34 CD34 
CD105 CD105 CD19 CD19 
MHC Ilow MHC Ilow CD11b CD11b 
CD140a CD71 CD11c CD11c 
 CD73 MHC II MHC II 
 CD90 CD31 CD79a 
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Figure 1-3. The types of specialized cells that MSCs can differentiate into and the 
significant therapeutic properties that MSCs exhibit. Reprinted from ref 8. 
 
 Figure 1-3 shows that MSCs can be differentiated into different types of 
specialized cells [8]. However, despite some reports suggesting that MSCs can 
transdifferentiate into non-skeletal cells such as endothelial cells, neural cells, and 
hepatocytes, it is now thought that MSCs are not able to do this, and previous reports 
suggesting this did not use appropriate evaluation methods [8]. The differentiation of 
MSCs is mainly regulated by the WNT canonical pathway and the TGFβ superfamily 
pathway, plus the influence of small molecules [9,15]. For example, MSCs can 
differentiate into osteogenic cells in the presence of dexamethasone, β-glycerol 
phosphate, and ascorbic acid. When the medium contains dexamethasone and TGFβ-3, 
MSCs can differentiate to chondrocytes. To differentiate into an adipogenic lineage, 
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MSCs can be cultured in the presence of dexamethasone, insulin, indomethacin, and 1-
methyl-3-isobutylxanthine [9].  
  
 
Figure 1-4. The diagram shows the physical factors regulating MSC differentiation. 
Reprinted from ref 15. 
 
In addition to the chemical cues, the differentiation of MSCs can be 
significantly influenced by physical factors including cell shape, elasticity of substrates, 
types of matrix, and nanoscale geometric features (Figure 1-4) [15]. These physical 
factors are investigated by constructing substrate mimicking the extracellular matrix 
(ECM) in order to regulate the fate of stem cells. Parameters of the ECM, including 
adhesion to stem cells, stiffness and topography, all play a role in influencing the 
growth and differentiation of the stem cells [16]. When culturing stem cells with the 
substrates, the mechanical forces and geometry can considerably influence stem cell 
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behavior [17]. For the MSCs, stiffer hydrogels enhance the differentiation to the 
neuronal direction with increased proliferation rates. Stiffer gels also favour osteogenic 
differentiation over an adipogenic course. Soft substrates with addition of a growth 
factor (VEGF) promote the differentiation into endothelial cells.  [17]. Using 
polyacrylamide gels of tunable stiffness, it was found that substrate stiffness and the 
presence of neighboring cells could regulate osteogenesis in MSCs [18]. Tensile forces 
have been shown to improve osteogenic differentiation of MSCs or towards smooth 
muscle cells upon application of growth factors [17].  
Patterned substrates can also regulate MSC differentiation. It was found that 
small islands promoted osteogenic differentiation while large islands enhanced 
adipogenic differentiation [19]. The substrates with different patterns of 100 nm-deep 
nanopits had a high impact on MSC differentiation into osteogenic cells [20]. For the 
substrates with patterned nanopillars (diameters 10/30 nm, interpillar distances 50 – 
120 nm and heights 20-35 nm), the MSC differentiation to osteogenic cells was 
enhanced with the higher nanopillars preferred [21. The surface modification of the 
substrates can also guide MSC differentiation. For example, -NH2 and –SH-modified 
surfaces promoted and maintained osteogenesis while –OH and –COOH-modified 
surfaces promoted and maintained chondrogenesis [22]. 
 MSCs can secrete soluble paracrine factors that contribute to endogenous 
cardiomyogenesis and angiogenesis, including a variety of cytokines and growth 
factors that can suppress the immune system, inhibit fibrosis/apoptosis, and improve 
angiogenesis [9] (Figure 1-3). In spite of promising results obtained from stem cell 
transplantation, it has been noticed in vivo that the engraftment and differentiation of 
the MSCs is very low. Consequently, the encouraging results have been attributed to 
the secretion of paracrine factors by the MSCs in the tissue microenvironment [9, 23]. 
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In a study by our group, intravenous (IV) administration of human kidney-derived cells 
in mice were found to promote renal regeneration [24]. However, the kidney cells were 
exclusively located in the lungs (instead of homing to the kidney) and disappeared by 
24 hours. The renal repair was believed to be mediated by the secreted paracrine 
factors [24]. An earlier report suggested that MSCs act in a similar way; i.e., after IV 
administration, MSCs were entrapped in the lungs and did not migrate to injured 
kidneys, but were still able to promote repair [25]. 
 Apart from their ability to promote the repair of injured tissues, MSCs are 
immunosuppressive, and can suppress both the adaptive immune system (e.g., T-cells) 
[26] and also the innate immune system (e.g., macrophages). This makes MSCs highly 
appealing for allogeneic (donated from someone else) transplantation. 
 
1.1.3 Safety and translation of RMTs 
A big barrier to the clinical translation of RMTs is safety. The main safety 
problems are tumourigenicity and immunogenicity [2,7,27].  
 It is not surprising that stem cell tumourigenicity has been recorded because 
stem cells share many of similar traits with tumour cells, e.g., long-term self-renewal, 
expression of similar markers [7]. Indeed, teratocarcinoma and its benign counterpart 
teratoma are tumours with high populations of pluripotent cells and differentiated 
tissues. The research on embryonic carcinoma cells (ECs) laid the foundation for 
isolating and propagating ESCs. ECs and ESCs both exhibit pluripotency and robust 
tumourigenicity [7]. One of the most common assays to demonstrate pluripotency is 
the teratoma assay. Also, a key assay of “stemness” is a tumour assay. iPSCs are 
obtained by re-programming with proto-oncogenes such as c-Myc and KLF4 , both 
strongly linked to tumourigenesis. With the advance of iPSC technology, it is now 
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possible to generate iPSCs without c-Myc. However, the absence of c-Myc has reduced 
the efficiency of generating iPSCs and yet these iPSCs can still produce tumours in the 
form of teratomas [7]. To address the tumourigenicity issue, it is suggested stem cells 
should be differentiated into progenitor cells or specialized cell types [28], and any 
remaining undifferentiated stem cells should be sorted out or killed before 
transplantation [7]. Another exciting route is to avoid the pluripotent stage, i.e., 
reprogramming somatic cells directly to the specialized cells or progenitor cells, for 
RMTs [4, 29]. 
 The main administration routes of RMTs are systemic injection (e.g., 
intravenous) and direct implantation (others including intranasal, endoscopic, surface 
application) [27]. Following systemic injection, the cells tend not to survive for a long 
time, which can be attributed to the attack on the injected cells by the immune system. 
Another challenge is that the stem cells can end up located in organs such as the lungs 
or liver rather than being enriched in the target tissues/organs. Implanting the cells 
directly at the injury/diseased sites could help to improve efficacy and also prevent off-
target effects. The immunogenicity issue could be addressed via cell encapsulation with 
hydrogels before implantation, as this can help to isolate the cells from the immune 
system. Furthermore, encapsulation with carefully designed hydrogel capsules can 
improve cell viability and prevent cells from migrating to non-target sites [3,8,11]. Cell 
encapsulation is discussed in details in section 1.4. 
 Understanding the biodistribution and fate of cells following implantation is 
very important for assessing safety and efficacy and also for understanding the mode of 
action  [2]. It is expected that a proportion of cells will die shortly following 
implantation, which can be due to various factors, such as lack of oxygen, attack by the 
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immune system, and in diseased tissues, inflammatory cytokines and reactive oxygen 
species could also have a negative effect on the cells  [30]. 
 Being able to assess the viability and biodistribution of implanted cells over 
time is therefore very important. For this purpose, non-invasive in vivo imaging 
techniques are required. 
 
1.2 Cell tracking by non-invasive imaging techniques 
1.2.1 Non-invasive imaging techniques 
There are many imaging techniques/modalities available for preclinical and 
clinical applications. The techniques may be generally divided into two categories: 
optical microscopy, where non-ionizing radiation, particularly visible and infrared light, 
is used to obtain images of cells, tissues and other objects (including fluorescence 
imaging (FI), bioluminescence imaging (BLI), and intravital microscopy (IVM)) and 
non-optical techniques (including magnetic resonance imaging (MRI), positron 
emission tomography (PET), single-photon emission computed tomography (SPECT), 
computed tomography (CT), ultrasound, and photoacoustic imaging (PAI)) (Figure 1-5) 
[31, 32]. The key features of the imaging modalities are given in Table 1-2. It should 
be noted that the data quoted in Table 1-2 for resolutions and sensitivity are 
approximate and they may vary between different reports or reviews [2, 32, 33].  
Among the imaging techniques mentioned here, optical imaging modalities are mostly 
only used in pre-clinical applications while the rest are employed in both preclinical 
and clinical applications.  
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Figure 1-5. Key imaging modalities for preclinical and clinical applications. Reprinted 
from ref 32. 
 
Table 1-2. Characteristics of different imaging modalities (adapted from ref 32) 
Modality Temporal resolution Spatial 
resolution* 
Penetration 
depth 
Sensitivity 
MRI Minutes - hours 25 – 100 µm 
[0.5 – 1mm] 
limitless 10-3 – 10-5 M 
PET Seconds-minutes 1 -2 mm 
[5 – 7 mm] 
limitless 10-11 – 10-12 M 
SPECT minutes 1 -2 mm 
[8 - 10 mm] 
limitless 10-10 – 10-11 M 
CT minutes 50 – 200 µm 
[0.5 – 1mm] 
limitless Not determined 
Ultrasound Seconds - minutes 0.01 – 2 mm mm-cm Excellent with 
microbubbles 
FI Seconds - minutes 2-3 mm < 1 cm 10-9 – 10-12 M 
BLI Seconds - minutes 3-5 mm 1-2 cm 10-15 – 10-17 M 
IVM Seconds - days 1 – 10 µm  ~ 700 µm 10-15 – 10-17 M 
PAI Seconds - minutes 10 µm – 1 mm 6 mm – 5 cm Not determined 
* The data without bracket indicate spatial resolution for preclinical imaging modalities while 
the data in brackets are spatial resolution for clinical imaging modalities.  
 
1.2.1.1 Non-optical imaging modalities 
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Magnetic resonance imaging (MRI): MRI uses magnets to polarize and align 
the hydrogen nuclei (protons) in water molecules in the tissue. When a radiofrequency 
(RF) is applied, the nuclei are excited to a higher energy level. When the RF is turned 
off, the nuclei go back to the ground state, releasing energy which is detected by 
radiofrequency coils [34]. MRI has unlimited penetration depth as well as high spatial 
resolution and thus provides excellent anatomical information.  However, the 
sensitivity of MRI is relatively low and temporal resolution is poor, making it difficult 
to assess the biodistribution of administered cells across the whole body. (Table 1-2). 
Furthermore, due to the presence of air or endogenous contrast (e.g., ferritin), it can be 
difficult to detect labelled cells in organs such as the lungs and spleen, respectively [2]. 
Positron emission tomography (PET): PET is a nuclear imaging technique 
that requires radioactive probes comprising positron (positive electron) emitting 
radionuclides [35].  PET probes have different half-lives, with the most commonly 
used probes for cell tracking being based on 18F (half-life, 110 minutes) or 89Zr (half-
life, 78.4h).  For PET imaging, the sensitivity for tracking cells is very high, with 
unlimited penetration depth. The temporal resolution is good but the spatial resolution 
is limited. The use of this imaging technique is also limited by the short-lived 
radioisotopes and the potential negative impacts on cell health due to the use of 
ionising radiation [2, 35]. 
Single-photon emission computed tomography (SPECT): SPECT is another 
nuclear imaging technique using radionuclide probes. Like PET, SPECT has a limitless 
depth of penetration and high sensitivity (slightly lower than that of PET clinically). 
SPECT employs nuclides such as 99mTc (half-life, 6 hours), 123I (half-life, 13.3 hours), 
and 111In (half-life, 2.8 days). These nuclides decay via the emission of single γ-ray 
with differing energies. The similar limitations as for PET apply to SPECT [2, 32]. 
	
	
	
	
14	
Computed tomography (CT): CT employs X-rays to scan the whole sample 
by sections and can produce 3D anatomical images. The X-ray source is linked to the 
detector array and both can be rotated together around the subject.  In the images 
produced, the parts (e.g., tissue, medium) that absorb X-rays strongly appear white 
while those poorly absorbing X-rays appear black. An iodinated contrast agent is often 
added to improve spatial resolution and contrast [32]. CT produces images with high 
spatial resolution, good temporal resolution, and has been widely used in clinics.  
However, the sensitivity is low and it is difficult to image soft tissue, and also uses 
radiation [32].  
Ultrasound (US): US detects and utilizes ultrasound waves (frequencies 1 – 20 
MHz) as they travel through tissues and media. It can be used for diagnostic imaging 
and as a therapeutic device. A transducer can detect the waves and convert the 
information into electrical signals, which are then processed to generate an image. US 
is relatively inexpensive, has good temporal resolution, and generates no ionizing 
radiation. However, it is limited to imaging soft tissues only and has a limited depth of 
penetration [32].  
 
1.2.1.2 Optical imaging modalities 
Optical imaging is based on the detection and quantification of light from the 
subject. The instruments are relatively cheap and there is no need for radioactive agents. 
A cooled charged coupled device (CCD) camera is usually used which facilitates the 
detection of weak light signals [36]. For optical imaging, the imaging quality can be 
improved by increasing the contrast between what is required (signal) and what is not 
required (background). 
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Bioluminescence imaging (BLI): BLI detects the bioluminescence emitted 
from cells labelled with light-generating enzymes (luciferase). Bioluminescence is 
generated by converting chemical energy to visible light via luciferase and their 
substrates in tissues. The wavelength of emitted light varies with the use of different 
luciferase. There are four types of luciferases that are widely used: Firefly luciferase 
(emission maximum wavelength, 562 nm; substrate, D-Luciferin), Renilla luciferase 
(emission maximum wavelength, 482 nm; substrate, Coelenterazine), Gaussia 
luciferase (emission maximum wavelength, 480 - 600 nm; substrate, Coelenterazine), 
Bacterial luciferase (emission maximum wavelength, ~ 490 nm; substrate, not 
necessary) [37]. Among them, the firefly luciferase-encoded gene obtained from 
Photinus pyralis is the most commonly used. The substrate, D-luciferin, is a small 
molecule that can freely diffuse across the cell membrane. To generate 
bioluminescence, the presence of D-luciferin and cofactors ATP, Mg2+, and oxygen are 
required [37]. BLI can be used to image cells and track stem cells/immune cells with 
high sensitivity. However, the depth of penetration is limited and the spatial resolution 
is low (Table 1-2). Furthermore, the signals cannot be quantified with great accuracy 
due to loss of light and scattered light in the body [37]. 
Fluorescence imaging (FI): With FI, a light source (higher energy, shorter 
wavelength, known as the excitation light) excites a fluorophore to an excited state. 
When the fluorophore returns to the ground state, light with greater wavelength is 
emitted, which is then detected. Fluorophores can be proteins, chemical dyes, or 
nanoparticles [36]. Because the emitted light travels through the medium and tissues, it 
is critical to design, fabricate, and employ suitable fluorophores with high 
photostability and minimal attenuation, absorption and scattering by the tissue and 
medium [32]. As with bioluminescence, FI is convenient to use (not so expensive), has 
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good temporal resolution and high sensitivity.  But the depth of penetration and spatial 
resolution are limited (Table 1-2). 
Intravital Microscopy (IVM): IVM works essentially in the same way as 
traditional fluorescence microscopy. However, for IVM, the data are collected with a 
digital camera set-up and an image acquisition network and then analyzed using a 
computer equipped with relevant algorithms and mathematical models [32]. Compared 
to FI, the depth of penetration and spatial resolution are improved although still rather 
limited (Table 1-2). IVM can be performed with various light microscopy techniques, 
such as wide-field fluorescence microscopy and confocal laser scanning microscopy 
[38]. However, the combination of IVM with two-photon (multiphoton) microscopy 
can further improve imaging depth. Compared to traditional one-photon FI, the 
fluorophores are excited by two or more photons simultaneously. Nearly no out-of-
focus emission is detectable and more detectors can be equipped to collect the emission 
efficiently, providing new insights into physiology and pathophysiology [39]. 
 
1.2.1.3 Photoacoustic Imaging (PAI) and MSOT 
PAI is a relatively new imaging modality [2, 32]. PAI detects the ultrasound 
wave generated by strong light (near infra-red (NIR) light) absorption using 
endogenous or exogenous molecules or probes, exhibiting both high sensitivity and 
high spatial resolution [40]. Multispectral optoacoustic tomography (MSOT) is a 
particular type of photoacoustic imaging (PAI) technique that utilizes multiple 
excitation wavelengths and allows multiple photo-absorbers to be identified 
simultaneously [41]. 
The basic principle of PAI is that the absorption of laser energy, either by 
endogenous photoabsorbers or exogenous photoacoustic probes, results in thermo-
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elastic expansion and the generation of a sound wave that can be picked up by an 
ultrasound detector [40, 42]. Figure 1-6 schematically describes how ultrasound is 
generated and detected.  
 
Figure 1-6. Photoacoustic generation and detection. Black dots in the left panel 
represent regions of high optical absorption. When heated by a laser pulse, they give 
rise to acoustic waves, which are picked up by an ultrasound detector. The ultrasound 
waveform shown in the right panel is approximately proportional to the time derivative 
of the optical pulse. Reprinted from Ref 42. 
 
 For PAI, spatial resolution is determined by the acoustic frequency. Penetration 
depth is considerably impacted by the wavelength of laser illumination. Greater depth 
is achieved with NIR light because of less optical absorption and diffraction. When 
travelling in tissue, the ultrasonic attenuation coefficient is nearly linear with operating 
frequency. Therefore, a trade-off between penetration depth and spatial resolution 
exists. Generally, penetration depth of 15 cm is associated with a sub-millimetre spatial 
resolution. A higher resolution of 100 µm may be achieved but with a reduced depth of 
several centimetres [42]. Mallidi et al compared ultrasound and PAI in terms of 
A B
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resolution and penetration depth (Table 1-3). The PAI techniques are grouped into 
macroscopic PAI, microscopic PAI, and optical PAI based on the transducer frequency 
and the size of objects to be imaged [33, 43]. Macroscopic PAI is used with lower 
frequency and higher imaging depth. However, both axial resolution and lateral 
resolution are low. Higher frequency can be used for microscopic and optical PAI, 
resulting in much higher resolution but lower imaging depth [43]. 
 
Table 1-3. Comparison of ultrasound and PAI imaging parameters (adapted from ref 
43) 
Parameter Transducer 
frequency 
(MHz) 
Axial resolution 
(µm) 
Lateral 
resolution (µm) 
Imaging depth 
(mm) 
Ultrasound 5 150 300 70 
20 75 165 30 
Macroscopic 
PAI 
5 150 300 40 
Microscopic PAI 50 15 50 3 
Optical 
resolution PAI 
75 15 5 0.7 
 
 
Figure 1-7. Scheme showing MSOT image generation (courtesy of iTheraMedical). 
 
•  Absorption of light, inducing a 
thermoelastic expansion. Repeat with 
up to 10 different wavelengths/second 
•  Generation of ultrasound wave 
Excitation of absorbers 
One signal per absorber 
Single transducer signal 
•  Recording of ultrasound waves (5 
MHz Centre) 
•  Simultaneous data acquisition from  
64-512 UT elements 
Ultrasound detection 
Tomographic Image 
(multiple transducers) 
•  Reconstruction of tomographic 
image 
•  Live view of reconstructed images 
Image formation 
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MSOT is a PAI technique which uses multispectral light beams to illuminate a 
sample or small animal such as a mouse. Figure 1-7 shows the diagram of how MSOT 
works. Compared to conventional PAI, MSOT is capable of imaging at multiple 
wavelengths and the information obtained from multiple wavelengths improves image 
accuracy as a function of penetration depth [31, 44]. Furthermore, multiple absorbers 
may be employed and the signals generated from multiple wavelengths can be 
spectrally unmixed. This allows the identification of these absorbers and provides 
detailed information about the imaged subject [45]. Due to the combined high spatial 
resolution and high depth of penetration, MSOT can be used in real time to monitor 
pharmacokinetics and biodistribution of cells in particular organs [46], enabling both 
cell tracking and efficacy studies [2]. 
 
1.2.1.4 Multimodal Imaging 
Each of the imaging modalities have their own intrinsic strength and weak 
points (Table 1-2). No single imaging modality can be used alone to sufficiently 
evaluate the safety and efficacy of the RMTs. Thus, multimodal imaging is always 
preferred in order to get a full picture of the RMTs at different stages, combining 
imaging modalities that can complement each other. For example, in the multimodality 
imaging of PET/CT, CT provides the anatomic context to interpret the functional PET 
study [47]. In general, the use of both imaging probes and genetic reporter is crucial for 
long-term in situ multimodal imaging. This may be a simple mixture of different 
probes/reporters and/or purposely designed multimodal probes.  
 
1.2.2 Imaging probes and reporters 
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Cells can be labelled directly with probes or can be genetically modified to 
express reporter genes [28]. There are various imaging probes which can be either 
taken up by the cells or attached to the cells via antigen-antibody interaction for 
antibody-modified probes before imaging. Figure 1-8 lists the main advantages and 
disadvantages of both labelling methods [2]. Imaging probes can generate very strong 
signals at the initial stage and are therefore good for short-term imaging. Compared 
with reporters, probes also tend to have a very rapid and efficient uptake, enabling a 
whole cell population to be labelled in a short time period.  However, with the growth 
and proliferation of the cells, the concentration of the imaging probes is diluted, so that 
after several cell divisions, the cells can no longer be detected.  There are also other 
potential problems, such as leaking of imaging probes, cell toxicity, and difficulties in 
distinguishing dead cells from live cells. For the reporter genes, the detection 
sensitivity and specificity can be very high, although this depends on the specific 
reporter gene used. Because reporter gene labelling is achieved via genetic 
modification of cells, they are transferred to daughter cells during cell proliferation and 
are thus suitable for long-term cell tracking without dilution of signal intensity. In 
principle, imaging signals from reporter genes are only generated from live cells. This 
property can be used to differentiate live and dead cells during imaging [2]. However, 
this biological alteration can permanently alter the phenotype of the cells and could 
adversely affect safety and/or efficacy for RMTs [2, 28, 48]. 
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Figure 1-8. Characteristics of direct cell labelling with probes and indirect cell 
labelling with reporter genes. Reprinted from ref 2. 
 
 For bioluminescence imaging, luciferase reporters are most commonly used 
(described in detail in section 1.2.1.2). For fluorescence imaging, both imaging probes 
and genetic reporters are frequently used. Because this project aims to develop imaging 
probes for MSOT and also fluorescence imaging, the main focus here is on imaging 
probes. 
 Fluorescent probes for cell labelling mainly includes the following 4 
approaches [48]: (i) Amine-reactive probes which diffuse into cells and react with 
cytosolic amine-containing residues; (ii) Lipophilic dyes which are incorporated into 
lipid membranes; (iii) Nanoparticle probes which are taken up by endocytosis and/or 
pinocytosis; (iv) Antibodies that bind to the extracellular domains of membrane 
proteins.  
 Fluorescence imaging microscopy detects the emitted light while MSOT uses 
light to generate ultrasound. In both cases, light wavelength is a critical factor for high 
quality imaging. Near infra-red (NIR) light enables imaging by both fluorescence and 
MSOT.  
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1.2.2.1 Importance of NIR light in imaging 
 
 
Figure 1-9. Light absorption by water and endogenous chromophores as a function of 
light wavelength. The wavelength range of 600 – 1100 nm (reprinted from ref 49). 
 
When light travels through tissues and medium, the absorption of light by water 
and endogenous chromophores, including melanin, oxyhemoglobin (HbO2) and 
deoxyhemoglobin (Hb), varies as a function of wavelength. The absorption by 
chromophores generally decreases with increasing wavelength whilst the absorption by 
water increases with increasing wavelengths. However, it should be pointed out that 
this trend is not linear. For NIR wavelengths of 2000 – 3000 nm, the penetration depth 
is limited to 0.1-1 mm because water is the major light absorber. In the UV region, the 
low absorption depth is caused by cellular macromolecules [42]. There is an ‘optical 
window’ between the wavelengths of 650 nm and 1300 nm where the penetration depth 
can reach several centimetres and the contrast is still high [33, 42-43], with the optimal 
optical window being in the wavelength range of 650 – 900 nm (Figure 1-9), as above 
A	
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900 nm, water within the tissues starts to absorb more light [49]. Therefore, imaging 
probes that absorb and emit light in this range are required both for fluorescence 
imaging and MSOT. 
NIR imaging probes are advantageous for both fluorescence imaging and PAI. 
They have different requirements but the requirement for reducing light absorption and 
scattering is the same. For fluorescence imaging, light emitted by the NIR probes is 
detected [49, 50]. For MSOT, it is the absorbed light that is detected. 
 
1.2.2.2 Imaging probes for fluorescence imaging 
Various imaging probes have been employed, including amine-reactive dyes 
(e.g., carboxyfluorescein succinimidyl ester (CFSE)), lipophilic dyes (e.g., PKH26, 
3,3,3’,3’-tetramethylindotricarbocynaine iodide (DiR), DiD, DiI) [48], fluorescent 
quantum dots [50], upconversion nanoparticles [51], nanodiamonds [52, 53], silicon 
nanoparticles [53], and other nanostructured fluorophores [54]. Different fluorescent 
proteins based on spectral class (far-red, red, orange, yellow-green, green, cyan, and 
UV-excitable green) may be selected to image live cells [55, 56]. 
 
1.2.2.3 Imaging probes for PAI/MSOT 
These agents can be small molecular dyes, quantum dots, carbon nanotubes, 
nanodiamonds, metal nanoparticles such as Au nanorods [57 - 59]. A range of the NIR 
agents for PAI have been recently summarized by Wu et al. [57]. Table 1-4 shows the 
commonly used small molecular dyes for PAI. In solutions, these dyes have sizes of < 
2 nm. 
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Table 1-4. Common small molecular NIR fluorescent dyes (adapted from ref 5) 
NIR dyes Absorption peak (nm) Application*  
Indocyanine-green  810  PAT, in tissue phantoms and in vivo 
Methylene blue 650 - 700 PAT, , in tissue phantoms 
Alexa Fluor 750 750 MSOT, in vivo 
IRDye800CW 750 - 800 PAS, in vivo 
IRDye800-c(KRGDf) 750 - 790 PAS, in vivo 
Evans Blue 550 PAT, in vivo 
PPCy-C8 754 - 789 Dual-modality, PAI-FI, in vivo 
Cypate-C18 754 - 790 Dual-modality, PAI-FI, in vivo 
Caspase-9 Probe 640  PAI, in vivo 
NMPSenceTM 680 620, 680 PAI, in tissue phantoms 
* Abbreviations: PAT, photoacoustic therapy; PAS, photoacoustic spectroscopy; PAI-
FI, photoacoustic imaging-fluorescence imaging. 
 
However, with some probes, particularly lipophilic dyes (e.g., DiI [red], PKH26 
[red], DiD[far red], DiR [NIR]), there is a risk of false positive staining due to the dyes 
being transferred to host cells. Dyes may be released by diffusion, or by transferring to 
neighbouring host cells via trogocytosis (exchange of membrane microdomains) and/or 
by extracellular vesicles [48]. Regarding nanoparticles that are uptaken by endocytosis, 
these have a lower tendency to transfer to host cells because they are located within the 
endosomes and/or lysosomes, and tend not to be readily transferred unless they are 
exocytosed. However, if the cells die, then the nanoprobes can be taken up by 
macrophages, generating misleading results. For this reason, for preclinical imaging, it 
can be useful to combine genetic reporters with nanoprobes to enable viability and 
biodistribution to be monitored simultaneously.  
Nanoparticles as PAI contrast agents have been designed, synthesized, and 
investigated extensively in recent years [60, 61]. The use of these nanoparticles are 
based on surface plasmon resonance or dye-containing nanoparticles. The former type 
is mainly for metal or inorganic nanoparticles. The latter type accounts for the dye-
modified nanoparticles and organic dye nanoparticles [62, 63]. For a NIR contrast 
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agent, the important characteristics include intensity (absorbance coefficient) and 
stability. Compared to small molecular dyes, nanoparticle probes usually exhibit high 
stability. Due to the concerns in cytotoxicity of heavy metals, which are always present 
in quantum dots and inorganic nanoparticles, the development and use of organic 
nanoparticle probes for PAI would be highly beneficial. 
 
1.3 Semiconducting polymer and perylene diimide (PDI) nanoparticles 
for PAI 
A key aim of this project is to develop new NIR probes for MSOT to facilitate 
cell tracking in vivo. Polymeric or organic dyes with NIR absorbance are potentially 
good candidates. For example, organic dyes and semi-conducting polymers are widely 
used for dye-sensitized solar cells (and other photo-electronic devices) where the 
absorbance of light is critical to achieve high efficiency of transformation from solar 
energy to electricity. These materials may be used as potential NIR agents for 
PAI/MSOT. However, these molecules are usually highly hydrophobic and bulky. To 
use them for in vivo imaging, aqueous nanoparticle suspensions are required.  
There are different methods that can be used to fabricate organic nanoparticles, 
either for drug nanoparticles or imaging probes [64-66]. The commonly used methods 
are nanoprecipitation and emulsion evaporation. For the nanoprecipitation method 
(Figure 1-10A), an organic compound or polymer is dissolved in a water-miscible 
organic solvent (e.g., acetone, methanol, tetrahydrofuran). The organic solution is then 
mixed (usually by dropwise addition) with an aqueous solution containing a surfactant 
or polymer (to stabilize the nanoparticles). After evaporating the volatile organic 
solvent, aqueous organic nanoparticle suspensions are formed. However, if the organic 
compound can only be dissolved in a non-polar organic solvent, an emulsion instead of 
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a mixing solution is formed. An aqueous nanoparticle suspension is formed after the 
evaporation of the volatile organic solvent from the emulsion (Figure 1-10B). This 
method is termed as emulsion evaporation. 
 
Figure 1-10. Schematic representations for the preparation of aqueous organic 
nanoparticle suspensions. Depending on the solubility of the stabilizers, they can be 
initially dissolved in water or in organic solvent. (A) Nanoprecipitation (reprinted from 
ref 66); (B) Emulsion evaporation (reprinted from ref 65). 
 
For the emulsion evaporation method, the difficult part is the stability of the 
emulsion. If the emulsion is stable during solvent evaporation, the droplets can fuse or 
coalesce, leading to larger microparticles or aggregated particles. This issue has been 
Organic	solu-on	
Organic	solu-on	
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addressed by an emulsion freeze-drying approach. The emulsion is immediately frozen 
after formation, followed by a freeze-drying process so that the emulsion stability is not 
a problem anymore [66]. The process is schematically described in Figure 1-11. The 
organic compound is dissolved in a non-polar (or water-immiscible) organic solvent. 
The resulting solution is emulsified into aqueous solution containing polymer and 
surfactant. When freezing the emulsion, the organic solute in the droplet phase is 
concentrated. The subsequent freeze-drying process removes both water and organic 
solvent, which ensures the formation of organic nanoparticles within a porous polymer. 
The organic nanoparticles with the dry porous polymer are highly stable and easy to 
store and transport. When required, the organic nanocomposites can be readily 
dissolved in water to instantly produce aqueous organic nanoparticle suspensions [67]. 
 
Figure 1-11. The schematic representation of preparing organic nanoparticles by 
emulsion freeze-drying. (A) An oil-in-water emulsion is formed; (B) During freezing 
of the emulsion, the organic solute is concentrated in the droplets; (C) After freeze-
drying, organic nanoparticles are formed in situ within the porous polymer; (D) The 
A B
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porous structure is dissolved in water to produce an aqueous nanoparticle suspension. 
Reprinted from Ref 67. 
 
Organic nanoparticles with NIR absorbance (either from the nanoparticle itself 
or by attaching an NIR dye to the nanoparticle) have been used for PAI. Some of the 
examples include cyanine dyes [57, 68], methylene blue [57], Prussian blue [69], 
polypyrrole [70], conjugated polymer [71], MTT formazan [72], PEGylated black 
phosphorous nanoparticles [73], dye-based nanoparticles (porphyrin-based, melanin-
based, squaraine dye-based [63].  
 
1.3.1 Semiconducting polymer nanoparticles (SPNs) 
SPNs have been investigated intensively as PAI probes, where the NIR 
absorbance results from the polymer (i.e., no further NIR dyes attached) [74]. Semi-
conductive polymers are optically and electronically active and are used in many 
applications such as sensors, solar cells, and electronic devices. These polymers may 
be commercially available or synthesized. Since these polymers are hydrophobic, a 
nanoprecipitation approach is usually employed to prepare SPNs [75]. The intraparticle 
molecular orbital engineering between the SPNs and ultra-small fullerene dots were 
found to simultaneously enhance photoacoustic brightness and photothermal therapy 
efficacy [76]. Other agents may be incorporated into the SPNs for imaging changes in   
pH, temperature, reactive oxygen species (ROS), and protein sulfenic acid in diseased 
tissues [63]. For example, a cyanine dye derivative (IR775S) was incorporated into the 
SPNs for ROS imaging; and a pH-responsive NIR croconine dye could induce the self-
assembly of human serum albumin (HSA). The resulting nanoparticles were used for 
real-time photoacoustic pH imaging and pH-responsive photothermal therapy [77].  
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1.3.2 Perylene/Naphthalene-based nanoparticles for PAI 
Very recently, naphthalene and perylene-based dyes have been used for PAI 
[78-82]. These dyes are highly hydrophobic and can exhibit both fluorescence and NIR 
absorption, with high quantum yield and high stability [83-86]. Naphthalocyanine 
derivative could self-assemble into nanoparticles of ~ 20 nm in the presence of the 
biocompatible polymeric surfactant Pluronic F127. There was no nanoparticle 
aggregation observed when the temperature was reduced to 4ºC [77]; this was 
attributed to the formation of frozen micelles. After oral administration, these 
nanoparticles could pass safely through the gastrointestinal tract of mice where the PAI 
technique could be used to visualize intestinal distribution with low background and 
high resolution [78]. These nanoparticles were further used for dual-colour 
photoacoustic lymph node imaging in both small animals and human breast cancer 
patients [79]. A hydrophobic perylene diimide (PDI) derivative was prepared and 
aqueous PDI nanoparticle dispersions were then formed by a solvent evaporation (or 
nanoprecipitation) method, with strong absorbance at around 700 nm and high 
extinction coefficient of 2 x 108 M-1 cm-1 [81]. The PDI nanoparticles were 
demonstrated to be highly effective photoacoustic agents for deep brain tumour 
imaging in living mice [80]. 64Cu-labeled PDI nanoparticles were prepared and 
employed as dual PET and PAI probes in lymph node mapping and cancer imaging 
while the photothermal therapeutic efficacy was also demonstrated [81]. 
Terrylenediimide (TDI) was modified with poly (acrylic acid), which produced a star-
like compound with hydrophobic TDI core and hydrophilic corona [82]. The 
spontaneously self-assembled nanoparticles were used as theranostic agents for 
efficient PAI-guided tumour photothermal therapy [82].  
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As discussed above, perylene diimide derivatives (PDIs) have been used as 
chromophores for imaging. However, the use of PDIs is quite new for PAI. 
Furthermore, the synthesis of PDIs has been extensively investigated for advanced dyes, 
photo-related devices, and semi-conducting materials for microelectronics [84, 85]. 
These methods may be adopted or developed further to produce PDI compounds with 
tuneable NIR absorbance. In addition, the nanoparticle fabrication methods can be used 
to fabricate aqueous PDI nanoparticle suspension, which will provide a novel and 
highly efficient platform for MSOT imaging. As such, the preparation of PDI 
nanoparticles as NIR probes for MSOT is the focus of this project. 
 The molecular structures of naphthalene, perylene, and PDIs are shown in 
Figure 1-12. Perylene is a chemically inert compound. The synthesis of PDIs usually 
starts with perylene-3,4,9,10-tetracarboxylic dianhydride (PTCDA), which is 
commercially available. Different functional groups may be introduced to the different 
positions on perylene. The hydrophilicity of the PDIs is achieved by adding 
hydrophilic groups to the amide position (or peri position for perylene in general). 
Similarly, hydrophobic PDIs can be formed if linear or cyclic alkyl chains are added to 
the amide position.  
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Figure 1-12. Molecular structures of naphthalene and perylene-based compounds. 
 
However, the change of light absorption properties is usually caused by adding 
functional groups (usually bulky) at the bay positions [84] or more effectively by 
enlarging the core of the PDIs via synthetic chemistry [86]. Higher rylene diimides can 
be synthesized by introducing naphthalene units (Figure 1-12), which can significantly 
move the absorption wavelength towards the NIR region.  Figure 1-13 shows how the 
absorption wavelength and extinction coefficient change with the higher rylene 
diimides [87]. The maximal absorption wavelengths are shifted bathochromically by 
about 100 nm per naphthalene unit, exhibiting strong NIR absorbance. And the 
extinction coefficient increases linearly with the increasing number of naphthalene 
Perylene	
Perylene	tetracarboxylic	
dianhydride	(PTCDA)	
Perylene	diimides	
(PDI)	
Naphthalene	
Higher rylene diimides: 
 
n = 0, PDI 
n = 1, terrylenetetracarboxylic diimides  (TDI) 
n = 2, quaterrylenetetracarboxylic diimides (QDI) 
n = 3 pentarylenetetracarboxylic diimides (5DI) 
n = 4 hexarylenetetracarboxylic diimides (HDI) 
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units in rylene diimides [85, 86]. As such, the synthesis and use of higher rylene 
diimides may be a highly effective route to highly efficient PAI agents.  
 
Figure 1-13. A) Absorption spectra of rylene diimides. B) The relationship between 
the extinction coefficient and the number of naphthalene units. Reprinted from Ref 87.  
 
1.3.3 Physicochemical characterization of organic nanoparticles 
The size, shape, and surface charge are important characteristics for 
nanoparticles. The size can be hydrodynamic size which is obtained by light scattering 
of nanoparticle suspensions [88], or the size of dry nanoparticles which can be obtained 
by electron microscopy (EM) or Atomic Force Microscopy (AFM). While the light 
scattering techniques provide the hydrodynamic diameters of spheres or equivalent 
spheres for non-spherical particles or irregular-shaped particles, the shape of the 
nanoparticles can be seen from EM or AFM images. UV-Vis spectroscopy may be used 
to determine the size of Au nanoparticles based on plasma effect. This, however, is not 
a universal technique for sizing nanoparticles. The surface charge of a nanoparticle can 
be measured by zeta potential. EM and AFM measure/image dry nanoparticles. The 
shape and surface morphology of the nanoparticles can be obtained. During the dry 
state, the stabilizer molecules on the nanoparticles are collapsed and the nanoparticles 
may aggregate. For biomedical applications, nanoparticles suspended in aqueous media 
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are always used. Due to the hydrated shell of the stabilizer, the size of nanoparticles is 
considerably different between dry states and hydrated cells. To better understand the 
effect of particles in biomedical applications, the size of hydrated nanoparticles in 
aqueous suspensions is more relevant. Dynamic light scattering (DLS) measures the 
size of hydrated nanoparticles in suspension, assuming the particles are spherical. 
Information on the shape and aspect ratio of nanoparticles cannot be obtained from the 
DLS technique. This can be a significant disadvantage for non-spherical nanoparticles. 
In this project, DLS and Scanning Electron Microscopy (SEM) have been mainly used 
to characterize the samples. 
DLS is sometimes mentioned as Photon Correlation Spectroscopy (PCS) or 
Quasi-Elastic Light Scattering (QELS). DLS measures the distance travelled by the 
particles during a certain period (the velocity) due to the random Brownian motion [88]. 
The larger the particles, the slower the motion. Due to the random movement of the 
particles, the scattering intensity fluctuates with time. The size of the particle is 
obtained from the correlation function by using various algorithms. The size 
distribution can be plotted as the intensity versus sizes. A smooth and sharp peak of the 
plot indicates the particles of uniform sizes. However, when multiple peaks are present, 
this suggests the particles of different sizes in the medium. As the intensity contributed 
from small particles is very small. Therefore, the intensity size distribution profile may 
not represent the true picture of the particles. With the input of other parameters, the 
Mie theory can be used to convert the intensity distribution to a volume or number 
distribution. Generally, the size of the particles follows the order of d(intensity) > 
d(volume) > d(number) [89]. This can be simply illustrated in Figure 1-14 when 
measuring a sample with equal populations of 5 nm and 50 nm particles.  
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 Figure 1-14. Different size distribution profiles for a sample containing equal number 
of 5 and 50 nm particles. Reprinted from ref 89. 
 
The DLS equipped with a zeta analyzer can also measure the charges (zeta 
potential) carried by the particles. These data can indicate the stability of the particles 
in the dispersing medium. The zeta potential value is independent of nanoparticle 
concentration in the stable region (10-2 – 10-4 wt% for the nanoparticles investigated, 
Ludox silica, gold, carbon nanotubes). However, below this concentration range, the 
zeta potential values shifted to become less negative, accompanied by an increase in 
particle size. This was attributed to the artifact signals from extraneous particles for 
zeta potential and the homodyne optical configuration of the instrument for particle 
size [90]. 
 
1.3.4 Cellular uptake of nanoparticles: mechanism and toxicity 
When nanoparticles are used as probes for bioimaging, their biological evaluation 
when exposed to cells or injected into a body is of paramount importance. The 
stabilizer (and ligands)-coated nanoparticles firstly bind onto cell membrane, initiating 
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a signaling cascade and leading to cellular uptake or internalization of the nanoparticles 
[91]. The mechanisms for cellular uptake of nanoparticles include [92]: 
• Phagocytosis. This process is completed by phagocytic cells of the 
mononuclear phagocyte system (MPS) and reticuloendothelial system (RES). It 
is usually initiated by opsonization and highly effective for larger nanoparticles. 
• Clathrin-mediated endocytosis. It is the main mechanism to obtain nutrients and 
plasma membrane components. This process can be achieved by receptor-
specific uptake or non-specific adsorptive uptake. During the process, vesicle 
with diameter of 100 – 150 nm are formed, engulfing a volume of extracellular 
fluid which may contain foreign nanoparticles. The nanoparticles from this 
process are localized in degradative lysosomes. 
• Caveolae-dependant endocytosis. This mechanism is used in many biological 
processes such as cell signaling, transcytosis, etc. 
• Clathrin/caveolae independent endocytosis. 
• Macropinocytosis. This process does not involve the use of pit-forming proteins. 
In this process, large membrane extensions are formed as a result of 
cytoskeleton rearrangement, generating a large vesicle with diameter of 0.2 – 5 
µm that traps a large volume of extracellular fluid. The nanoparticles in this 
volume of fluid are taken up by the cell. 
• Enhanced permeation and retention (EPR) effect [91]. Relatively larger 
nanoparticles (usually in the range of 30 – 200 nm but can be larger) are taken 
up by tumor cells via the EPR effect. This is due to the large fenestrations 
generated between endothelial cells and blood vessels by angiogenesis. 
The physical properties of the nanoparticles, such as size, shape, and surface charge, 
have significant impacts on cellular uptake of the nanoparticles. As discussed above of 
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the uptake mechanism, different size of nanoparticles can be taken up by different cells 
and via different mechanism. When cultured with cells, there are no definite trends of 
particle size on cellular uptake. Size dependent uptake is related to membrane-
wrapping processes. Small nanoparticles have less ligand-to-receptor interaction than 
larger particles, which reduces the tendency of cellular uptake. However, for much 
larger particles, the uptake is limited by the redistribution of the surface charges. It has 
been observed that 50 nm spherical nanoparticles are optimal for the uptake by certain 
mammalian cells [91, 93, 94]. Aggregated nanoparticles can have lower uptake but this 
effect is different from single large nanoparticles, as demonstrated by the aggregated 
gold nanoparticles (15 nm) [95]. 
The effect of particle shape influences the cellular uptake considerably [91]. For 
nanospheres and nanorods with similar diameters, the uptake of nanorods is less, as 
demonstrated with gold [96] and silver [97] nanoparticles. However, if the volume of 
the nanoparticles is kept the same, for example, by stretching 200 nm polystyrene 
nanospheres in one direction (394 nm nanorod) or in two directions (forming disc with 
diameter of 293 nm), the uptake of both nanorods and discs by Caco-2 cells was found 
to be twice quickly as nanospheres [98]. 
Surface charge and surface functionality of the nanoparticles are also important 
parameters. In general, positive surface charge facilitates fast uptake by cells. This is 
because cell membranes possess a slightly negative charge [91]. The adsorption of 
proteins onto the nanoparticles can modulate cellular uptake, as found with gold 
nanoparticles (40 nm, 80 nm, both with negative, positive, and neutral charges) and 
hepatocyte cells [99]. Compared to human plasma protein (HPP), the adsorption of 
human serum albumin (HAS) showed reduced uptake and toxicity [99]. For sub-10 nm 
gold nanoparticles (2 nm, 4 nm, 6 nm) with neutral, anionic, and cationic stabilizers, it 
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was found that the uptake by HeLa cells decreased with increasing particle size for 
particles with neutral and negative surface charges whilst the cellular uptake increased 
with increasing size of positively charged gold nanoparticles [100]. This was attributed 
to the energy-dependent cellular uptake pathways for sub-10 nm particles [100]. 
The toxicity of nanoparticles is complicated and under investigated. It is associated 
with the properties exhibited by nanoparticles including small size, high surface energy, 
and surface composition [101]. Nanoparticles can be taken up by a body via different 
routes such as gastrointestinal tract, skin, lung, and systemic administration. The 
nanoparticles can interact with cells, body fluid, and proteins. Accelerated protein 
denaturation on nanoparticles leads to biological functional and structure change. The 
nanoparticles in the body may be excreted or deposit in organs, penetrate cell 
membranes, and lodge into mitochondria [101].  
In order to utilize the excellent properties shown by nanoparticles, their toxicity 
must assessed first. This can be achieved by in vivo assessment and in vitro 
cytotoxicity assay [102]. In vivo assessment is the ultimate target by evaluating the 
effect of the injected or absorbed nanoparticles on the whole organs. This is realized by 
investigating the pharmacokinetic behavior of the nanoparticles, i.e., the absorption, 
biodistribution, metabolism, and elimination. However, before moving to the stage of 
in vivo assessment, the in vitro evaluation should be completed first. The in vitro 
cytotoxicity evaluation employs different assays to look at the response of the cells 
when the nanoparticles are cultured with or exposed to cells [102]. It should be pointed 
out that the cytotoxicity may be different for different cells, even for the same 
nanoparticles. Common assays to assess cytotoxicity include [102]: 
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• Lactate dehydrogenase (LDH) assay: a colorimetric assay measuring the release 
of LDH into the culture medium as an indicator of cellular membrane 
disruption. 
• MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide):  a 
metabolic and colorimetric assay measuring the enzymatic activity of cellular 
mitochondria. MTT is added into the culturing medium usually at a 
concentration of 0.2-0.5 mg/mL. Viable cells convert MTT into a purple 
formazan with an absorbance peak around 570 nm. The dead cells cannot 
convert MTT to formazan. 
• Reactive oxygen species (ROS) assay: used to monitor oxidative stress by 
measuring the ROS level. 
Cytotoxicity data are obtained by exposing different nanoparticles to the cells [103]. 
It is often related to the uptake level by the cells. Higher uptake by the cells usually 
indicates higher toxicity. Therefore, the factors (size, shape, surface property) that 
influence cellular uptake have significant impact on cytotoxicity [95, 97, 99]. For 
example, size dependent toxicity was observed for citrate stabilized gold nanoparticles 
(5 nm and 15 nm) when exposed to mouse fibroblasts [104]. Cytotoxicity was only 
observed for the cells treated with 5 nm nanoparticles at > 50 µM for 72 hours. 
Disruption of the actin cytoskeleton was greater for the cells exposed to 5 nm 
nanoparticles [104]. 
 
1.4 Cell encapsulation and cell delivery 
1.4.1 The need for cell encapsulation and hydrogels 
Cell encapsulation has been frequently carried out when transplanting 
therapeutic cells. This is because the encapsulation can provide several benefits. These 
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mainly include: (i) Improving viability by reducing or preventing immunogenicity, 
especially when transplanting allogeneic cells; in this case, the encapsulation can  
provide  an immune-isolating layer to prevent the immune cells from attacking  the 
implanted cells; (ii) Providing a scaffold with suitable mechanical and chemical cues to 
support the growth and differentiation of stem cells; (iii) To serve as a barrier to avoid 
or reduce the leaking of therapeutic cells from the transplantation site. 
Hydrogels are mostly used to encapsulate cells (other materials may include 
semi-permeable membranes, etc.). Hydrogels are hydrated polymer networks, formed 
either by chemical crosslinking or physical crosslinking, which can retain a large 
amount of water [105]. The use of hydrogels gained popularity in the 1960s, and from 
hydrogels formed by  simply polymerizing water-soluble monomers and polymers, we 
now have smart hydrogels where gelation can be controlled using various triggers, and 
stereocomplexed hydrogels that can be synthesized from the self-assembly of 
peptides/polypeptides [105]. When selecting hydrogels for cell culture, mechanical, 
structural, and compositional cues are often considered because they can regulate cell 
behaviour, either alone or in synergy [106]. These cues are reflected by the hydrogel 
properties such as type of polymer, stiffness, porosity, and biodegradability [107]. In 
general, hydrogels are formed from natural polymers (e.g., fibrin, collagen, gelatin, 
polysaccharides) and synthetic polymers (e.g., polyacrylamides, poly (acrylic acid), 
poly (ethylene glycol), polyoxazolines, poly(vinyl alcohol), poly(lactide-co-glycolide), 
polycaprolactone) [107]. There are commercial hydrogels which can be purchased 
from providers and used for cell culture directly. The commonly used ones are from 
collagen, fibrin, alginate, polyacrylamide, poly (ethylene glycol), hyaluronic acid, and 
polypeptides [108]. 
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1.4.2 The basics of cell encapsulation 
Cell encapsulation may be classified into two categories. The first category is to 
encapsulate cells in biodegradable hydrogels for tissue engineering [109]. This is in 
contrast to seeding cells in prefabricated porous scaffolds or hydrogels. To achieve cell 
encapsulation, cells are suspended in a liquid precursor solution and the solution is 
injected to the site of interest. In situ gelation of the solution ensures the encapsulation. 
Because the presence of the cells in the solution, the components in the solution should 
be non-toxic and the gelation condition should be mild so that the cells can survive and 
are not negatively impacted upon [109]. For the hydrogels used in cell encapsulation, 
small molecular monomers are usually not used due to cytotoxicity issues. Macromers 
with molecular weight of 3 kDa or higher and natural polymers are generally used 
instead. The biodegradation rate of these hydrogels may be adjusted by choosing 
suitable precursors or incorporating hydrolytically or enzymatically labile segments 
during gelation [109]. 
 The second category of cell encapsulation, probably the more often referred to 
meaning, is to encapsulate cells for cell transplant, aiming for cell delivery and/or drug 
delivery [110, 111]. Encapsulation helps to prevent the implanted cells from being 
attached by the host’s immune cells, which include macrophages, granulocytes, 
lymphocytes, fibroblasts, etc. A key objective of cell encapsulation is to suppress the 
attack by the immune system whilst enabling factors secreted by the cells to be able to 
diffuse out of the hydrogel [112].  
 In this work, the focus is on the second category of cell encapsulation although 
many of the properties might also be useful for the first category of cell encapsulation.  
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Figure 1-15. Timeline showing key milestones in cell encapsulation technology. 
Reprinted from Ref 113. 
  
While the first concept of cell encapsulation was mentioned in 1933, it is 
generally regarded that the attempt to generate ‘artificial cell’ by Chang in 1964 
intensified the studies on cell encapsulation (Figure 1-15) [113, 114]. In Chang’s work, 
carbonic anhydrase was encapsulated in semipermeable microcapsules, which showed 
efficient catalytic hydration of CO2 as was obtained by the enzyme in free solution, and 
the activity remained after weeks of storage [114]. 
 For the encapsulated cells to survive, nutrients and oxygen should be able to 
sufficiently move across the hydrogel membrane while antibodies and immune cells 
are kept out. Therapeutic agents excreted by the cells diffuse out of the hydrogel 
membrane to achieve the objectives of cell therapy [115]. This process is schematically 
illustrated in Figure 1-16A. A sufficient supply of oxygen is critical for the survival 
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and healthy growth of the cells. This can be enhanced by the use of pre-vascularized 
support system (Figure 1-16B). 
 
Figure 1-16. Schematic representation of cell microencapsulation. (A) Nutrients and 
stimuli diffuse across the membrane while antibodies and immune cells are kept out. (B) 
Pre-vascularized support promotes the transfer of oxygen and nutrients. Reprinted from 
Ref 115. 
 
1.4.3 Important parameters of cell encapsulation 
1.4.3.1 Encapsulation materials 
The criteria used in finding or selecting an encapsulation material include 
biocompatibility, immune-isolation ability, and ability to maintain viability and 
phenotype [116]. Different types of synthetic and natural polymers have been used to 
encapsulate cells [117]. Natural polymers are more often used due to their intrinsic 
biocompatibility and biodegradability. These may include DNA-based hydrogels, 
protein-based hydrogels (also peptide hydrogels), polysaccharide-based hydrogels 
(alginate, chitosan, chondroitin sulfate, hyaluronic acid, agarose) [109, 117]. The 
hydrogels are formed by physical crosslinking (via hydrophobic interactions and ionic 
interactions), free radical polymerization, or chemical crosslinking using novel 
A B
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chemistry [109, 117, 118]. Some of the crosslinking methods that are particularly 
effective for injectable hydrogels are Michael addition (e.g., between thiols/amines and 
double bond next to the carbonyl bond), click reaction (Cu(I)-catalyzed reaction 
between azide and terminal acetylene groups), Schiff based reaction (between an amine 
group and an aldehyde group), and photocrosslinked hydrogels  (acrylate monomers or 
macromers by UV radiation) [118]. 
In terms of preparing encapsulated cells for pre-clinical and clinical 
applications, simple physical crosslinking methods via hydrophobic interaction (e.g., 
chitosan thermosetting gels) or ionic crosslinking (e.g., alginate crosslinked by Ca2+) 
can be used. For example, in a study to find the encapsulation system for pancreatic 
islets, a thousand combinations of polyanions and polycations were tested to form 
capsules simply by dropping each polyanion solution into each polycation solution 
[119].  
 
Figure 1-17. The molecular structure of alginate and description of M and G blocks. 
Reprinted from Ref 117. 
 
Alginate is the most commonly used polymer for cell encapsulation. The 
majority of the encapsulating gels are formed from sodium alginate (Alg) as polyanion 
and poly-L-lysine (PLL) as polycation [112]. Alginate is a natural anionic polymer 
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composed of 1,4’-linked β-D-mannuronic acid (M) and α-L-gluoronic acid (G) 
residues in different sequences (Figure 1-17) [117]. The ratio of G and M blocks is an 
important parameter, which varies depending on its natural sources (e.g., algae). It is 
generally believed that high G content contributes a more rigid structure whilst high M 
content in alginate is preference for pliable gels [117]. There are contradictory findings 
about the G content of alginate for cell encapsulation, with some researchers believing 
that high G alginates are more suitable for cell encapsulation based on their results 
[113]. 
Mechanical stability of the microscapsules is an important parameter. Stable 
microscapsules can protect the cells and are easy to handle. In general, mechanical 
stability may be improved by using a high concentration of precursors and a high 
crosslinking density. This, however, may not be easily applicable for a selected 
encapsulation system. In the case of alginate, this has been achieved by the use of 
different polycations, e.g., the use of poly-L-ornithine, Ba2+, layer-by-layer coating 
[112]. 
 
1.4.3.2 Fabrication methods 
Cells can be encapsulated in bulky hydrogels, hydrogel beads, microcapsules 
and other micronized systems. For encapsulation in bulky hydrogels, cells are 
suspended in a liquid precursor solution, followed by gelation. The cell-encapsulated 
hydrogels are also formed in hollow fibers to suit the need of different applications [89]. 
To form hydrogel beads, as often seen with alginate beads, alginate solution containing 
cells can be injected into aqueous CaCl2 solution and the gel beads are formed in the 
solution. When a polycation solution is used, capsules instead of beads may be 
	
	
	
	
45	
produced [119], due to the limited mass transfer of polycation molecules. The size of 
the beads may be reduced by using a pressurized nozzle or vibration nozzle [120]. 
However, bulky hydrogels and thick capsules can be a significant barrier for the 
diffusion of nutrients and oxygen, which can negatively impact on cell viability. When 
cells are encapsulated in microcapsules, the large ratio of surface-to-volume facilitates 
transport of nutrients. For example, one study showed that cell viability and metabolic 
activity was optimal when the cells were encapsulated in microcapsules in the order of 
100 µm [121]. Cell encapsulation in microcapsules or microspheres can be prepared 
via an emulsion-based approach, where the droplets are turned into microspheres or 
microcapsules [120, 122]. There may be limitations for the emulsion method because 
of the use of organic solvent or oil phase. Cell encapsulation can be effectively 
fabricated by microtechnologies, including microfluidics and micromolding methods 
[110]. 
 
1.4.3.3 Nutrient and oxygen transport 
While the pores in the microcapsules are small enough to keep out immune 
cells, and to prevent the cells from exiting, they should be large enough to allow 
sufficient transport of nutrients, oxygen, and therapeutic agents. In addition to 
shortening the diffusion path, increasing the porosity is a route to promoting transport. 
One of the big challenges is to supply sufficient oxygen to maintain the 
viability and function of the encapsulated cells [123]. The oxygen transport may be 
enhanced by (i) Using a smaller device or microcapsules to reduce diffusion distance; 
(ii) Using organic compounds with high oxygen solubility (such as perfluorocarbons, 
silicone oils, soybean oils) with the microcapsules or in the device, thus increasing the 
permeability of oxygen; (iii) Induction of neovascularization adjacent to the 
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microcapsules or use of a pre-vascularized support (Figure 1-16B) to bring blood flow 
close to the tissue; (iv) Provision of exogenous oxygen (gaseous oxygen supply, in situ 
oxygen generation) to increase partial pressure of oxygen adjacent to the tissue [123]. 
 
1.4.4 Applications of cell encapsulation 
Cell encapsulation has been used for cell delivery, which can also be combined 
with drug delivery [111,124]. There have been enormous research activities in 
encapsulating pancreatic islet cells to treat diabetes [116, 120, 122] and also other 
diseases such as cancer [111, 115], brain [125], kidney [126]. More examples are given 
in Table 1-5. It is clear that different cell types are encapsulated for a wide range of 
biomedical applications, with alginate being the mostly used polymer. More details can 
be obtained from Ref 112 and the references therein. 
 
Table 1-5. Different cell sources used for cell encapsulation (adapted from ref 112). 
Cell	type	 Application	 Material	
Fibroblasts		 Metabolic	deficiencies,	epilepsy		 Alginate,	HEMA-MMA	
Myoblasts	 Metabolic	deficiencies,	cancer	 Alginate,	HEMA-MMA	
Pancreatic	islets	 Diabetes	 AN69,	Cellulose	sulfate	
Ovary	cells	 Fabry	disease	 Alginate,	HEMA-MMA	
Parathyroid	cells	 Artificial	organs	 Alginate	
Hepatocytes	 Liver	transplantation	 Alginate,	HEMA-MMA	
Chondrocytes	 Bone	and	cartilage	regeneration	 Alginate	
Leydig	cells	 Hormone	replacement	 Alginate	
Adrenal	chromaffin	
cells	
Parkinson’s	disease,	chronic	pain	 Alginate	
Stem	cells	 Bone	regeneration	 Alginate	
Myeloma	cells	 Hepatic	growth	factor	 Alginate	
Hybridoma	cells	 Antibody	production	 Alginate,	acetate,	alginate-
agarose	
Tumor	cells	 Cancer	vaccine,	interleukins	 Alginate,	chitosan	
Virus	producer	cells	 Cancer		 Cellulose	sulfate	
Bacteria	 Elimination	of	urea	 Alginate	
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The use of cell encapsulation for delivery of therapeutic agents has two 
advantages: (i) the immunoisolating microcapsules make it unnecessary to take 
immunosuppressant drugs and (ii) long-term delivery depending on the types of cells 
used (Figure 1-18) [124]. 
 
Figure 1-18. Represented timescale of drug delivery and cell delivery via cell 
encapsulation. Reprinted from Ref 124. 
 
The selection of suitable cells for encapsulation is essential for biomedical 
applications. Many cell types have been used, some of which are given in Table 1-5. 
The proliferation behaviour of the cells should be considered, as with continued 
proliferation, the cells may eventually fill the capsular space, which may hinder 
diffusion of the therapeutic agents. For cells that do not proliferate, it can be an 
advantage for long-term delivery [112]. 
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MSCs have been mostly used for encapsulation approaches in in regenerative 
medicine applications [111, 116, 127]. Examples include implanting encapsulated 
MSCs to accelerate bone regeneration or induce vascularization [124].  
As such, the degradation of the capsule hydrogel with a suitable rate is a critical 
factor. The rate of degradation is determined by polymer type, molecular weight, pH, 
temperature, ionic strength, and presence of other molecules in aqueous medium. For 
some applications, where the therapeutic effects are mediated by paracrine factors, it 
would be desirable for the hydrogel to remain intact until after the implanted cells have 
died, as this would prevent the cells migrating to off-target sites. For other applications, 
where the aim is for the implanted cells to integrate into the diseased tissue, then it 
would be desirable for the hydrogel to degrade while the cells are still viable.  Thus, 
monitoring the integrity of the hydrogels in vivo using non-invasive imaging 
approaches can provide key information on their effectiveness for specific applications. 
For PAI/MSOT imaging, this can be achieved by functionalizing the hydrogels with 
fluorescent groups [126], encapsulating NIR dye particles [72] and/or more advanced 
PDI nanoparticles that are to be developed in this project. 
The understanding of the fate of the cells and the change of the 
capsules/hydrogels and the surrounding microenvironment in vivo after implanting 
with robust data is crucial for developing enhanced therapeutic methods based on cell 
encapsulation.  
 
1.5 Chitosan hydrogels 
As mentioned in section 1.4, there are many types of polymers or composites 
that are used to form hydrogels. For biomedical applications, the basic requirements 
include biocompatibility, biodegradability, mild processing conditions, and the ease for 
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further modification. Chitosan hydrogels can meet all these requirements and uniquely 
exhibit positive charges, which may facilitate strong interactions with cells and/or high 
uptake by cells. Chitosan is the only cationic natural polymer and has been extensively 
used as scaffolds for tissue engineering [129, 130], cell culturing [131], and drug 
delivery [132, 133]. Chitosan is the deacetylation product of chitin (Figure 1-19). 
Chitin is a natural polysaccharide, poly (β-(1→4)-N-acetyl-D-glucosamine) and is the 
second most abundant polymer after cellulose [134]. The common source of chitin has 
been crab and shrimp shells. There are two forms of chitin, α-chitin and β-chitin. α-
chitin is the most common one. It is difficult to dissolve chitin in conventional solvents, 
which limits its applications. Chitin can be deacetylated under heating in concentrated 
NaOH to produce chitosan [135]. Chitosan is usually present as a copolymer, defined 
by the degree of acetylation or degree of deacetylation. When the degree of 
deacetylation is greater than 50 %, it is called ‘chitosan’ and can be soluble in acidic 
water. The structure of chitosan (considering it is 100 % deacetylated) is very similar to 
cellulose, with –NH2 group replacing one of the –OH groups on cellulose. The 
presence of the –NH2 groups on chitosan is significant. It can be protonated to be 
soluble in water, provide positive charges, and offer facile chemical modifications 
[134]. One of the most common ways to modify chitosan is by carboxylation at the –O 
or –N position [134]. Carboxymethyl chitosan is soluble in neutral water and has found 
unique applications in drug delivery and tissue engineering [136]. There are also other 
chemical modifications [134], for example, amino acid-modified chitosan for 
biomedical applications [137]. Chitosan can also be blended with other polymers for 
hybrid hydrogels, e.g., chitosan-alginate hydrogel for tumour treatment [138], collagen-
chitosan for endothelial differentiation and angiogenesis [139]. 
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Figure 1-19. Molecular structures of (A) chitin and (B) chitosan. 
Chitosan hydrogels can be formed by chemical crosslinking, physical 
crosslinking, or electrostatic interaction [140]. Due to the positive charge of chitosan in 
solution, multivalent cations or negatively charged polymers (e.g., certain proteins, 
nucleic acids) are employed to form hydrogels via ionic interaction. Another way to 
produce physically crosslinked hydrogels is by adding base into the chitosan solution. 
The increase of pH leads to deprotonation of chitosan chains, reduced solubility, and 
assembled gels by H bonding, hydrophobic interaction, and Van der Waals forces. This 
can be simply achieved by adding NaOH or Na2CO3. These hydrogels are more 
heterogeneous due to the dramatic local pH change. The hydrogels for cell culturing 
are usually produced by crosslinking chitosan with calcium phosphate [131], 
triphosphate [141], and β-glycerol phosphate [142-144]. Chitosan is often chemically 
crosslinked with glutaraldehyde [134, 145]. However, due to its toxicity, 
glutaraldehyde is usually replaced with biocompatible crosslinkers such as heparin 
[146] and genipin [147]. Chitosan hydrogels may be prepared as bulky gels (by simple 
gelation of chitosan solution), injectable gels [142-144], microparticles [148], 
nanoparticles [135, 148-149], and nanofibers [150]. Chitosan hydrogels are not often 
A	 B	
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used for cell encapsulation as alginate hydrogels [112]. This may be partly due to the 
relatively harsh conditions used for forming chitosan hydrogels. However, with the 
recent development in forming thermosensitive chitosan gels at body temperature [141-
144], there is a good opportunity to use chitosan hydrogels for cell encapsulation, as 
will be investigated in this project. 
Because of the biocompatibility, biodegradability, the unique positive charge, 
and various mild fabrication methods available, this project will aim to develop or 
optimize procedures to prepare chitosan hydrogels, particularly injectable 
thermosetting chitosan hydrogels to encapsulate cells and the PDI nanoparticles. 
 
1.6 Project Aims 
The main aim of this PhD study is to develop novel NIR probes for cell 
labelling and for hydrogel functionalization that will enable the biodistribution of 
administered cells and the integrity of cell-encapsulating hydrogels to be monitored 
non-invasively in vivo using MSOT. 
 In Chapter 2, a hydrophobic PDI compound with NIR absorption (wavelength > 
650 nm) will be synthesized and characterized by NMR and UV-vis spectroscopy. 
Because of very poor solubility of PDI in water, aqueous PDI nanoparticle suspensions 
will be prepared for potential biomedical applications. PDI nanoparticles with polymer 
stabilizers of low cytotoxicity will be fabricated by nanoprecipitation or emulsion 
freeze-drying. In order to investigate the potential for MSOT, the NIR absorbance of 
aqueous PDI nanoparticles will be confirmed by UV-Vis spectroscopy. The PDI 
nanoparticles will be characterized by DLS and SEM. 
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In Chapter 3, the PDI nanoparticles will be used to label MSCs for 
fluorescence imaging and MSOT. In order to achieve these targets, cytotoxicity and 
NIR signals for imaging will be initially evaluated by flow cytometry, UV-Vis, and 
confocal laser scanning microscopy. Furthermore, the PDI-labelled mouse MSCs will 
be injected into mice for in vivo imaging. Fluorescence imaging will be used to 
confirm the injection of PDI-labelled MSCs while bioluminescence imaging will be 
used to confirm cell viability. Most importantly, in vivo imaging of the PDI-labelled 
MSCs in mice will be performed by MSOT longitudinally (e.g., over 1 – 2 weeks), thus 
to confirm PDI nanoparticles as efficient NIR probes for MSOT imaging. Finally, any 
effect of the PDI nanoparticles on MSC differentiation will be investigated by 
assessing their ability to differentiate to bone and cartilage cells following in vivo 
transplantation. 
In Chapter 4, in order to monitor the status of hydrogel scaffolds by MSOT, 
the potential of using PDI nanoparticles to functionalize cell-encapsulating hydrogels 
will be investigated. To this end, an injectable thermosetting chitosan hydrogel system 
will first be developed. PDI nanoparticles will then be used to functionalize the 
hydrogels by suspending them in the chitosan solution at room temperature. The 
behaviour of mouse MSCs in the functionalized hydrogels will be monitored using live 
cell imaging, and the imaging properties of the hydrogel will be assessed using UV-Vis 
and MSOT. 
 In Chapter 5, a summary of conclusions for the whole project is included, with 
perspective for the future development of this project. 
 In addition to the main results chapters, I have also included one manuscript in 
appendix. This manuscript is not directly linked to the main project aims of in vivo cell 
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imaging, but nevertheless, describe some interesting materials chemistry and some of 
associated applications. 
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Chapter 2 Synthesis of perylene diimide derivative with NIR 
absorption and its aqueous nanoparticle suspensions 
 
2.1 Introduction 
Perylene-based dyes are widely used in the dye industry [1]. Perylene is poorly 
soluble in most common solvents and therefore, modified perylene-based compounds 
are required for processing and formulation. One of the most widely used types are 
perylene diimide (PDI) compounds (see Figure 1-12 in chapter 1). The modification of 
PDIs usually starts with the halogenated compound, which typically utilize 
perylenetetracarboxylic dianhydride (PTCDA) as the starting material. Conventionally, 
PTCDA is treated in concentrated sulphuric acid or chlorosulfonic acid in the presence 
of I2 or Br2 [2]. Not only is the reaction condition harsh and demanding, a mixture of 
halogenated isomers is formed without purification. The synthesis of brominated 
PTCDA is improved without the use of concentrated acid and the isomers are separated 
by extraction and running through a silica column [3]. 
 Halogenated PDIs can be used to synthesize various diimides with functional 
groups at the bay position. While the groups at the imide positions can significantly 
change the solubility in water or organic solvent, the modification at the bay positions 
can considerably vary the UV-vis absorption [1,4]. For example, by adding pyrrolidine 
to the bay position, the maximum absorption wavelength is changed from 531 nm to 
704 nm in dichloromethane [2].  
 The core of PDI is a planar π-conjugated system, prone to forming crystal 
aggregates or nanofibers via π-π interaction and hydrophobic interaction. When 
introducing naphthalene units into the perylene core, higher perylene diimmides are 
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formed with significant shift of light absorption in the NIR region. Approximately, a 
shift of 100 nm towards the higher NIR wavelength region can be achieved [5]. These 
dyes cover the light-absorbing region of visible 400 – 760 nm and NIR 760 – 1300 nm. 
Quite importantly, these dyes usually exhibit fluorescence with high quantum yields. 
They also show excellent thermal, chemical, and photochemical stabilities [5]. 
Therefore, PDIs could be useful for in vivo bioimaging applications involving both 
NIR fluorescence and photoacoustics if their maximum absorbance was above 650nm, 
 Because of the conjugated aromatic core of the PDIs, they usually dissolve in 
organic solvent although it is possible to modify the PDIs at the immide position to 
make them water-soluble. However, even in the latter case, the PDIs are only soluble in 
basic water instead of neutral water [6]. Therefore, it is essential to fabricate aqueous 
nanoparticle suspensions for biomedical applications, e.g., as probes for NIR imaging. 
 In general, organic nanoparticles can be fabricated by top-down or bottom-up 
approaches [7]. The top-down approaches mainly include milling and high-pressure 
homogenization. However, these methods always produce sub-micron particles (or 
larger nanoparticles, e.g., > 500 nm) that have a tendency to aggregate. This is not 
suitable for biomedical applications such as bioimaging where the nanoparticles are 
usually required to be < 200 nm [7,8]. Among various bottom-up approaches, where 
the organic compound is dissolved in an organic solvent and then processed, the 
nanoprecipitation is most widely used because it is simple and versatile [7]. Another 
bottom-up method developed by Zhang et al [9], emulsion freeze-drying, can produce 
dry porous nanocomposites with hydrophilic polymer, which offers high nanoparticle 
stability and facile storage and transport. The aqueous nanoparticle suspensions can be 
instantly formed by simply dissolving the porous nanocomposite in water. 
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 In this chapter, surfactants and polymers to stabilize PDI nanoparticles and that 
are not cytotoxic will be identified for subsequent cell imaging applications. In addition 
to commercially available surfactants/polymers, a new type of block copolymer  
DEAMA50DEGDMA2OEGMA80 developed by the Zhang group will also be examined. 
This block copolymer has been shown to stabilize emulsions and hydrophobic drug 
nanoparticles [10]. 
 
Objectives 
1. Synthesize  PDI nanoparticles in organic solvents with NIR absorbance  
wavelength > 650 nm  
2. Prepare aqueous PDI nanoparticle suspensions using a nanoprecipitation and 
emulsion freeze-drying approach that maintains the NIR absorbance > 650 nm  
 
2.2 Experimental Details 
2.2.1 Chemicals and reagents 
Perylenetetracarboxylic dianhydride (PTCDA, 97%) was purchased from Alfa 
Aesar.  Bromobutane, bromine, acetonitrile (ACN), and p-toluenesulfonic acid 
monohydrate (p-TsOH.H2O) were obtained from Acros Organics.  Butanol and 
magnesium sulfate were bought from BDH laboratory supplies.  1,8-
Diazobicyclo[5.4.0]undec-7-ene (DBU), potassium carbonate, hexane, sodium 
bisulfate, cyclohexamine, acetic acid, N-methyl-2-pyrrolidinone, poly(vinyl alcohol) 
(Mw 9-10K, 80% hydrolysed), cyclohexane, D-α-Tocopherol polyethylene glycol 1000 
succinate (TPEG) were purchased from Sigma Aldrich.  Dichloromethane (DCM), 
methanol, sodium bisulfate, toluene and pyrrolidine were purchased from Fisher.  All 
chemicals were used as received. A hyperbranched block copolymer 
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DEAMA50DEGDMA2OEGMA80 was synthesized and provided by Miss Ulrike Wais 
(H. Zhang laboratory, Dept of Chemistry, University of Liverpool). 
 
2.2.2 Synthesis of brominated PTCDA (compound 4 in Scheme 2-1) 
The synthesis followed a previously reported method with modifications [3]. 
PTCDA (4.0 g), bromobutane (20.0 g), butanol (13.0 g), DBU (15.0 g) and ACN (160 
ml) were placed in a 500 ml round bottomed flask.  The content in the flask was 
refluxed at 100ºC (heated in an oil bath) and left overnight (~ 18 hours).  The red 
suspension turned orange during the reaction. After cooling down the reaction to room 
temperature, methanol (200ml) was added.  The resulting precipitate was filtered and 
dried in a vacuum oven. The crude was purified from boiling butanol to produce 
compound 2 (4.42 g). 
 Compound 2 (perylene tetrabutyl ester, 4.0 g) and potassium carbonate (2.0 g) 
in dichloromethane (50 ml) was added to a 100 ml round bottomed flask to give an 
orange-red solution.  Bromine (4 ml) was added slowly dropwise to the reaction 
mixture,   turning the solution a dark purple colour.  After stirring for 24 h, a saturated 
aqueous solution of sodium bisulfate was added dropwise with continued stirring until 
no more gas was released. The mixture separated into two layers: the organic layer at 
the top and the aqueous layer at the bottom. The aqueous layer was decanted and the 
final solution was washed three times using distilled water, and dried over magnesium 
sulfate. The aqueous layer was washed with dichloromethane, in order to obtain more 
product.  The solvent was removed by rotary evaporation under reduced pressure.  This 
crude product was recrystallised using dichloromethane (48 ml) and acetonitrile 
(400ml) and left for 3 days.  The orange crystals (3.004 g) obtained by filtration were 
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compound 3. A small amount of additional product was obtained from the filtrates, 
which was believed to be compound 3a but not used in the following procedures. 
 Compound 3 (3.0 g), p-toluene sulfonic acid monohydrate (3.6 g), and toluene 
(105 ml) were added into a 250 mL round bottom flask. The contents were heated to 
100ºC while stirring for 30 h.  The reaction was stopped by cooling to room 
temperature. The precipitate was filtered and washed with methanol and water.  The 
dried dark red solid was refluxed in chloroform (150ml) at 77ºC for 3 h and then 
collected by filtration as a dry product that was compound 4 (1.35g).  
 
2.2.3 Synthesis of perylene diimide derivative (PDI) with NIR absorbance 
(compound 6 in Scheme 2-2). 
The preparation followed a method reported before with modifications [2]. 
Typically, the compound 4 (brominated PTCDA, 0.95 g), cyclohexamine (0.58ml), 
acetic acid (0.477ml), and N-methyl-2-pyrrolidinone (20ml) were added into a 50 mL 
round bottom flask. The contents were stirred at 85ºC under N2 atmosphere for 6 h in 
an oil bath.  After cooling the reaction to room temperature, the precipitate was filtered 
and washed with methanol. The dark purple precipitate turned light red when washed.  
Compound 5 was obtained after drying using a vacuum oven (0.60 g). 
Compound 5 (0.1 g) was dissolved into pyrrolidine (4.5g) and stirred under 
Argon for 48 h at 70ºC. The reaction mixture was then poured into 25ml diluted 10% 
HCl solution with stirring. A liquid extraction process was then performed 3 times with 
dichloromethane. The hydrophobic compound in dichloromethane was dried over 
MgSO4 and then filtered.  The dry dark green solid (0.045 g) was obtained after 
evaporating dichloromethane. This product was the PDI compound with NIR 
absorbance, compound 6.  
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2.2.4 Preparation of aqueous PDI nanoparticle dispersions by solvent evaporation 
A PDI solution in acetone was prepared by dissolving 10mg PDI in 10 ml 
acetone. Aqueous PVA solution was formed by dissolving 100mg PVA in 10 ml water. 
2 mL PDI solution was added into the PVA solution (8 ml) dropwise while stirring 
with a magnetic bar at the speed of 800 rpm. The resulting solution was kept stirring 
overnight in a fume cupboard to allow the full evaporation of acetone. This produced a 
clear and dark green nanoparticle suspension, with a concentration of 0.25mg/ml. 
In the above preparation, PVA was used as a stabilizer to form stable 
nanoparticle dispersions. TPEG/PVA (0.1 wt%/1 wt% aqueous solution) and PVA-
DEAE-Dextran (both are 1 wt% aqueous solution) were also employed to prepare PDI 
nanoparticle suspensions, following the same procedures as described above. 
A slightly different method was used to prepare a PDI nanoparticle suspension 
when the block copolymer DEAMA50DEGDMA2OEGMA80 was used as stabiliser. A 
PDI solution in acetone was prepared by dissolving 10mg PDI in 10 ml acetone. The 
block copolymer DEAMA50DEGDMA2OEGMA80 solution in acetone was prepared by 
dissolving 20 mg block copolymer DEAMA50DEGDMA2OEGMA80 in 10 ml acetone. 
These two stock solutions were used to prepare the mixing solutions with the ratios of 
PDI: DEAMA50DEGDMA2OEGMA80 being 1:1, 1:2, and 2:1. The detailed preparation 
procedures are described here. (I) for the ratio of 1:1: 2 ml PDI solution, 1 ml 
DEAMA50DEGDMA2OEGMA80 solution and 1 ml acetone were mixed to obtain a 
solution with the concentrations of PDI and DEAMA50DEGDMA2OEGMA80 both at 
0.5 mg/ml. (II) for the ratio of 1:2: 2 ml PDI solution and 2 ml 
DEAMA50DEGDMA2OEGMA80 solution to make 0.5mg/ml for PDI and 1mg/ml for 
DEAMA50DEGDMA2OEGMA80 mixture solution. (III) for the ratio of 2:1: 2 ml PDI 
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solution, 0.5 ml DEAMA50DEGDMA2OEGMA80 solution and 1.5 ml acetone to make 
0.5mg/ml for PDI and 0.25mg/ml for DEAMA50DEGDMA2OEGMA80 mixture 
solution. In order to prepare the PDI nanoparticles, each of the solutions (2 ml) were 
slowly added dropwise into water (8 ml) while stirring with a magnetic bar at a speed 
of 800 rpm. The resulting solution was kept stirring overnight in a fume cupboard to 
allow the acetone to evaporate. This produced a clear dark green nanoparticle 
suspension.  
 
2.2.5 Preparation of aqueous PDI nanoparticle dispersions by emulsion-freeze-
drying  
The emulsion-freeze-drying approach is highly effective for the preparation of 
aqueous organic nanoparticle suspensions, firstly reported by Zhang et al. [9]. A 
saturated PDI solution in cyclohexane (0.5mg/mL) was first prepared at room 
temperature. The PDI-cyclohexane solution (6 mL) was then emulsified into 2 mL of 
aqueous solution containing 1 wt% PVA (or 1 wt% TPEG or 1 wt% PVA and 1 wt% 
TPEG), by dropwise addition with mechanical stirring. After stirring for 5 minutes, the 
raw emulsion was homogenized for 2 minutes at the scale of 5 using a Fisher brand 
homogenizer (FB Gen 1200). The finer emulsion was immediately frozen by 
immersing in liquid nitrogen. The frozen emulsion was then placed in a freeze dryer 
(Cool Safe, 100-9 Pro, Labogene) for 48 hours to remove both water and cyclohexane 
by sublimation. The freeze-dried samples were stored in a desiccator before use. To 
form aqueous PDI nanoparticle dispersions with the desired concentrations, the 
controlled amount of freeze-dried sample could be readily dissolved in water within 
one minute. 
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2.2.6 Characterizations 
The synthesized compounds were analysed using the Bruker Fourier 300HD for 
1H NMR and 13C NMR. The elemental analysis was conducted using the Thermo flash 
EA 112 series. The NMR analysis and elemental analysis were used to assess the purity 
of the synthesized compounds. The UV-Vis profiles for aqueous suspensions were 
obtained using the µ-Quant Microplate Reader. The suspensions were filtered using a 
0.22 µm syringe filter before the UV-vis analysis. For the PDI organic solutions, a 
conventional quartz cuvette was used for analysis on the UV instrument in the central 
teaching lab (CTL) of the University of Liverpool. 
The size of the PDI nanoparticles in aqueous suspensions was measured by the 
Dynamic Laser Scattering (DLS) method at 25ºC using a Malvern ZetaSizer equipped 
with a zeta potential detector. The scattering intensity signal for the detector was 
passed through a correlator where the data was analysed by the software to give a size 
distribution of the hydrated nanoparticles. An attempt was also made to observe the 
PDI nanoparticles using a Hitachi S-4800 field emission scanning electron microscope 
(SEM) at 3.0 kV. A drop of the aqueous suspension was deposited on a SEM stud or 
carbon film grid and the water was evaporated overnight in a fume cupboard before 
imaging.  
 
2.3 Results and discussion 
2.3.1 Synthesis of PDI nanoparticles with NIR absorbance 
The synthesis started from PTCDA, which is an industrial dye. PTCDA is 
highly hydrophobic and shows low solubility in most of the common solvents. It is also 
a highly inert compound. In order to increase the absorbance wavelength into the NIR 
region, halogenated PTCDA was modified at the bay position [2,4,5]. Halogenation at 
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the bay positions (usually with Br2 or Cl2) is usually performed in concentrated 
sulphuric acid at elevated temperatures [2]. Despite the harsh reaction conditions, the 
reactions produce a mixture of 1, 7-dihalogenated and 1, 6-dihalogenated perylene-
based compounds, as confirmed by NMR analysis. The procedures for the separation of 
these isomers are time-consuming and not suitable for large-scale synthesis. Therefore, 
a method recently developed by Jager and co-authors with mild conditions and 
regioisomerically pure brominated PTCDA was used, as detailed in Scheme 2-1 [3]. 
 
 
Scheme 2-1. Synthesis of brominated perylene-3,4,9,10-tetracarboxylic dianhydride 
(PTCDA). This synthesis method was adopted from ref 3. 
 
Compound 2, tetrabutyl perylene-3,4,9,10-tetracarboxylate, was formed by an 
esterification reaction with DBU as catalyst. The crude product was purified from 
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boiling butanol.   Figure 2-1 shows the 1H NMR spectrum of compound 2.  The clean 
spectrum indicates the compound has high purity. The doublets at 8.25ppm and 8.05 
ppm are for the hydrogens directly bonded to the perylene core.  The spectrum suggests 
two aromatic hydrogen environments: the hydrogens at the bay positions and at the 
other positions. The peak at 7.26 ppm is ascribed to the residual solvent peak of CDCl3.  
The peak at 1.55 ppm is due to the presence of trace amounts of water in CDCl3 when 
it is used and stored for a long time.  The triplet at 4.35 ppm is due to the O-CH2- being 
coupled to the neighbouring CH2 group, and it has an integration of 8H.  The multiplets 
at 1.80 ppm and 1.60 ppm are the CH2 groups in the middle of the butyl chain. This is 
supported by the integration of 8H. The multiple peaks at 1.80 ppm are for the CH2 
group closer to the oxygen.  This is because of the oxygen drawing electron density 
away via an inductive effect, causing the chemical shift to be further downfield 
chemical shift as shown.  The triplet peaks around 1.0 ppm are for the terminal methyl 
group, coupling to the neighbouring –CH2 group, with integration of 12H. The element 
analysis of compound 2 gave 73.34 % C and 6.72 % H, very close to the theoretically 
calculated values (73.6% C and 6.8% H).  Compounds 1 and 2 can be distinguished by 
the presence of the chemical shifts from the butyl chains. 
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      Figure 2-1. The 1H NMR spectrum of compound 2 as described in Scheme 2-1. 
 
In the synthesis of compound 3, a high yield was observed, including both 
isomers. After recrystallization to separate the isomers (see experimental details), a 
high percentage of compound 3 was obtained (~ 75 wt%, with the rest being compound 
3a). The 1H NMR for compound 3 is given in Figure 2-2.  Again, the clean spectrum 
indicates a highly pure compound. Due to the bromination, three aromatic hydrogen 
environments are observed.  The singlet peak at 8.30 ppm is assigned to the hydrogen 
between -Br and the ester group because it is not coupled to any other hydrogens.  The 
integration of 2H for this peak is obtained because there are two such hydrogens in the 
molecule. The doublets at 8.98 ppm and 8.10 ppm are for the other aromatic hydrogens 
with the peaks at 8.10 ppm being the hydrogens in bay positions.  As expected, the 
peaks for the butyl chains are still observed.  
 
 
         Figure 2-2. The 1H NMR spectrum of compound 3 as described in Scheme 2-1. 
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Compound 4 was prepared from compound 3 at a temperature of 100ºC in a 
good solvent of toluene containing p-TsOH.H2O. This was to prevent the precipitation 
of monoanhydride product from the solution.  The reaction occurs via the initial 
insertion of the p-TsOH into the carbonyl, resulting in the release of butanol.  The 
neighbouring ester adds into the carbonyl, which causes TsO- to eliminate, facilitating 
the removal of the butyl group on the linking oxygen atom.  The elemental analysis of 
compound 4 showed 52.17% C and 1.96% H, close to the calculated values of 52.3 % 
C but higher than the calculated H content of 1.1 %.  Figure 2-3 shows the 1H NMR 
spectrum of compound 4 in DMSO.  The peak intensities are relatively weak. This is 
due to the poor solubility of compound 4 in CDCl3. Even with the use of DMSO, the 
solution was prepared by warming the contents in a NMR tube with hot water. Some of 
the compound 4 precipitated during the NMR analysis. Deuterated sulfuric acid was 
used previously as the solvent for NMR analysis [3], but was not used in this project 
due to safety concerns in handling concentrated acids.  
 
 
         Figure 2-3. The 1H NMR spectrum of compound 4 as described in Scheme 2-1. 
 
From the NMR spectrum in Figure 2-3, the chemical shifts from the aromatic 
hydrogens on the perylene core are shifted further downfield than in  compound 3 due 
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to the larger electron withdrawing nature of the anhydride groups.  The multiplets at 
7.5 ppm and 7.1 ppm, and the singlet at 2.3 ppm are likely caused by the presence of 
toluene which was not removed entirely in the drying process [11].  The singlet at 3.6 
ppm and multiplet at 2.5 ppm are unknown impurities, which could be other residual 
solvent or reactants. 
Brominated PTCDA can be used as the starting reagent for the synthesis of a 
range of perylene diimide derivatives. We adopted a procedure in ref 2 for the 
synthesis of PDI with NIR absorbance. As shown in Scheme 2-2, cyclohexamine was 
used as the nucleophile to form the amide bonds, catalysed by acetic acid. This step is 
necessary to protect the anhydride group in the next-step synthesis.     
 
 
Scheme 2-2. Synthesis of perylene diimide derivatives with NIR absorbance from 
brominated PTCDA. This synthesis method was adapted from ref 2. 
 
The 1H NMR for compound 5 is given in Figure 2-4. As expected, there is no 
change of proton peaks in the aromatic region, because of the reaction occurring at the 
end groups (or the peri position).  The peaks that demonstrate the formation of 
compound 5 are the multiplet at around 5.0 ppm from the cyclohexamine ring.  The 
peak at 2.6 ppm is the downward facing axial hydrogens, which is supported by the 
integration of 4H.  The remaining alkyl hydrogens on the cylcohexamine rings occur 
between 1.25 ppm and 2.0 ppm.  The solvent used for this analysis was CDCl3.   
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Figure 2-4. The 1H NMR spectrum of compound 5 as described in Scheme 2-2. 
 
The final step of the synthesis is the nucleophilic substitution of the bromines in 
the bay positions with pyrrolidine (Scheme 2.2). Figure 2-5 shows the 1H NMR of 
compound 6. Compared to the previous compounds, the broad peaks at 3.8 ppm and 
2.8 ppm are caused by the two differing hydrogen environments on the pyrrolidine 
rings, showing the formation of compounds. However, there are some small peaks on 
the spectrum. Together with the discrepancy of the elemental analysis data between the 
measured and calculated values, it can be confirmed that there are some impurities, 
even after the recrystallization procedure. 
 
 
        Figure 2-5. The 1H NMR spectrum of compound 6 as described in Scheme 2-2. 
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Because the objective was to synthesize a PDI compound with NIR absorbance, 
it was therefore critical to examine the PDI solutions by UV-vis spectroscopy. The as-
synthesized compound was dried in a vacuum oven at 60ºC overnight. It was then 
dissolved in different organic solvents. Figure 2-6 shows the UV-vis profiles of the 
PDI solution in cyclohexane, acetone, and dichloromethane. The shapes of the profiles 
were similar for all solvents, but peak shifts were observed for different solvents. This 
can be attributed to the different interaction between the solvent and PDI. This also 
results in different absorbance coefficients, indicating different absorbance intensity 
with the same concentration. The strongest absorbance peaks of these solutions fall in 
the NIR region, with the wavelength being 670 nm for cyclohexane, 696 nm for 
acetone, and 715 nm for dichloromethane (DCM). This shows the PDI compound 
synthesized has the potential for NIR imaging. 
 
 
Figure 2-6. The UV-vis profiles of PDI solution in different solvents (acetone, 
cyclohexane, and dichloromethane (DCM)). The concentration is 0.05 mg/ml for all 
solutions. 
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2.3.2 Aqueous PDI nanoparticle suspensions 
 
Aqueous PDI nanoparticles via nanoprecipitation 
The PDI compound (always referring to compound 6 in this chapter) was 
hydrophobic and hence insoluble in water. Thus, despite its NIR absorbance, the PDI 
compound could not be used directly for bioimaging. Although some commercial dye 
particles have been directly used for photoacoustic imaging [12], due to the poor 
control of particle size, aqueous organic nanoparticles have often been used. The 
organic nanoparticles in water are either formed by self-assembly [13] or 
nanoprecipitation via solvent evaporation [14]. In this study, both the nanoprecipitation 
and the emulsion-freeze-drying method were used to produce PDI nanoparticles 
suspended in water. The latter method was developed in our group and has since been 
used for the preparation of poorly water-soluble drug nanoparticles [10]. 
For the nanoprecipitation preparation, 1 mg/ml PDI solution in acetone was 
added dropwise into aqueous PVA solution with a concentration of 1 wt % while 
stirring. These concentrations were selected based on previous studies [9, 14] with an 
aim to form stable nanoparticle suspensions with the higher ratio of PDI:stabilizer. 
After addition, the mixing solution was kept stirring at 500 rpm overnight to remove 
acetone. For the method to work, the organic solution must be miscible with the 
aqueous solution. Organic solutions from acetone, methanol, and tetrahydrofuran 
(THF) are usually employed. This study chose to use acetone because of the good 
solubility of PDI in acetone. During stirring and gradual evaporation of acetone, more 
PDI molecules are exposed to water and tend to aggregate. PVA then acts to stabilize 
the PDI nanoparticles and prevents aggregation. After the solvent evaporation process, 
	 83	
a clear dark green nanoparticle suspension was formed. A typical UV-Vis profile of the 
nanosuspension prepared by solvent evaporation is given in Figure 2-7. The 
absorbance peaks are clearly in the NIR region with a high wavelength peak around 
700 nm, similar to the profile obtained from the PDI-acetone solution. Indeed, there is 
strong absorbance in the range of 640 – 700 nm.  
 
 
Figure 2-7. The UV-Vis profiles of aqueous PDI nanoparticle suspensions prepared by 
solvent evaporation using PVA and DEAMA50DEGDMA2OEGMA80 as stabilizers. 
The concentration of the PDI was 0.17 mg/mL for all the suspensions. 
 
The size of the PDI nanoparticles in the suspension with PVA stabilizer was 
determined by DLS analysis. Figure 2-8a shows the DLS graphs of the suspensions. A 
peak is seen around 100 nm with the particle sizes in the range of 50 – 200 nm. The 
zeta potential, depicting the charges on the surface of the nanoparticles, was measured 
to be 0 mV, as indicated by the peak position in Figure 2-8b.  
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Figure 2-8. (a) The DLS graph of aqueous PDI nanosuspensions prepared by solvent 
evaporation with PVA as stabilizer; (b) the relevant zeta potential graph. 
 
To compare the difference between PDI nanoparticles prepared using the 
nanoprecipitation and emulsion-freeze-drying methods, the nanoprecipitation 
experiments were also carried out by dropwise addition of PDI solution into aqueous 
TPEG (0.1 wt%) solution. Clear nanoparticle suspensions were produced. However, 
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the nanoparticles prepared in the presence of TPEG were found to be toxic to the 
MSCs. For this reason, a hyperbranched block copolymer  
DEAMA50DEGDMA2OEGMA80 was tried. This type of block copolymer has 
been used to stabilize hydrophobic drug nanoparticles and has not been found to be 
cytotoxic to cells [10]. Figure 2-9 gives the structure of 
DEAMA50DEGDMA2OEGMA80. The hydrophobic DEAMA core is surrounded by 
hydrophilic OEGMA arms. The block copolymer is pH-sensitive due to the 
protonation/deprotonation at the amine groups under different pHs. However, in this 
study, we only utilized its amphiphilic nature as stabilizer to form PDI nanoparticles. 
Figure 2-7 gives the UV-vis profile of the PDI prepared with 
DEAMA50DEGDMA2OEGMA80 as stabilizer at the mass ratio of 1:1. It has the same 
absorbance peaks as the PDI nanosuspension prepared with PVA as stabilizer.  
 
 
Figure 2-9. (a) The molecular structure of DEAMA50DEGDMA2OEGMA80. (b) The 
schematic representation of the core-shell nanoparticle formed by the block copolymer 
DEAMA50DEGDMA2OEGMA80. 
 
The PDI particle sizes in the nanosuspensions were measured using DLS. As 
shown in Figure 2-10a, the particle sizes are very similar for the suspensions with 
a b
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PDI:block copolymer ratios of 1:1 and 1:2, with the peak sizes at around 100 nm. The 
particle sizes are slightly smaller with the PDI:block copolymer ratio of 2:1. The size 
of DEAMA50DEGDMA2OEGMA80 nanoparticles is around 50 – 60 nm. At lower pH 
(e.g., pH = 5), the nanoparticles are protonated and more hydrophilic. At neutral pH 
and high pH, the surface of the nanoparticles is deprotonated and the nanoparticle may 
become smaller. However, the hydrophobicity change may lead to particle aggregation 
so that the measured particle sizes are not small. Figure 2-10b shows there are no 
charges at the nanoparticle surface. This is because the nanosuspensions were prepared 
from neutral water. 
 
 
Figure 2-10. Characterization of aqueous PDI nanoparticle suspension prepared with 
different concentrations of block copolymer DEAMA50DEGDMA2OEGMA80. (a) The 
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DLS graph shows the particle size distribution. (b) The zeta potential data measured for 
aqueous PDI nanosuspensions. 
 
Aqueous PDI nanoparticles via emulsion-freeze-drying 
The main advantage of the emulsion-freezing-drying is that a dry porous 
nanocomposite is prepared [9]. The organic nanoparticles are formed in situ within a 
porous material, presumably on the pore surface. Due to the highly interconnected 
porous structure, the porous nanocomposite can be dissolved in water and produce 
aqueous nanoparticle suspensions on demand [9]. An oil-in-water (O/W) emulsion, i.e., 
droplets of organic solution/solvent dispersed in the continuous aqueous water phase, is 
usually employed for this approach. Due to its miscibility with water, PDI-acetone 
solutions cannot be used for this preparation.  A cyclohexane solution was therefore 
used to form the O/W emulsion. This is because cyclohexane is highly volatile and has 
a high melting point (~ 4ºC), which facilitates the freeze-drying process. Cyclohexane 
is also known to have low residual toxicity [7]. However, cyclohexane is not an 
effective solvent to dissolve highly hydrophobic compounds. A saturated PDI solution 
(estimated to be 0.62 mg/mL from my experiment) was thus used to form the emulsion. 
PVA has been widely used as a surfactant or co-surfactant to stabilize emulsions or 
colloids, but PVA alone is usually difficult to form a stable emulsion. A conventional 
surfactant, for example, the anionic sodium dodecyl sulfate (SDS), is usually used 
together with PVA [9]. Because the intended application of the PDI nanoparticles is for 
in vitro and in vivo bio-imaging, it is essential to use a biocompatible and low toxic 
surfactant. TPEG has been selected as the surfactant in this study because it is a widely 
used surfactant for drug delivery [15]. 
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As described in the Experimental section, the emulsion was frozen in liquid 
nitrogen and then freeze-dried to produce a dry blue monolith. Figure 2-11A shows a 
photo of a blue freeze-dried monolith in a glass vial. The pore structure of the monolith 
and the in-situ formed PDI nanoparticles were examined by SEM, as shown in Figure 
2-11 B-D at different magnifications. The layered structure is formed from ice-
templating whilst the cellular (near spherical) pores are templated from the emulsion 
droplets [16]. The uniform blue colour indicates the presence of PDI nanoparticles in 
the monolith. And the PDI nanoparticles can also be clearly observed within the 
monolith by SEM.  
 
Figure 2-11 Photo (A) of freeze-dried PDI monolith and SEM images (B-D) of PDI 
nanoparticles with different magnification. Yellow circles indicate a lot of PDI 
nanoparticles together. Red arrows indicate the pore structures. 
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The dry porous PDI nanocomposites were stored in a desiccator before use. 
Upon dissolution in water, aqueous nanoparticle dispersions are instantly formed. 
Furthermore, the concentration of the PDI nanoparticles can be readily controlled by 
dissolving suitable amount of PDI nanocomposites in a certain amount of water while 
the ratio of PDI:stabilizer is unchanged.  
The UV-vis profiles in Figure 2-12 show the same absorbance peaks among the 
PDI nanosuspensions with different surfactants. It was noticed that the absorbance 
intensity of the PDI suspension with PVA as surfactant was much smaller than those 
containing TPEG as surfactant. PVA has been widely used as stabilizer but is not an 
efficient surfactant to form stable emulsions. The less stable emulsions can result in 
large droplets, translating into large PDI nanoparticles or aggregates. When filtered 
before the UV-vis analysis, larger PDI nanoparticles are filtered out, leading to lower 
concentrations and hence lower absorbance. The absorbance peaks of aqueous PDI 
nanosuspensions are similar to those of PDI solution in acetone. However, when 
comparing Figure 2-12, Figure 2-6, and Figure 2-7, the relative intensities of the 
absorbance peaks at 640 nm and 700 nm are changed – peak at 700 nm > peak at 640 
nm for PDI-acetone solution, peak at 700 nm ≈ peak at 640 nm for aqueous PDI 
suspension from solvent evaporation, peak at 700 nm < peak at 640 nm for aqueous 
PDI suspension prepared by emulsion freeze-drying. Although the exact reason is not 
clear, this may be attributed to the difference of PDI status (molecules vs 
nanoparticles), the morphology/phase of PDI nanoparticles, and the types of stabilizer 
and surfactant. 
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Figure 2-12. The UV-vis profiles of aqueous PDI nanoparticle by dissolving the 
freeze-dried materials in water, giving a raw concentration of 0.36 mg/mL PDI in the 
suspension. The suspensions were filtered before analysis using a 0.22 µm syringe 
filter. 
 
The sizes of the PDI nanoparticles were measured by the DLS method. Figure 
2-13 shows the size distribution of the PDI nanoparticles based on scattering intensity. 
The PDI nanoparticles were in the region of 30 nm (based on peak size) when TPEG 
was used as the surfactant. Larger particles were produced when PVA was used as the 
only surfactant or used together with TPEG. 
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Figure 2-13. The DLS profiles of aqueous PDI nanoparticle by dissolving the freeze-
dried materials in water, after filtering with a 0.22 µm syringe filter. 
 
2.4. Conclusions 
Starting from a commercially available and inexpensive perylene 
tetracarboxylic dianhydride, via a multiple-step synthesis, a perylene diimmide 
derivative (PDI) has been successfully synthesized. The PDI has been characterized by 
NMR and mainly evaluated by UV-vis to confirm the NIR absorbance. This PDI is 
hydrophobic and only soluble in organic solvents. In order to use PDI as probes for 
bioimaging, aqueous PDI nanoparticle suspensions have been produced by both 
nanoprecipitation and emulsion freeze-drying methods. PVA, TPEG, and the custom-
synthesized block copolymer DEAMA50DEGDMA2OEGMA80 have been used as 
stabilizers. Stable aqueous PDI nanoparticle suspensions were formed in all cases, with 
the NIR absorbance at 700 nm. This paves the way for using PDI nanoparticles as NIR 
probes for cell imaging. 
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Chapter 3 Perylene diimide derivative nanoparticles for 
MSOT imaging 
 
3.1 Introduction 
Bio-imaging in vivo may be divided into two categories: optical imaging 
methods and non-optical imaging methods [1].   A limitation of optical techniques is that 
light scattering and absorption by tissues means that there is signal attenuation with 
increasing depth, and spatial resolution is poor [1, 3].  However, there is an ‘optical 
window’ between the wavelengths of 650 nm and 1300 nm where the penetration depth 
can reach several centimetres [2, 3].  
Photoacoustic imaging (PAI) is a non-invasive technique developed recently 
with high penetration depth and high spatial resolution achieved by ultrasound imaging 
[3, 4]. The basic principle of PAI is that the absorption of laser energy, either by 
endogenous photo-absorbers or exogenous photoacoustic probes and contrast agents, 
results in thermo-elastic expansion and the generation of a sound wave that can be picked 
up by an ultrasound detector [3, 4].  
Multispectral optoacoustic tomography (MSOT) is a type of PAI that has the 
advantage of being multispectral, which means that information can be obtained at 
multiple wavelengths, thus improving the accuracy of the reconstructed images as a 
function of depth. Furthermore, due to the spectral differences of the photoacoustic 
probes (molecules or nanoparticles) from the background tissue, it is not always 
necessary to obtain baseline measurements [1]. However, in practice, a baseline 
measurement of the tissue or organ is usually performed before administering cell 
therapies. 
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PAI and MSOT have been intensively used for non-invasive biomedical imaging. 
However, in order to fully achieve imaging with high resolution and high penetration 
depth, the use of effective photoacoustic probes is essential. Various photoacoustic 
probes/contrast agents have been employed, which can be categorized into two main 
types: particles based on surface plasmon resonance (SPR) and dye-containing 
nanoparticles [5]. The SPR particles include noble metal nanoparticles and transition 
metal dichalcogenides [6]. Gold nanoparticles with different morphology are the most 
widely investigated metal nanoparticles [7], with some examples including Au 
nanovesicles [8] and Au nanoparticles [9, 10]. The NIR dye-containing nanoparticles 
including cyanine dyes [7]/MTT formazan [11] and light-sensitive semi-conducting 
polymers nanoparticles (SPNs) have been used [12]. Despite the use of such a variety of 
photoacoustic imaging both in vitro and in vivo [5-12], there have been uncertainty in 
toxicity (particularly for probes containing heavy metals), disadvantage of 
photobleaching and low emission intensity (e.g., currently used dyes), and difficulty in 
tuning absorption/emission wavelengths. There are continuously high demanding in 
developing less-toxic, photostable, high quantum yield, wavelength tuneable, and cost-
effective probes for PAI. 
The development and use of aromatic conjugated compounds may have the 
potential as photoacoustic probes, that can meet all the requirements in principle. 
Multiple aromatic conjugated organic compounds synthesized from naphthalene and 
more often perylene usually exhibit high hydrophobicity, fluorescence, high quantum 
yield and NIR absorbance [13-17]. The absorbance wavelengths can be tuned by the 
modification on the bay and peri-positions of the perylene-based compounds. The 
maximal absorption wavelengths are shifted bathochromically by about 100 nm per 
napththalene unit, exhibiting strong NIR absorbance [14]. Perylene diimide derivatives 
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can be synthesized with hydrophilic groups, which are soluble in basic solution. The 
basic solutions can form nanofibrous hydrogels, triggered by low pH [18-20]. Our group 
has prepared nanofibrous monoliths and microspheres from perylene diimide derivatives 
modified with 5-aminoisophthalic acid with the gelation triggered by the hydrolysis of 
glucone-δ-lactone, which ensured the formation of uniform hydrogels. These structures 
were then carbonized to produce porous carbon nanofiber structures [21,22]. For these 
hydrogels, the modifications were performed at the anhydride groups of perylene-based 
compounds. The absorbance of these compounds is not in the NIR region. However, by 
modifying the perylene compounds at the bay positions and peri positions with bulky 
group and/or alkane chains, not only could 1D nanostructures and organogels be formed 
from organic solutions, but also the light absorbance could be shifted into the NIR region 
[17,23,24]. 
Naphthalene- and perylene-based nanoparticles have been used for PAI [25-27]. 
A hydrophobic perylene diimide (PDI) derivative was prepared and aqueous PDI 
nanoparticle dispersions were then formed by a solvent evaporation (or 
nanoprecipitation) method, with strong absorbance at around 700 nm and high extinction 
coefficient of 2 x 108 M-1 cm-1 [27]. The PDI nanoparticles were demonstrated to be 
highly effective photoacoustic agents for deep brain tumour imaging in living mice [27].  
As discussed above, PDIs have the potential to be a good candidate as effective 
probes for PAI and particularly MSOT. Drawing from our strong background in 
chemical synthesis and development of nanomaterials, the long-term target of the 
research is to develop PDI nanoprobes and hydrogels with wavelength-tuneable NIR 
absorbance. Such materials will then be evaluated for in vitro cytotoxicity and in vivo 
PAI/MSOT. The novelty lies in the development of NIR-active PDI materials but they 
have to show equivalent or improved imaging performance compared to currently 
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available PAI probes. Specifically in this work, we designed and synthesized a 
hydrophobic PDI which showed strong absorbance in the NIR region. Subsequently, the 
PDI nanoparticles in aqueous media were prepared by solvent evaporation or an 
emulsion-freeze-drying approach. The absorbance profiles of the PDI nanoparticles were 
confirmed (detailed in chapter 2). The focus of this chapter is to assess the effectiveness 
of these PDI nanoparticles for labelling mouse MSCs and enabling them to be tracked in 
vivo with MSOT. 
 
Objectives: 
1. Investigate the cytotoxicity effects of PDI nanoparticles on MSCs. 
2. Optimise PDI nanoparticles for cell labelling, based on nanoparticle size, 
stabilizer type and nanoparticle concentrations. 
 
3. Investigate the performance (fluorescence/NIR absorbance) of PDI nanoparticles 
and their localization after being up-taken by MSCs  
4. Evaluate the effectiveness of PDI nanoparticles as MSOT imaging probes in 
vivo, based on long-term imaging intensity and quality. 
 
3.2 Experimental Details 
3.2.1 Chemicals and reagents 
High glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (containing 
pyruvate), L-glutamine, non-essential amino acid, mercapethanol, phosphate-buffered 
saline (PBS), trypsin/EDTA, cell freezing medium, Alizarin red-s, alcian blue solution 
(1% in 3% actic acid), penicillin-streptomycin, mitomycin-c, saponin were purchased 
from Sigma Aldrich.  D-Luciferin and Cell Titer Glo ATP assay kit were purchased from 
Promega. Foetal bovine serum (FBS), secondary antibody chicken anti-rabbit Alexa 488 
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were purchased from Life Technologies. Lysosome associated membrane protein 2 
(Lamp-2) rabbit anti-mouse antibody and early endosome antigen 1 (EEA 1) antibody 
(rabbit anti-mouse) were obtained from Abcam.  
 
Note: The experimental details described below were used to complete the experimental 
work and produce the data that are discussed in the Results and Discussion section. Prior 
to this, a lot of screening work had been carried out in order to find out the suitable 
experimental conditions. The details of the screening work are not included in the 
chapter. 
 
3.2.2 Cell line  
The murine mesenchymal stem/stromal cell line MSC D1 (CRL-12424) was 
obtained from ATCC and transduced with lentiviral particles encoding firefly luciferase 
and ZsGreen or just ZsGreen under control of the constitutive promoter EF1a, by Dr 
Arthur Taylor (Murray and Poptani group, Centre for Preclinical Imaging, University of 
Liverpool) as previously described [28].   
 
3.2.3 Cytotoxic evaluation of aqueous PDI nanoparticle suspensions 
Mesenchymal stromal cells (MSCs) were seeded at a density of 200,000 cells/ml 
in the culture medium comprised of high glucose DMEM (Sigma, D6546), 10% FBS 
(Gibco, 10270), 2mM L-glutamine, 1% non-essential amino acids, 0.1mM 2-
mercaptoethanol and 1% pen-strep. The cells were incubated at 37oC in a humidified 
incubator with 5% CO2. This standard MSCs culture method was used for all 
experiments.  After 24 hours, the PDI nanoparticle suspension was added to the medium 
to achieve a PDI concentration range from 5 µg to 36 µg/ml. The MSCs were cultured 
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for a further 24 hours in the presence of the nanoparticle suspension, and were imaged 
live with phase contrast optical microscope using Leica DM IL inverted microscope 
coupled to a DFC420C camera. To assess cytotoxicity, an ATP assay (Cell Titer Glo kit, 
Promega) was used as follows. 
  MSCs were seeded at a density of 2 X 104 cells/well (96-well plate) in 200 µl 
MSC medium. 24 hours later, the medium was replaced with fresh medium containing 
PDI nanoparticles at the following concentrations: 0 µg/ml, 3 µg/ml, 6 µg/ml, 9 µg/ml, 
12 µg/ml, 15 µg/ml, 20 µg/ml, 25 µg/ml, 30 µg/ml, 40 µg/ml. Controls consisted of wells 
that contained medium or medium with 40µg/ml PDI nanoparticles in the absence of 
cells. Samples were prepared in triplicate. Following 24h incubation, the medium was 
aspirated and after gentle washing with PBS, 100 µl complete medium and 20 µl ATP 
solution were added to each well. The plate was shaken at 600- 700 RPM for 1 minute, 
incubated at room temperature for 5 minutes, and then transferred to a plate reader 
(Fluostar Omega, BMG Labtech) to record the luminescence.  The results are expressed 
as a fraction relative to the 0 µg/ml PDI containing medium samples which is expressed 
as 100 %. 
To assess the effect of the PDI nanoparticles on MSC proliferation, cells were 
seeded at a density of 2 X 105 cells/well (6-well plate) in 1mL MSC culture medium. 
After the cells had attached, PDI nanoparticle suspension (prepared with hyper-branched 
block copolymer as stabiliser) was added at the concentration range 0-25 µg/ml. At the 
following time points, cells were removed from the wells and counted using an 
automated cell counter (TC10, Biorad):  24 h, 48 h and 72 h.  
 
3.2.4 Intercellular location and fate of PDI nanoparticles 
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MSCs (expressing ZsGreen) were seeded in 8-well chamber slides (Ibidi) at a 
density of 2000 cells/well in a volume of 300µl MSC medium. PDI nanoparticle 
suspension (prepared with freeze drying method) were then added at a concentration of 
360 µg/ml in a volume of 30µl and the MSCs were incubated for a further 24 h. Cells 
were imaged with a confocal microscope (3i spinning disc confocal microscope, CXU-
X1, Intelligent-imaging). 405 nm, 488 nm, 640nm wavelength diode lasers were used 
and cells were images using a 63 x oil objective. Cells were either imaged live, or for 
immunostaining experiments, were first fixed for 5 min in 4% paraformaldehyde at room 
temperature.  The data were acquired with Slidebook 6 software and analysed with Image 
J. 
 
3.2.5 Mitomycin-C treatment 
ZsGreen-expressing mouse MSCs were plated in Ibidi chamber slides at a density 
of 5000 cells/well and cultured in MSC medium supplemented with 15 µg/ml PDI 
nanoparticles (sample prepared with hyperbranched block copolymer as stabiliser).  
After 24 hours, the medium was replaced with mitomycin-c (Sigma, M4287) -containing 
medium at a concentration of 20µg/ml. Following 4 hours incubation, the cells were 
washed X3 with PBS, and were then incubated in MSC medium.  Cells were analysed 
using a confocal microscope (details above).  
 
3.2.6 Flow cytometry  
ZsGreen-expressing MSCs were labelled with PDI nanoparticles by adding the 
nanoparticles at a concentration of 15ug/ml to the culture medium. After 24 h, the culture 
medium was replaced with fresh MSC medium. Cells were then analysed with flow 
cytometry.  
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A single cell suspension in 1×PBS (1×106 cells/mL) was prepared by dissociation 
with 1×trypsin/EDTA. Then the cells were washed with PBS X3 and fixed with 4% PFA 
followed by washing with PBS X2.  Prior to the analysis, the cell suspension was filtered 
using a 40 µm strainer (BD Falcon, 352340) and cells were examined using a BD 
FACSCalibur (BD Biosciences) flow cytometer according to manufacturer’s 
instructions. A 635 nm red diode laser was used for excitation and 670 nm long pass 
(LP) filter to detect the PDI signal. Data were acquired by the BD CellQuest (BD 
Biosciences) software based on 104 events and analysed using the Cyflogic (CyFlo Ltd) 
software.    
 
3.2.7 Preparation of phantoms 
4% agar phantoms were prepared by dissolving 4 g agar in 100 ml water and 
heating in a microwave. The molten agar was then poured into 30 ml tubes and two 
straws were placed in the agar, secured by inserting them into the lid tightly. The gel was 
refrigerated overnight to allow it to set. To prepare phantoms containing PDI 
nanoparticles, a suspension of the PDI nanoparticles at different concentrations was 
injected into the channels (created by the straws). PBS was injected into one channel to 
serve as a control and the phantom was imaged using MSOT (see below). 
  To prepare phantoms containing PDI nanoparticle-labelled MSCs, 105 cells 
expressing ZsGreen and luciferase were suspended in 150 µl PBS and injected into one 
of the channels. As a control, a suspension of unlabelled MSCs was injected in a channel 
and then imaged with MSOT (see below).  
 
3.2.8 Experimental animals 
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All the working involving animals was performed by Dr Jack Sharkey. The 
immune-compromised nude CD1 mouse strain (purchased from Charles River, UK) was 
used to facilitate imaging. 6-8 week-old female mice were used. The mice had free access 
to water and food with 12 hours light/12 hours dark. The mice were habituated for 1 
week prior to being prepared for imaging.  All animal experiments were performed under 
a licence granted under the Animals (Scientific Procedures) Act 1986 and were approved 
by the University of Liverpool ethics committee. Mice were culled when their overall 
tumour burden exceeded 2 cm diameter.  
MSCs expressing ZsGreen and luciferase were labelled with 15 µg/ml PDI 
nanoparticles for 24 hours. 1 X 106 cells were then suspended in 150 μl PBS. The mice 
was anaesthetised with isoflurane (flow rate 1 litre/min) and the cells were then injected 
subcutaneously into the back of the mouse at discrete locations. Then the mouse was 
imaged with MSOT under anaesthesia for about 30 minutes, followed by imaging using 
the IVIS Spectrum (for bioluminescence and fluorescence measurements) for about 5 
minutes under the same anaesthetic session. The mouse was imaged three times (day 1, 
day 7, day 11) by MSOT and IVIS Spectrum and each time, imaging with both 
instruments was performed under the same anaesthetic session. On day 11 after the final 
imaging session, the mice was culled according to home office guidelines (schedule 1). 
 
3.2.9 MSOT Imaging 
The photoacoustic instrument used was an MSOT inVision 256-TF small animal 
imaging system (iThera Medical GmbH, Munich, Germany). For imaging PDI 
nanoparticle suspensions and cell suspensions, the scans were performed with phantoms 
wrapped in film and submerged in the MSOT water tank. 9 wavelengths ranging from 
660 nm to 900 nm were chosen for PDI nanoparticle suspension scans. For cell 
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suspension scans, 26 wavelengths were chosen and 12 positions with 2 mm steps were 
performed.  While under anaesthesia with isoflurane, mice were wrapped in film and 
submerged in the MSOT water tank. The water temperature was maintained at 34ºC. 
Whole body scans were performed with 0.5-1 mm steps. 26 wavelengths were used for 
acquisition: range from 660 nm to 900nm. All the data were acquired with viewMSOT. 
Linear-mode-based reconstruction and linear regression multispectral processing were 
applied using viewMSOT software (iThera Medical GmbH). 
 
3.2.10 Fluorescence and bioluminescence imaging 
Fluorescence and bioluminescence were acquired using an IVIS Spectrum 
system (Perkin Elmer, Seer Green, UK). While under anaesthesia (isoflurane) the mouse 
was placed in the IVIS imaging chamber. For fluorescence, mice were exposed to 710 
nm wavelength laser light (760 nm emission) and the acquired data analysed with IVIS 
live imaging software. For bioluminescence, 150 µl D-Luciferin solution was injected 
into the peritoneal cavity, and after about 13 minutes, IVIS bioluminescence imaging 
was undertaken to detect the Luciferase+ cells. All data were analysed with Living Image 
(Perkin Elmer) and displayed in radiance for bioluminescence and radiance efficiency 
for fluorescence. 
 
3.2.11 Histology  
Following animal sacrifice (day 11), the MSC masses which were visible with 
the naked eye, were surgically removed from the animals and fixed in 4% 
paraformaldehyde (PFA) for 24 hours at 4°C, then washed with PBS twice, and soaked 
overnight in 30% sucrose at 4°C.  Then the tissues were cryo-embedded in OCT (Thermo 
Fisher Scientific, 6769006) with dry ice and isopropanol, and stored at -80°C. Frozen 
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sections were prepared by cutting at 7 um thickness using a cryostat.   Sections were 
stored at -20 °C. 
Alcian blue staining: Frozen sections were soaked in PBS for 3 minutes, then 
stained with alcian blue solution (1% in 3% acetic acid) for 5 minutes, then washed with 
PBS.  The cells were imaged under bright field using Leica DM IL inverted microscope 
coupled to a DFC420C camera. 
Alizarin red staining: After soaking in PBS for 3 minutes, frozen sections were 
stained with alizarin red-s solution (prepared fresh by dissolving 2g Alizarin red in 100 
ml distilled water, and adjusting the pH to 4.1-4.3 with 10% ammonium hydroxide).  
Cells were imaged under bright field (details above). 
 
3.3 Results and discussion 
3.3.1 Cytotoxicity evaluation of the PDI nanoparticles 
 The cytotoxicity of the PDI nanoparticles was evaluated by assessing their effect 
on MSC viability. This was carried out by adding PDI nanoparticles into the culture 
medium at a range of concentrations (5 – 36 μg/mL). Figure 3-1 shows the representative 
optical images of MSCs after culturing for 24 h. For the PDI nanosuspensions containing 
TPEG as stabilizer (Figure 3-1a and c), the cells rounded up and detached from the 
substrate, suggesting that this nanosuspension had a toxic effect. However, for the PDI 
nanoparticle suspension containing only PVA as stabilizer, the cells remained attached 
to the substrate and appeared healthy, similarly to controls (Figure 3-1d). This was 
observed for the whole range of PDI concentrations tested in this study. This experiment 
shows that the presence of TPEG in the PDI suspensions is toxic, while PVA does not 
appear to be toxic at the concentration range used. The PDI nanosuspensions containing 
TPEG were thus not evaluated further. 
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Figure 3-1. Representative optical images of MSCs cultured with medium containing 
PDI nanoparticles for 24 hours. The PDI nanoparticles were prepared by emulsion 
freeze-drying with different surfactants (a) TPEG, (b) PVA, and (c) TPEG + PVA. (d) 
Shows the result with PDI-free medium. All the images have the same magnification. 
 
To further confirm that PDI nanoparticles prepared with PVA as stabilizer were 
not toxic, an ATP assay was performed to determine cell viability over a concentration 
range. As shown in Figure 3-2, the cell viability for PDI concentrations up to 50 μg/mL 
was not significant different from control cells where no PDI nanoparticles were added.  
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Figure 3-2. The effect of PDI nanoparticles prepared using PVA as stabilizer on MSC 
viability. Cells were cultured with PDI-containing medium for 24 h and analysed using 
an ATP assay. Error bars show standard division (SD) of three technical replicates. 
 
However, although the PDI nanoparticles stabilized by PVA were not toxic, the 
signal intensity of labelled MSCs suspension by UV-vis analysis was too weak (see 
detail below). Therefore, the block copolymer DEAMA50DEGDMA2OEGMA80 was 
used as stabiliser. Figure 3-3 shows the effect of PDI concentrations (PDI: 
DEAMA50DEGDMA2OEGMA80 = 1:1 w/w) on MSC viability. 100% cell viability was 
shown for PDI concentration up to 25 μg/mL. When the PDI concentration was higher, 
the cell viability deteriorated rapidly. Because higher PDI concentrations with PVA as 
stabilizer were not found to be cytotoxic, the low cell viability of PDI nanosuspensions 
with concentrations > 25 μg/mL is attributed to the presence of 
DEAMA50DEGDMA2OEGMA80. Therefore, concentrations below 25 μg/mL were used 
in further studies as this was the highest concentration that could be used without any 
cytotoxic effects. 
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Figure 3-3. The effect of PDI nanoparticles prepared using block copolymer 
DEAMA50DEGDMA2OEGMA80 as stabilizer on MSC viability. Cells were cultured in 
PDI-containing medium for 24 h and analysed using an ATP assay. Error bars show SD 
of three technical replicates. 
 
To determine if the PDI nanoparticles (withblock copolymer as stabiliser) 
affected the proliferation rate of the MSCs, MSCs were cultured in the presence of PDI 
nanoparticles in the concentration range 3-25 μg /mL for 72 h, with cell numbers being 
counted at 24 h, 48 h and 72 h. Even at the highest concentration used, the degree of 
proliferation was not significantly different than the controls (Figure 3-4).  
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Figure 3-4. Proliferation of MSCs cultured in the presence of 25 μg/mL PDI 
nanoparticles with the ratio of PDI: block copolymer at 1:1 w/w. Error bars are standard 
deviation (SD) of three technical replicates. 
 
3.3.2 Optimising PDI nanoparticles for cell labelling 
After obtaining evidence that the PDI nanoparticles were not toxic to the MSCs, 
the study then moved on to investigate and optimise the use of PDI-labelled cells for 
MSOT imaging. MSCs were labelled with PDI nanoparticles for 24 hours and the 
labelled cell suspensions were analysed with UV-Vis. Figure 3-5a shows when PVA 
was used as a stabiliser, no signals by UV-vis could be detected even at the highest 
concentration of PDI particles used, despite the fact that with the naked eye, it was 
observed that the centrifuged cell pellets were pale green. This may be attributed to the 
low uptake of PDI nanoparticles by the MSCs. When using the PDI nanoparticles with 
the block copolymer as stabilizer, high intensity signals could be readily detected in the 
cells by the UV-vis spectroscopy after 24 hours labelling (Figure 3-5b). Based on this 
finding, PDI nanoparticles prepared with the block copolymer as stabiliser were used for 
further in vivo experiments.  
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Figure 3-5. The UV-vis profiles of the MSC cell suspensions in PBS after culturing with 
PDI nanoparticles 24 hours at different concentrations with different stabilisers: a) PVA 
as stabiliser, b) the block copolymer as stabilizer. 
 
Before carrying out the in vivo MSOT imaging, a study to find out the optimal 
PDI concentration (low toxicity high signal intensity) was performed by flow cytometry. 
The PDI concentrations in the range of 1.7 – 27.2 μg/ml were investigated.  Figure 3-6 
shows that intensity increases with increasing PDI nanoparticle concentration up to 13.6 
µg/ml. Further increases in PDI concentration (up to 27.2 µg/ml) did not lead to further 
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increases in intensity, suggesting that the PDI concentration was saturated beyond this 
point. This suggests that the uptake of PDI nanoparticles is optimal at 13.6 μg/ml, i.e., 
the highest uptake per unit cell. This concentration should result in higher MSOT signals 
as well because of the high uptake in the MSCs. For convenience, the medium with PDI 
nanoparticles at a concentration of 15 µg/ml was used for all MSOT imaging below. 
 
Figure 3-6. The effect of PDI concentrations on the intensity of the PDI-labelled 
MSCs as measured by flow cytometry.  MSCs were cultured in medium containing PDI 
nanoparticles (with the block copolymer as stabilizer) at the defined conditions. 
 
3.3.3 The fate of PDI nanoparticles after uptake by MSCs 
What happens to the PDI nanoparticle after being taken up by the MSCs is an 
interesting and important question. Do the PDI nanoparticles remain inside the MSCs or 
are they exocytosed into the medium? In the latter case, the result would be decreasing 
signal intensity in the cells due to there being fewer PDI nanoparticles.  This would mean 
that the particles would not be useful for cell tracking in vivo, because in addition to the 
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reduced signal intensity, there could be problems with false positive results if the 
particles were taken up by host cells.  
To investigate if there was any evidence of exocytosis, MSCs labelled with PDI 
nanoparticles were co-cultured with unlabelled MSCs to see if any of the PDI particles 
were taken up by the unlabelled cells.  To prevent the load of PDI nanoparticles per cell 
from being diluted due to cell division, the labelled cells were treated with mitomycin-
c. The results show that PDI nanoparticles are not transport out of the MSCs and instead, 
remain inside the MSCs after uptake (Figure 3-7).  
 
 
 
Figure 3-7. Confocal images showing MSCs after co-culturing PDI-containing MSCs 
(mitomycin-c treated) and ZsGreen+ MSCs in PDI-free medium for 5 days. The PDI 
nanoparticles were prepared with block copolymer as stabilizer. (a: ZsGreen, b: PDI, c: 
compsite of a and b), the yellow stars are PDI labelled cells, the white stars are ZsGreen+ 
cells. 
 
After culturing the MSCs with PDI-containing medium for 24 h and then treating 
with Mitomycin-c, the non-proliferating MSCs were cultured in PDI-free medium for up 
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to 14 days. The fluorescence of the PDI nanoparticles inside the MSCs was monitored 
and measured by flow cytometry with the excitation wavelength of 635 nm. If the PDI 
nanoparticles were exocytosed this would result in a decrease in fluorescence intensity. 
Figure 3-8 shows no change of intensity after culturing for 14 days. This further 
confirms that the PDI nanoparticles are retained inside the MSCs after uptake. 
 
Figure 3-8. Flow cytometry analysis shows the intensity change of mitomycin C-treated 
non-proliferating PDI-containing MSCs cultured in PDI-free medium for 14 days with 
the control being non-labelled MSCs. The PDI nanoparticles were prepared with block 
copolymer as stabilizer 
 
Instead of treating the labelled MSCs with mitomycin-C to stop them from 
proliferating, following a 24 h labelling period, MSCs were then cultured in fresh 
medium without PDI nanoparticles for 1 day and 3 days.  The fluorescent intensity of 
the MSCs was measured by flow cytometry and the data are shown in Figure 3-9. The 
mean intensities of MSCs are 208 immediately after labelling, compared with 159 and 
23 on the 1st and 3rd day following growth in nanoparticle-free medium. It is clear that 
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following culture in PDI-free medium, due to the proliferation of the MSCs, the density 
of PDI nanoparticles per cell decreases. This is evidenced by the decreasing intensity 
after culturing the PDI-containing MSCs in fresh medium for 1 day and 3 days. As 
expected, a very low intensity is observed for the non-labelled control sample. By 
comparing the results in in Figure 3-9 and Figure 3-8, it can be confirmed that the 
decrease of intensity in Figure 3-9 is because of the cell proliferation rather than the loss 
of PDI nanoparticles from the cells into the culture medium. 
 
Figure 3-9. Flow cytometry analysis shows the signal intensity of the MSCs cultured in  
PDI-containing medium for 1 day (the ‘labelled’ sample), then in a fresh PDI-free 
medium for a further 24 h (sample ‘day 2’) or 72 h (sample ‘day 4’), with the control 
being non-labelled MSCs. The PDI nanoparticles were prepared with block copolymer 
as stabilizer. 
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3.3.4. Evaluation of PDI nanoparticles as MSOT imaging probes in vivo 
 
MSOT imaging of MSCs labelled with PDI nanoparticles 
 Before evaluating the potential of PDI nanoparticles as MSOT imaging probes 
for in vivo cell tracking, PDI-labelled MSCs were first imaged in a phantom with MSOT 
to compare with unlabelled MSCs.  
MSC suspensions were injected into channels within an agar phantom for MSOT 
imaging. Figure 3-10 show the multispectral processed images comparing the difference 
between PDI-labelled MSCs and non-labelled MSCs (1 X 105 cells in 150 µl PBS each 
sample). While the red image shows clearly the PDI-labelled MSCs, the non-labelled 
cells cannot be detected.  
 
 
 
Figure 3-10. MSOT imaging of the MSCs in the phantom: PDI-labelled MSCs (left, red 
spot) and non-labelled MSCs (right, white circle).  
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In vivo imaging of PDI-labelled cells injected into mice 
PDI-labelled MSCs expressing luciferase and ZsGreen were injected 
subcutaneously into a mouse with the unlabelled MSCs (expressing the same genetic 
reporters) serving as reference. Either 1 x 106 unlabelled MSCs, or 1 x 106, 0.5 x 106 or 
0.25 x 106 labelled MSCs were injected at one of four locations on the dorsal aspect 
(back) of the mouse. Two mice were used for duplicate experiments and the data from 
one representative mouse is shown in this chapter. 
After injecting with the MSCs, the mouse was imaged by MSOT. An initial quick 
preview scan was performed to locate the approximate position of the injected MSC 
spots. The mouse was then scanned slice by slice from shoulder to bottom. The data were 
acquired and analysed with MSOTview software, and images were obtained after 
multispectral processing accordingly and are shown in Figure 3-11. The series of images 
are arranged from left to right, then continue on to the 2nd row, and then from left to right 
again. Each of the images may be located by the coordinate of row number and column 
number. From Figure 3-11, when the scan is moved from top to bottom, the MSC spots 
are not seen first, but at location (1, 3), a bright spot starts to appear, which is represents 
the  1 x 106 PDI-labelled MSCs injected at the top right position of the mouse. With the 
scans moving down, the PDI-labelled MSC spot become brighter (indicated by the red 
circles in the image of (1, 4) to (1, 9). As expected, the un-labelled MSCs cannot be 
detected (the position indicated by the white arrow). 
With the scanner moving further down past the top right MSC spot, no bright 
spots are observed (images of (2, 5) to (4, 1)). At the location (4, 2), the bright spots for 
the bottom positions of injected PDI-labelled MSCs start to appear. In the image of (4, 
3) to (4, 7) the two bright spots (indicated by the yellow circles for 0.5 x 106 cells and 
green circles for 0.25 x 106 cells) are for the bottom left and bottom right positions of 
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injected PDI-labelled MSCs. Because the two bottom spots are not on the same level, 
the bright spot for the bottom left position is fading with the scan moving down, whilst 
the spot for the bottom right position gradually comes into view.  When the scanner 
moves past the injected PDI-labelled MSCs, no bright spots can be seen any more.  The 
higher number of PDI-labelled MSCs results in a more intense spot. However, the lowest 
number of PDI-labelled MSCs (0.25 x 106) can also be detected. Figure 3-12 are three 
enlarged images from Figure 3-11 showing the three different injected cell spots at their 
brightest slice respectively.  The same scans were performed after 7 days and 11 days of 
injecting the labelled MSCs. A similar quality of MSOT images were obtained and day 
11 images are shown in Figure 3-13 for the whole scan, and Figure 3-14 shows three 
larger images for the three different injected cells spots at their brightest positions 
respectively. 3D images (Figure 3-15) were created with the software and three cross-
sections are shown for each imaging time points: day 1, day 7 and day 11. The three 
injected PDI labelled- cell masses in the 3D views were found at the expected locations 
in the mouse, with the highest number of injected cells giving the most intense signal 
with MSOT throughout the imaging period from day 1 to day 11.  All of the MSOT 
images were analysed with the same colour scale bars.  These results show the potential 
of the PDI nanoparticles as photoacoustic probes for long-term cell tracking. 
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Following MSOT imaging, bioluminescence imaging was used to confirm 
whether the cells were still alive and proliferating. Figure 3-16a-c shows the cells were 
still alive and proliferated 11 days after injection in the mouse, indicated by strong and 
increasing signals over time by the luminescent radiance. It should be noted that in 
contrast to the MSOT images, the bioluminescence image is only a planar image and has 
poor spatial resolution.  
Subsequently, fluorescence imaging was employed to determine if the PDI-
labelled MSCs generated sufficient signal to be detected with NIR fluorescence imaging. 
As can be seen from Figure 3-16d-f, fluorescent spots were clearly visible for the two 
areas that were implanted with the highest numbers of PDI-labelled MSCs, with the area 
injected with 106 PDI-labelled MSCs generating a more intense signal than the area 
injected with 0.5 x 106 PDI-labelled MSCs. For the area injected with the lowest number 
of cells, the signal could not be distinguished from background, indicating that in vivo 
fluorescence imaging of the PDI-labelled cells is not as sensitive as MSOT. As expected, 
no fluorescence signal was detected for the non-labelled MSCs. It was observed that at 
day 7 and day 11, the overall degree of fluorescence signal increased, but this was not 
restricted to the areas where the cells had been injected. Given that bioluminescence and 
MSOT imaging showed signals that were restricted to the areas where the cells were 
injected, it can be concluded that the increase in fluorescence in other parts of the 
mouse’s back must have been due to an increase in the background signal over time. It 
is not clear what the explanation is for this.  
These observations indicate that MSOT is superior to fluorescence imaging for 
indicating the precise position of PDI-labelled cells, and is also a more sensitive 
technique, as it enabled fewer numbers of cells to be detected than with MSOT. Ideally, 
for in vivo cell tracking, it is best to combine bioluminescence (firefly luciferase) with 
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MSOT (PDI nanoparticles), because this allows the viability and proliferation of the cells 
to be monitored with bioluminescence, while at the same time allowing then to be 
precisely located with MSOT. 
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After imaging on day 11, the mouse was sacrificed and the four MSC masses 
were surgically removed from the mouse. Figure 3-17 shows images of the MSC 
masses. Compared to the non-labelled MSC masses, a dark blue core (due to the presence 
of PDI nanoparticles) can be seen in all three PDI-labelled MSC masses while the 
peripheral regions are clear. This may be attributed to the fact that it is probably the cells 
at the periphery that are more likely to proliferate, due to the inner cells being contact 
inhibited.  The more the cells proliferate, the more the load of PDI particles per cells will 
be diluted.   
 
 
Figure 3-17. Images of the four dissected MSC masses at day 11, following 
culling. The original positions of the MSC masses in the mice are described in the image. 
 
Frozen sections (7 μm in thickness) of the MSC masses were imaged by confocal 
microscopy (Figure 3-18). The implanted MSCs can be identified due to their expression 
of ZsGreen, which confirms that most of the cells within the masses are derived from 
the MSCs. As expected, the MSC mass derived from unlabelled MSCs did not display 
any red fluorescence. In contrast, the MSC masses derived from PDI-labelled MSCs 
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displayed a central area of red fluorescence, which faded towards the periphery (Figure 
3-18). This agrees with the visual observation in Figure 3-17.  
 
 
Figure 3-18. Confocal microscope images of frozen sections of dissected MSC 
masses co-stained with the nuclear stain, DAPI (blue). Green indicates ZsGreen-
expressing MSCs and red indicates PDI-labelled MSCs.  (a) top left MSC mass 
comprising unlabelled ZsGreen-expressing MSCs; (b) top right MSC mass comprising 
PDI-labelled ZsGreen-expressing cells. In each panel, image (i) is the composite images 
of (ii – iv); image (ii), DAPi staining; image (iii), ZsGreen fluorescence; image (iv), PDI 
fluorescence. 
 
It has been reported previously that MSCs can differentiate into bone and 
cartilage when subcutaneously injected in mice [29]. The potential effects of PDI 
nanoparticles on MSC differentiation were investigated by staining the MSC masses for 
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the detection of bone and cartilage. Figure 3-19 shows the images after staining sections 
of the MSC masses using alizarin red. The red colour in the image shows the presence 
of calcium, which is indicative of bone cell differentiation [28]. No obvious difference 
was found between non-labelled MSCs and PDI-labelled MSCs. Figure 3-20 shows the 
image of the MSC sections stained with alcian blue. The light blue colour in the images 
indicates cartilage differentiation. Both Figure 3-19 and Figure 3-20 suggest that the 
uptake of PDI nanoparticles did not inhibit the ability of MSCs to differentiate into bone 
and cartilage in vivo. 
 
 
 
Figure 3-19 Histology of the MSC masses stained with alizarin red for the detection of 
calcium. (a) non-labelled MSCs (top left MSC mass); (b) PDI-labelled MSCs (top right 
MSC mass). 
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Figure 3-20 Histology of the MSC masses stained with alcian blue for the detection of 
cartilage. (a) non-labelled MSCs (top left MSC mass); (b) PDI-labelled MSCs in the 
position of top right.  
 
3.4 Conclusions 
 Cytotoxic effects of aqueous PDI nanoparticle suspensions were evaluated by 
adding increasing concentrations to MSC culture medium.  This showed that TPEG was 
toxic while aqueous PDI nanoparticle suspensions with PVA as stabilizer allowed the 
growth and proliferation of MSCs at high concentrations (up to 50 μg/ml where the cell 
viability was very close to the MSCs cultured in PDI-free medium). However, MSCs 
labelled with these particles showed very low or no absorbance as measured by UV-vis 
spectroscopy. This is probably due to low uptake of these PDI nanoparticles by the 
MSCs, which would render them unsuitable for cell tracking in vivo. 
The low intensity problem from the PVA-stabilized PDI nanoparticles was 
addressed by using a hyperbranched block copolymer DEAMA50DEGDMA2OEGMA80 
which was developed in our group. This block copolymer was used as the stabilizer to 
prepare aqueous PDI nanoparticle suspensions by the solvent evaporation approach. 
High uptake of these PDI nanoparticles by the MSCs was noticed by visual observation 
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and confirmed by UV-vis analysis and flow cytometry of PDI-labelled MSC 
suspensions. 
The PDI nanoparticles fabricated with the block copolymer as stabilizer had no 
effect on MSC viability when used at concentrations up to 25 μg/ml, based on the ratio 
of PDI: DEAMA50DEGDMA2OEGMA80 = 1:1 w/w. The flow cytometry study showed 
a concentration of 15 μg/ml gave good labelling efficiency, and indicated a high uptake 
of the PDI nanoparticles. The PDI nanoparticles with the block copolymer as stabilizer 
at a concentration of 15 μg/ml were then used for in vitro and in vivo evaluation of PDI-
labelled MSCs. The confocal imaging and flow cytometry analysis showed that the PDI 
nanoparticles remained inside the MSCs after uptake and did not appear to be 
exocytosed. After injecting the PDI-labelled MSCs subcutaneously in mice, fluorescent 
imaging showed the presence of PDI-labelled cells in the mouse while the 
bioluminescence images indicated the MSCs were still alive and proliferated. In vivo 
MSOT imaging clearly showed the injected PDI-labelled MSCs in the mouse for 1 day, 
7 days, and 11 days. The subsequent histology study showed that the MSCs could 
differentiate into bone and cartilage cells, demonstrating minimal or no impact on MSC 
differentiation from the PDI nanoparticles. 
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Chapter 4 Synthesis of PDI-functionalised thermo-setting 
chitosan hydrogel and evaluation of its potential for imaging 
with MSOT 
 
4.1 Introduction 
Hydrogels have been extensively used as scaffolds for drug delivery and tissue 
engineering, especially the second generation, stimuli-responsive hydrogels, which 
have taken the main stage [1]. These stimuli include temperature, pH, oxidation states, 
and ionic strength. Some types of hydrogels are injectable or ‘in situ’ forming 
hydrogels where the gelation is usually initiated by a particular stimulus [2]. Injectable 
hydrogels can offer advantages including easy encapsulation of drugs/cells, minimally 
invasive implanting, complete filling of the injection site [3]. Injectable hydrogels have 
been used in various biomedical applications particularly including cartilage, bone 
tissue engineering, dental and craniofacial regeneration, and other regenerative 
medicine applications [2-7]. There are two important issues to be considered if the 
injected hydrogels are used for biomedical applications. The first is biocompatible 
gelation conditions which may include the use of non-toxic reagents and by-products, 
mild temperature, and physiological pH. This can be particularly important for 
biopharmaceuticals and cells. The second issue is the biodegradability of the hydrogel 
scaffolds. In an ideal situation, the hydrogels should degrade over time and be naturally 
excreted from the body. 
Natural polymers and polysaccharides have thus been extensively used to 
generate hydrogels, although synthetic polymer hydrogels are also intensively 
investigated as it is possible to control their molecular structure and functional group 
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composition [2, 3, 7, 8]. Some widely used natural polymers include chitosan, collagen, 
gelatin, alginate, hyaluronic acid, and fibrinogen [6]. Cell encapsulation technology is 
important for regenerative medicine as it provides a way to deliver cells to specific sites 
in vivo [7, 9], and the encapsulating gel can be tailored for each specific application.  In 
terms of using stimuli to trigger gelation, pH and temperature are mostly used. 
However, when pH is used, ensuring it is maintained within a physiological range can 
be difficult, and a pH outside the normal physiological range is detrimental to the 
survival of the cells. Furthermore, because the host tissue is mostly pH neutral (pH 7), a 
lower or higher pH would have to be used in the solution before injecting. As such, a 
thermally-induced (by body temperature) injectable hydrogel is preferred, in which 
case, the cells would be conveniently suspended in the solution at room temperature 
(around 20°C), with gelation occurring following implantation in vivo (body 
temperature, 37°C). 
Different types of temperature-sensitive hydrogels have been fabricated and 
used [1,2,10]. The common systems include poly(N-isopropylacrylamide) (PNIPAm) 
and their copolymers and amphiphilic tri-block copolymers. The PNIPAm utilizes a 
phenomenon of low critical solution temperature (LCST) below which a solution is 
present and above which a gel is formed. The LCST can be tuned to close to body 
temperature when suitable PNIPAm copolymers are synthesized and used [1,10]. The 
triblock copolymers include the widely known Pluronics (e.g., F127, PEG-PPG-PEG) 
or Poloxamers and biodegradable block copolymers with the hydrophobic blocks 
replaced by the biodegradable poly (ɛ-caprolactone) (PCL) or poly (lactide-co-
glycolide) (PLG) etc. The gelation mechanism is attributed to the aggregation of the 
self-assembled micelles from these amphiphilic block copolymers [10].  
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Chitosan-based thermal gelation systems have also been proposed [11]. The 
credibility of using chitosan hydrogels for biomedical applications has been discussed 
in Chapter 1.  In order to form in situ hydrogels, polyol salts are always required to mix 
with chitosan in the solution state. For example, glycerol phosphate disodium salt was 
added in aqueous chitosan solution facilitated by HCl solution. The pH value of the 
final solution was adjusted to 7.15 before adding cells and heating [11]. In another 
case, chitosan was dissolved in 0.1 M HCl solution followed by the addition of aqueous 
β-glycol phosphate disodium salt solution in an ice cold bath [12]. Ringe and co-
authors prepared a solution of chitosan- β-glycol phosphate-hydroxyethyl cellulose 
which exhibited a sol-gel transition at 37°C [13]. Injectable chitosan-based hydrogels 
were also prepared by crosslinking chitosan with the biocompatible cross-linker, 
genipin, facilitated by the ionic bonds between chitosan and sodium salts [14]. 
Different types of sodium salts, including tri-sodium phosphate, sodium sulfate, sodium 
sulfite or sodium bicarbonate were added to the chitosan-genipin solutions and the gels 
were formed at room temperature [14].  
Cell encapsulation by hydrogels have tremendously advanced regenerative 
medicine therapies [15], as have been described in Chapter 1 of this thesis. 
Mesenchymal stem/stromal cells (MSCs) have been widely used in cell encapsulation 
for enhanced therapy and tissue engineering. Alginate is the commonly used polymer 
for MSC encapsulation. For example, MSCs were encapsulated in alginate microsphere 
to enhance the neuro-inflammatory response [16], in injectable oxidized alginate 
microbeads for bone tissue engineering [17], in 3D alginate and hyaluronic acid 
hydrogels for sustained release of nerve growth factor and nerve regeneration [18], and 
in alignate-polyethylene glycol microspheres to decrease liver fibrosis [19]. Some other 
newly developed hydrogels have also been used to encapsulate MSCs, for example, 
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injectable crosslinked oligo(poly(ethylene glycol) fumarate and gelatin microparticles 
[20], injectable thermosensitive poly(N-vinylcaprolactam) hydrogels [21], cell-
degradable peptide-functionalized poly(ethylene glycol) hydrogels [22], and 
poly(ethylene glycol) hydrogels with tethered functional groups [23]. 
Chitosan hydrogels are used often for cell encapsulation but only limited reports 
on MSC encapsulation [13, 15, 24]. The thermosensitive injectable chitosan gels for 
MSC encapsulation is particularly attractive, as demonstrated in β-glycol phosphate-
chitosan gel [13]. In this project, our motivation for developing injectable chitosan gels 
was to encapsulate MSCs for future implantation under the mouse kidney capsule, a 
previous study having shown that this increased MSC viability and improved 
therapeutic efficacy following renal ischaemia reperfusion injury [25]. A key aim of 
this chapter was to functionalise the gels with perylene diimide derivative (PDI) 
nanoparticles so that they could be monitored in vivo using multispectral optoacoustic 
tomography (MSOT).  
 
Objectives 
1. Optimise a protocol for fabricating chitosan-GP hydrogel  
2. Investigate optical properties of the chitosan-GP-PDI hydrogels (MSOT) 
3. Monitor release of PDI nanoparticles from chitosan-GP-PDI hydrogel  
4.	Investigate	effect of chitosan-GP-PDI hydrogel on mouse MSC population growth 
 
4.2 Experimental Details 
4.2.1 Chemicals and Reagents 
β-glycerol phosphate disodium salt hydrate (GP, 99 %), sodium triphosphate 
pentabasic (NaTPP), chitosan (medium molecular weight), poly(vinyl alcohol) (PVA, 
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Mw 10K, 80% hydrolysed), hydroxyethyl cellulose (HEC), and acetic acid were 
purchased from Sigma Aldrich. Chitosan (purified powder, MW 15000) was purchased 
from Polyscience, distributed by Park Scientific. Distilled water was used for all the 
water solutions. All chemicals were used without further treatment. 
Biological reagents: phosphate buffer solution (PBS), high glucose DMEM 
(Dulbecco's Modified Eagle's Medium) base medium, non-essential amino acid, L-
glutamine, and trypsin- EDTA (Ethylenediaminetetraacetic acid) were obtained from 
Sigma-Aldrich. The mouse MSC D1 line (CRL-12424) was obtained from ATCC and 
transduced with lentiviral particles encoding a green fluorescent protein (ZsGreen) and 
firefly luciferase (Luc) [26]. 
 
4.2.2 Synthesis of thermo-setting chitosan-GP hydrogels 
Several synthetic recipes for chitosan-GP hydrogels were tried and described 
below: 
(i) 200 mg chitosan (medium MW, Sigma) was dissolved in 9 ml aqueous HCl 
solution (0.1 M or 0.08 M) while stirring. 600 mg GP was dissolved in 1 ml distilled 
water. These solutions were cooled down and stored at 4°C. For the preparation of 
chitosan-GP hydrogel, 1 ml GP solution was added dropwise into 9 ml chitosan 
solution while stirring at 600 rpm on ice for 10 min and then transferred into a warm oil 
bath in the temperature range 37°C -60°C for 30 min. 
(ii) 150 mg chitosan (Polyscience) was dissolved in 9 ml 0.08 M HCl while 
stirring. 324 mg GP was dissolved in 1 ml distilled water. 1 ml GP solution was added 
into 9 ml chitosan solution dropwise while stirring at 600 rpm on ice for 10 minutes, 
then transferred into a warm oil bath at 37°C for 30 minutes. 
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(iii) 200 mg chitosan (Polyscience) was dissolved in 10 ml 0.08 M HCL while 
stirring and 1 g GP was dissolved in 1 ml distilled water. Perylene diimide (PDI) 
nanoparticle suspension was prepared by the emulsion freeze-drying method with PVA 
as surfactant (Please see experimental details in Chapter 1. Chitosan-GP-PDI mixture 
solutions were prepared by mixing 2 ml chitosan solution and 200 µl PDI suspension 
and then adding a different amount of GP solution by dropping slowly while stirring at 
600 rpm: 200 µl, 300 µl, 400 µl, 500 µl and 600 µl. These five different solutions were 
kept stirring for another 10 minutes. All above procedures were carried out in an ice 
bath. The solutions were then transferred into an oil bath at 37°C for 30 min. 
(iv) The same as (iii) except that 0.07 M HCL was used instead of 0.08 M HCl. 
 
4.2.3 MSOT imaging 
MSOT was utilized to image chitosan hydrogels containing PDI nanoparticles. 
The Chitosan-GP hydrogel solution was prepared with method shown in (iii) above 
with GP concentration of 5% and PDI concentration of 0.0125 mg/ml. The solution 
was kept in ice bath to prevent gelation. Then 150 µl solution was injected into one 
channel in a phantom (4% agar phantom, prepared with the same method detailed in 
chapter 2) followed by incubation at 37°C for 30 min. The phantom was then moved 
back to ice bath followed by injection another 150 µl solution into the other channel 
while kept in ice bath. The phantom was then imaged in MSOT instrument for 10 min.  
31 wavelengths from range 680 - 900 nm were chosen for the imaging. 
 
4.2.4 Encapsulating mouse MSCs in chitosan-GP-HEC thermo-setting gel 
In order to investigate the potential of using the chitosan hydrogel for the 
encapsulation of MSCs, the following procedure was developed. Mouse MSCs 
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expressing ZsGreen and firefly luciferase were used in this experiment. The cell culture 
conditions are described in chapter 2. 
The cell suspension was prepared by suspending 1 x 107/ml mouse MSCs in 0.5 
ml HEC solution. The HEC solution was prepared by dissolving HEC 200 mg in 10 ml 
DMEM at a concentration of 20 mg/ml. Firstly, 1.6 ml 2% chitosan solution in 0.07 M 
HCL (autoclaved for sterilization) and 200 µl PDI suspension (0.2 mg/ml, filtered with 
0.22 µm syringe filter) were mixed on ice with stirring under a Lamnar hood. 200 µl β-
GP solution (0.3 g/ml, also sterilized by filtration) was added dropwise while stirring 
on ice for 10 min, followed by the addition of 0.5 ml cell suspension in HEC. The final 
mixture was transferred into a 12 well plate (0.5 ml/well) and incubated for 30 min at 
37ºC to induce gelation. The gels were washed gently with MSC medium twice and 
then 2 ml fresh medium was added and then incubation proceeded for a total of 2 
months. The medium was changed every 3 days. Control experiments were prepared at 
the same time using the same procedures except that the PDI suspension was replaced 
with PBS. 
 
4.2.5 Cell-IQ real-time imaging 
This technique was employed to evaluate the MSCs encapsulated in chitosan 
hydrogels. To do this, the 12-well plate with MSCs in chitosan gels was placed in the 
Cell-IQ instrument (ChipMan Technologies) for live imaging for 3 days. Cells were 
imaged using phase contrast and fluorescence microscopy (488 nm laser for ZsGreen 
and 560 nm laser for PDI) with a 10x objective. Images were taken once an hour. 
 
4.2.6 Monitoring the release of PDI from the chitosan-GP hydrogel 
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After the encapsulation of PDI nanoparticles within chitosan-GP hydrogels, it 
was important to know whether all the PDI nanoparticles remained within the 
hydrogels. This is a critical issue when monitoring the change of hydrogel scaffolds for 
tissue engineering via imaging PDI nanoparticles MSOT. This issue was investigated 
by evaluating the release of PDI nanoparticles from the hydrogel.  
The chitosan-GP hydrogel with encapsulated PDI nanoparticles was prepared 
with the above procedures (no cells added). The hydrogel was formed from 1.25 ml 
solution in a 10 ml glass vial. The gel was washed with PBS twice and then 2 ml PBS 
was added to the top of the hydrogel at room temperature. UV-Vis analysis (UV plate 
reader) was performed to monitor the release of PDI nanoparticles over 27 days. At the 
defined time, 150 µl x3 PBS solution was taken and measured in a 96-well plate by 
UV-vis at the wavelength of 698 nm. After the analysis, the PBS was replaced back on 
the hydrogel. 
 
4.3 Results and discussion. 
4.3.1 Optimisation of chitosan-GP-PDI hydrogel fabrication 
Based on a previous method [11], chitosan (medium molecular weight) 
purchased from Sigma was first used to produce the thermo-setting hydrogels. When 
the chitosan solution was heated in an oil bath, the gels only formed at 60°C under the 
investigated conditions, which would not be suitable for in situ gelation at body 
temperature. 
Therefore, another grade of chitosan (Mw 15000 from Polysciences) was used 
for the rest of study. The synthesis was first repeated with a slight modification from 
ref 12, but gelation still did not occur at 37°C (method (ii) in section 4.2.2). This was 
improved by increasing the concentration of chitosan and decreasing the concentration 
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of HCl (200 mg in 10 ml 0.08M HCl solution), and varying the amount of added GP 
solution. This system was investigated with the inclusion of PDI nanoparticles. Figure 
4-1 shows the chitosan solution and the gels formed. It is clear that the gels can only be 
formed when the amount of GP solution ≥ 400 µl, equivalent to 16.6 mg/ml GP in the 
whole gel. 
 
Figure 4-1. Photos show (a) chitosan solution with green PDI nanoparticle and (b) the 
hydrogel formed after incubation at 37 °C for 30 min. The numbers on the glass bottles 
indicate the amount of GP solution (1 g/ml) added, i.e., (1) 200 µl, (2) 300 µl, (3) 400 
µl, (4) 500 µl, and (5) 600 µl. 
 
It has been reported that cell growth may be reduced by the presence of GP 
when the concentration is higher than 5%, presumably due to the high osmolality [27]. 
For this reason, lower concentrations of GP were tested, using a lower concentration of 
HCl solution (0.07 mM) to dissolve the chitosan (method (iv) in section 4.2.2). It was 
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found that the gels could be formed with all volumes of added GP solution, from 200 µl 
to 600 µl, with a GP concentration of 8.8 mg/ml or 8.8 %.  
Based on this finding and considering a previous study [13], the concentration 
of GP was reduced to 0.03 g/ml (3%) with the presence of HEC in the chitosan 
solution, with gelation being successfully achieved. This methods was then used for 
subsequent experiments. 
 
4.3.2	Optical properties of the chitosan-GP-PDI hydrogels (MSOT) 
The purpose of incorporating PDI nanoparticles in chitosan hydrogel was to 
monitor the stability of the gels following implantation in vivo using NIR fluorescence 
or photoacoustic imaging techniques.  The chitosan-GP-PDI hydrogel in a phantom 
was imaged with MSOT and Figure 4-2 shows the 3D view. It is obvious that both 
solution and gel states generate a strong signal, although MSOT intensity decreased 
slightly after gelation (see Figure 4-3). The signals in the 3D images are uneven 
because the injected chitosan-GP-PDI hydrogel solution is highly viscous and therefore 
not evenly dispersed in the channels.  
 
 
Figure 4-2. MSOT image shows 3 D view of chitosan-GP-PDI hydrogel in a phantom 
with solution state and gel state (after gelation). Red circles indicate gels and yellow 
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circles indicate solutions. There are three different cross section images: top left/xy, 
/top right/xz and bottom left/xy. 
 
 
            Figure 4-3. Optical property of chitosan-GP-PDI hydrogel with MSOT  
 
4.3.3	Monitoring release of PDI nanoparticles from the chitosan-GP-PDI hydrogel 
In order to investigate whether PDI nanoparticles are retained within the 
chitosan-GP-PDI hydrogel or released over time, the gel was put into PBS solution and 
monitored over 27 days.  When the fresh PBS solution was placed onto the top of the 
hydrogel, the colourless PBS solution turned light green with time, suggesting the PDI 
particles were being released from the gel. This release was monitored by UV-vis 
analysis of the PBS solution, as shown in Figure 4-4. 
The release of PDI nanoparticles was negligible in the first 5 days but then a 
relatively slow rate of particle loss was observed between days 5 and 12, which 
increased from 12 to 19  (Figure 4-4).  This may be attributed to the degradation of the 
chitosan gel in the presence of PBS as tiny pieces of gel were observed floating in the 
PBS solution. One would expect the release profile to flatten even without further 
release. A peculiar phenomenon was that the absorbance began to decrease after day 
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20.	 The hydrogel was still intact by visual observation, but the appearance of gel 
fragments in the PBS solution suggested that some degradation must have taken place, 
and it is possible that these fragments might have affected the absorbance reading. 
Another contributing factor might have been that every time the UV-Vis was checked, 
some particles were left behind in the reading plate, leading to a small amount of 
particle loss with each measurement. The exact reason is unknown at this stage.  
 
 
Figure 4-4. The release profile of PDI nanoparticles from chitosan-GP hydrogel, 
measured by UV-vis at 698 nm. 
 
4.3.4	Effect of chitosan-GP-PDI hydrogel on mouse MSC population growths 
 Mouse MSCs were encapsulated to evaluate whether the mouse MSC 
population could expand within the PDI-functionalised hydrogel, and if the cells 
behaved differently in the PDI-functionalised gel compared with a gel that lacked the 
PDI particles. After incubating for 24 hours, the hydrogel with mouse MSCs was 
placed inside the Cell IQ for real-time imaging for 3 days. Figure 4-5 shows that in 
both gels, there appeared to be a slight decrease in cell number from day 1 to day 3, as 
shown by a decrease in the number of ZsGreen-expressing cells. The data from 3 fields 
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of view from each sample was analysed with Image J. The result shows that the 
integrated ZsGreen density decreased 37.46% for chitosan hydrogel without PDI 
nanoparticles and 31.93% for PDI containing chitosan hydrogel (figure4-6). This 
suggested that the cells were not proliferating within the hydrogels, irrespective of the 
presence of PDI nanoparticles. From all the images over 3 days, the cells appeared 
spherical and tended to stay in the same place, which suggested they were not 
migrating within the hydrogel over the 3 day period. 
 
Figure 4-5. The representive ZsGreen images of incubated mouse MSCs after 24 h 
culture in thermo-setting chitosan-GP-hydrogel, as imaged by Cell IQ, without PDI 
nanoparticles (a for day 1, c for day 3) and with PDI nanoparticles (b for day 1, d for 
day 3). 
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Figure 4-6. The integrated ZsGreen density changes over 3 days imaging time. The 
controls are for chitosan hydrogel without PDI nanoparticles. The error bars represent 
SD of 3 technical replicates.  
 
The MSCs in chitosan-GP hydrogels were imaged with Cell-IQ for PDI 
fluorescence as well as imaging for ZsGreen over the 3 days. The images after 
incubating for 24 h are shown in Figure 4-7. Without PDI nanoparticles in chitosan 
hydrogel, no fluorescent image was obtained (Figure 4-7c). With the inclusion of PDI 
nanoparticles in the gel, both cells and hydrogels could be clearly observed, with some 
cells showing even stronger red fluorescence intensity than the gel. However, not all 
bright red spots corresponded with ZsGreen fluorescence. The most likely explanation 
for the presence of red spots that did not display green fluorescence is that some of the 
cells that became labelled with PDI nanoparticles from the gel might have died 
sometime later, leaving cell remnants containing PDI nanoparticles. There was no 
noticeable loss of PDI signal strength, suggesting minimal loss of PDI nanoparticles 
over the 3 days.  
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Figure 4-7.	The images of incubated mouse MSCs after 24 h culture in thermo-setting 
chitosan-GP-hydrogel, as imaged by Cell IQ, without PDI nanoparticles (a for 
ZsGreen, b for PDI) and with PDI nanoparticles (c for ZsGreen, d for PDI). Yellow 
arrows indicate ZsGreen-expressing cells that appear to have uptaken PDI 
nanoparticles. Blue arrows indicate bright spots of PDI fluorescence that are not 
positive for ZsGreen. 
 
The incubation was continued for a total of 2 months to investigate if cells 
could remain viable over the long-term and if the hydrogel maintained its integrity. For 
the chitosan hydrogel without PDI, the red colour comes from the phenol in the culture 
medium. For chitosan hydrogel with PDI, the gel systems look slightly green, due to 
the dispersed PDI nanoparticles. In all the wells, colonies of MSCs were observed on 
the gel surface, indicating that these cells must have undergone proliferation (Figure 4-
8).    
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Figure 4-8. The photo of mouse MSCs in chitosan hydrogel after incubating for 2 
months. Top row: chitosan hydrogel without PDI nanoparticles; bottom row: chitosan 
hydrogel with PDI nanoparticles. 
 
Taken together, these results suggest that while MSCs embedded in the gel do 
not proliferate, those on the surface of the gel are able to do so, as shown by the 
presence of cell colonies (Figure 4-8). 
 
4.4 Conclusions 
Thermo-setting chitosan hydrogels have been prepared by carefully controlling 
the concentrations of chitosan, solution pH, and amount of GP added. The solution was 
prepared in an ice bath and a stable hydrogel could be formed when incubating the 
solution at 37 °C for 30 min. Efforts have been made to reduce the amount of GP used 
because a higher concentration of GP in the gel could negatively affect cell viability. 
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With the addition of hydroxyethyl cellulose, the concentration of GP could be as low as 
0.3 mg/ml with a stable chitosan hydrogel formed at 37 °C. 
NIR-active PDI nanoparticles and mouse MSCs were readily encapsulated 
within the chitosan hydrogel. The loss of PDI nanoparticles from the hydrogel was 
recorded, and was slow in the first 5 days and then increased. This could have a 
negative impact on monitoring the stability and change of the chitosan hydrogel. For 
the encapsulation of mouse MSCs together with PDI nanoparticles in chitosan 
hydrogel, the mouse MSCs were found to grow in the hydrogel with or without PDI 
nanoparticles for 2 months. The fluorescence signals from PDI nanoparticles could be 
used to image the cells, indicating the uptake of PDI nanoparticles by the mouse MSCs, 
for up to two weeks. This would render the PDI-functionalised hydrogels unsuitable for 
in vivo monitoring. Future work should focus on developing functionalised hydrogels 
where the NIR particles do not transfer to the cells.   
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Chapter 5. Conclusions and future work 
 
5.1 General conclusions from my PhD work 
This is a project that has been carried out in the Department of Chemistry and 
the Institute of Translational Medicine at the University of Liverpool. The overall 
target has been to design and fabricate (i) nanoprobes for tracking cells with 
fluorescence and multispectral optoacoustic tomography (MSOT), and (ii) cell-
encapsulating hydrogels functionalised with NIR nanoprobes so that the hydrogels can 
be monitored in vivo with MSOT. MSOT is a novel type of photoacoustic scanner that 
can detect multiple photoabsorbers simultaneously, and could therefore allow both the 
cells and their encapsulating hydrogels to be monitored at the same time in a single 
animal, as long as the absorbance spectra of the nanomaterials was 40 – 50 nm apart 
[1]. To this end we synthesized a perylene diimide derivative (PDI) compound and PDI 
nanoparticles as nanoprobes for cell tracking and hydrogel functionalization.  PDI was 
used because it has strong absorbance in the near infra-red (NIR) region of the 
spectrum, as well as high photo-stability and low cytotoxicity. Also, PDI is highly 
tunable, which means that it could be possible to synthesize nanoparticles with 
different absorbance maxima that could then be distinguished from each other using 
MSOT.  
 
5.1.1 Synthesis of PDI nanoparticles 
In Chapter 2, a perylene diimide derivative (PDI) compound was synthesized. 
The PDI organic solutions showed NIR absorbance, with the absorbance maxima 
varying according to which solvents were used. However, these first PDI nanoparticles 
were hydrophobic and could not be dissolved in water. Subsequently, aqueous PDI 
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nanoparticle suspensions were formed by solvent evaporation (nanoprecipitation) and 
emulsion freeze-drying methods. For both methods, poly (vinyl alcohol) (PVA) and a 
biocompatible surfactant Tocopherol polyethylene glycol succinate (TPEG) were 
effective in stabilizing PDI nanoparticles in water. In addition, a novel block copolymer 
DEAMA50DEGDMA2OEGMA80 was used with the solvent evaporation method to 
prepare a stable PDI nanoparticle suspension. An NIR absorbance between 650-700 nm 
was recorded for the aqueous PDI nanoparticle suspensions in all cases. 
 
5.1.2 Cell tracking with PDI nanoparticles 
In Chapter 3, the focus was on evaluating the potential of PDI nanoparticles as 
cell labelling probes for MSOT. First, the cytotoxicity of the PDI nanoparticle 
suspension on MSCs was assessed. TPEG-stabilized nanoparticles were found to be 
toxic, whereas PVA-stabilized PDI nanoparticles were not.  However, the uptake of 
these PDI nanoparticles was too low to be detected by UV-vis and MSOT. The low 
uptake of PVA-stabilized PDI nanoparticles by MSCs was addressed by the use of a 
novel block copolymer DEAMA50DEGDMA2OEGMA80 in the solvent evaporation 
method. Strong signals by UV-Vis and flow cytometry were recorded for the MSC cell 
suspensions labelled with the block copolymer-stabilized PDI nanoparticles. A suitable 
concentration, with PDI and DEAMA50DEGDMA2OEGMA80 (1:1 w/w), of 15 µg/ml, 
was found to generate strong signals and no toxicity. Based on these results, the PDI 
nanoparticles with the block copolymer as stabilizer at the concentration of 15 µg/ml 
were always used to label the MSCs. 
PDI-labelled MSCs were imaged following subcutaneous implantation into 
mice with various imaging modalities over 11 days. In order to determine if the PDI 
nanoparticles had any effect on viability of the cells in vivo, MSCs expressing 
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luciferase were used in the in vivo experiment. By comparing PDI-labelled luciferase+ 
MSCs with unlabelled luciferase+ MSCs, it could be seen that there was no obvious 
difference in the bioluminescence signal. This suggested that there were no noticeable 
effect of the PDI nanoparticles on cell viability and proliferation. Furthermore, 
histology studies of the MSC masses stained with alizarin red and alcian blue indicated 
that the labelling with PDI nanoparticles did not affect the ability of MSCs to 
differentiate into bone or cartilage cells in vivo. 
 NIR fluorescence imaging could locate the PDI-labelled MSCs, but signal-to-
noise was poor, so that it was difficult to distinguish the weakest signals from 
background.  On the other hand, the PDI-labelled MSCs could be easily visualised with 
MSOT over 11 days (the study end point). This clearly demonstrates the high photo-
stability of PDI nanoparticles. Compared with fluorescence imaging, apart from the 
increased sensitivity, MSOT is better able to pinpoint the location of the cells as it 
generates a high resolution tomographic image. For preclinical work, it may be ideal to 
combine bioluminescence imaging with MSOT using the genetic reporter, luciferase, 
and PDI nanoparticles, respectively, in order to have whole body and tissue-focussed 
imaging that allows viability and biodistribution to be monitored simultaneously.  
Based on the results, PDI nanoparticles could have great potential as NIR 
imaging probes for regenerative medicine therapies (RMTs). The low toxicity, high 
photo-stability, and negligible leaking of PDI nanoparticles from the cells, are likely to 
be very useful for this kind of application. However, it must be considered that the cells 
were injected as a bolus subcutaneously, which facilitates imaging because the signal 
intensity per voxel is high. It is likely that imaging PDI-labelled cells following 
systemic injection would be more challenging because the signal would be much more 
dilute. 
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Lipophilic dyes such as DiR and DiO are commonly used for NIR fluorescence 
imaging in vivo. However, they may not have strong absorbance in the NIR region 
(emission NIR wavelength for NIR fluorescence imaging) and thus may not be suitable 
for MSOT. Secondly, these dyes have been found to transfer to neighbouring cells, 
leading to microenvironment contamination, as discussed in Chapter 1 [2]. Quantum 
dots, Au nanoparticles, and particularly Au nanorods have been reported widely as NIR 
probes for fluorescence imaging and MSOT. However, there are potential toxicity 
issues relating to quantum dots and Au nanorods when they are used in vivo. For 
instance, quantum dots contain heavy metals, such as cadmium, which are known to be 
toxic, and as Au is a very stable metal, it is not degraded in vivo, and could potentially 
persist in organs such as the liver and spleen, leading to toxicity in those organs [3,4]. 
Furthermore, quantum dots have a broad absorbance spectrum which is not favourable 
for MSOT [5].   
We have shown that the PDI nanoparticles can be very useful for cell tracking 
pre-clinically, and they could also have some potential for clinical applications. For 
clinical application, the safety and the fate of PDI nanoparticles (their accumulation 
and excretion from the body) are crucial issues. While PDIs can be tailor-synthesized 
with desirable NIR absorbance wavelengths (which is very useful for imaging), the size 
and surface functionality of the PDI nanoparticles may also be finely tuned to promote 
excretion from the body after their diagnostic/therapeutic function is completed. This 
has been considered for further work. 
 
5.1.3 Cell encapsulation with chitosan hydrogel functionalised with PDI 
nanoparticles  
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Chapter 4 describes the encapsulation of MSCs in PDI functionalised chitosan 
hydrogel in order to enable in vivo monitoring of hydrogel with MSOT.  The aim was 
to develop a biocompatible hydrogel that would be fluid at room temperature to 
facilitate cell incorporation, but would gelate at body temperature. The gel could then 
be functionalised with PDI nanoparticles. This has been achieved with the preparation 
of an injectable thermosetting chitosan hydrogel. The key was to control the 
concentration of glycol phosphate disodium salt solution added into the aqueous 
chitosan solution. The resulting solution remained as fluid at room temperature but 
underwent gelation when switched to 37ºC. Aqueous PDI nanoparticles were blended 
into the chitosan solution, followed by temperature-triggered gelation at 37ºC. 
Similarly, PDI nanoparticles and the MSCs could be both encapsulated in chitosan 
hydrogel.  
MSOT imaging of the encapsulating chitosan hydrogel functionalised with PDI 
nanoparticles has been performed in a view to monitoring the status/integrity of the 
hydrogel. Two problems were encountered with this part of the project. The first 
problem was that the cells were found to engulf the PDI nanoparticles. This could 
potentially be addressed in future by using larger PDI nanoparticles or modifying the 
surface of the PDI nanoparticles so that they would be less likely to be uptaken by the 
cells and/or would be more firmly attached to the hydrogel (e.g., by crosslinking). The 
second problem was the loss of NIR nanoparticles from the hydrogels over the longer 
term. The results suggested that this was likely due to hydrogel degradation. The level 
of analysis undertaken (due to time constraints) did not allow us to ascertain whether 
the degree of hydrogel degradation showed a good correlation with the degree of 
particle loss. This situation may also be improved by using larger NIR particles or 
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modifying the surface of the NIR nanoparticle so that they can better attached to the 
hydrogel. 
 
5.2 Perspective for future work 
5.2.1 NIR organic nanoparticles 
Promising results have been obtained with the use of PDI nanoparticles for 
MSOT imaging. Although they are very exciting, the observation and data are mostly 
qualitative, e.g., coefficient for NIR absorbance, the relationship between the 
absorbance and concentration in different medium. From the point of materials 
chemistry, there are many things that can be investigated in future. These include (1) 
Synthesis of perylene diimide derivatives with different functional groups at bay and 
peri positions to tune absorbance wavelength and solubility; (2) Varying the ratio of 
block copolymer to PDI to maximise absorbance intensity with high nanoparticle 
stability and low amount of block copolymer; (3) Using other block copolymers that 
have been developed in the group to stabilize PDI nanoparticles so that an  even better 
stabilizer can be identified that can be used at lower concentrations. This can improve 
signal strength per mass and hence reduce potential side effects of the probe material. 
For MSOT imaging with the PDI nanoparticles, future work may include (i) Labelling 
other types of cells with PDI nanoparticles; (ii) Further improving the uptake of PDI 
nanoparticles in the cells (although we don’t know yet the maximum uptake) so that 
even a small number of cells or under greater depth can be tracked; (iii) Investigate if 
and how the PDI nanoparticles would be excreted out of the body. 
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5.2.2 Hydrogels with NIR properties 
The erosion and degradation of hydrogels have been monitored in vivo by non-
invasive fluorescence [6]. Due to its superior properties (e.g., high imaging depth and 
imaging resolution), the use of MSOT to monitor the change of hydrogels in vivo has 
been highly anticipated. However, research in this area is rare. This can be mainly 
attributed to the lack of NIR-active hydrogels with strong absorbance. There has been 
previous attempts to trap large dye particles in porous PLGA scaffold [7], but these are 
not hydrogels and there is always the potential risk of dye particles leaching out. 
Indeed, my own research on encapsulating PDI nanoparticles in chitosan gel has been 
hampered by the leaking problem although over a relatively long time scale (Chapter 
4). This may be addressed by forming PDI hydrogels with NIR absorbance in future 
work.  
 
Scheme 5-1. Proposed routes for the synthesis of perylene diimide derivatives. 
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 The Zhang group reported previously the formation of perylene diimide 
derivative (Compound B) hydrogel, following a synthetic route from Compound A to 
Compound B, as shown in Scheme 5-1 [8]. The hydrogels were formed by a pH-
triggered gelation process. During my project, Compound C was synthesised via the 
reaction of 3-aminopropanoic acid with Compound A (Scheme 5-1). Similarly, 
hydrogels could be formed (Figure 5-1A). After freeze-drying the hydrogel, 
nanofibrous structures could be observed by SEM imaging (Figure 5-1B). This 
demonstrates the potential of synthesizing different compounds that can then be used to 
form hydrogels, preferably with desirable functional groups. 
 
 
Figure 5-1. (A) The photo shows the hydrogels formed with Compound C in Scheme 
5-1 and (B) the dry structure of the hydrogel 1.  
 
It should be pointed out that compounds B and C do not have absorbance in the 
NIR region due to the lack of functional groups at the bay positions. However, it may 
be possible to use the PDI synthesized in Chapter 2 to produce the anhydride analogue 
(Compound A in Scheme 5-1). This anhydride compound may be used to produce 
hydrogels with NIR absorbance, like the synthesis of the compounds B and C (Scheme 
5-1).  
21 3 4
5	μm
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The gelation of perylene diimide derivatives can be initiated by the addition of 
acid or via the hydrolysis of glucono-σ-lactone (GdL) [3]. It may be also formed by 
blending with aqueous acidic polymer solution. In this regard, the hydrogel has been 
formed by blending the solution of Compound B in Scheme 1 with chitosan solution. 
The control of concentration and pH was critical for the formation of uniform 
hydrogels.  
A big challenge is to encapsulate cells into these hydrogels. Because the 
hydrogels are triggered by low pH, the cells may not survive the low pH environment. 
Ideas may be borrowed from the chitosan thermosetting hydrogels, by adding some 
salts, or controlling the rate of hydrolysis so that the pH values do not go down too low. 
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A-1: List of figures 
Figure 1-1. Diagram showing how stem cells can be used to generate patient-specific 
cells of a desired type for regenerative medicine or drug discovery.  Reprinted from ref 
4. (Page 2) 
Figure 1-2. Schematic showing the division patterns of stem cells. Reprinted from ref 
13.  (Page 4) 
Figure 1-3. The types of specialized cells that MSCs can differentiate into and the 
significant therapeutic properties that MSCs exhibit. Reprinted from ref 8. (Page 6) 
Figure 1-4. The diagram shows the physical factors regulating MSC differentiation. 
Reprinted from ref 15. (Page 7) 
Figure 1-5. Key imaging modalities for preclinical and clinical applications. Reprinted 
from ref 32. (Page 12) 
Figure 1-6. Photoacoustic generation and detection. Black dots in the left panel 
represent regions of high optical absorption. When heated by a laser pulse, they give 
rise to acoustic waves, which are picked up by an ultrasound detector. The ultrasound 
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waveform shown in the right panel is approximately proportional to the time derivative 
of the optical pulse. Reprinted from Ref 42. (Page 17) 
Figure 1-7. Scheme showing MSOT image generation (courtesy of iTheraMedical). 
(Page 18) 
Figure 1-8. Characteristics of direct cell labelling with probes and indirect cell 
labelling with reporter genes. Reprinted from ref 2. (Page 21) 
Figure 1-9. Light absorption by water and endogenous chromophores as a function of 
light wavelength. The wavelength range of 600 – 1100 nm (reprinted from ref 49). 
(Page 22) 
Figure 1-10. Schematic representations for the preparation of aqueous organic 
nanoparticle suspensions. Depending on the solubility of the stabilizers, they can be 
initially dissolved in water or in organic solvent. (A) Nanoprecipitation (reprinted from 
ref 66); (B) Emulsion evaporation (reprinted from ref 65). (Page 26) 
Figure 1-11. The schematic representation of preparing organic nanoparticles by 
emulsion freeze-drying. (A) An oil-in-water emulsion is formed; (B) During freezing 
of the emulsion, the organic solute is concentrated in the droplets; (C) After freeze-
drying, organic nanoparticles are formed in situ within the porous polymer; (D) The 
porous structure is dissolved in water to produce an aqueous nanoparticle suspension. 
Reprinted from Ref 67. (Page 27) 
Figure 1-12. Molecular structures of naphthalene and perylene-based compounds. 
(Page 31) 
Figure 1-13. A) Absorption spectra of rylene diimides. B) The relationship between 
the extinction coefficient and the number of naphthalene units. Reprinted from Ref 87. 
(Page 32) 
Figure 1-14. Different size distribution profiles for a sample containing equal number 
of 5 and 50 nm particles. Reprinted from ref 89. (Page 34) 
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Figure 1-15. Timeline showing key milestones in cell encapsulation technology. 
Reprinted from Ref 113. (Page 41) 
Figure 1-16. Schematic representation of cell microencapsulation. (A) Nutrients and 
stimuli diffuse across the membrane while antibodies and immune cells are kept out. 
(B) Pre-vascularized support promotes the transfer of oxygen and nutrients. Reprinted 
from Ref 115. (Page 42) 
Figure 1-17. The molecular structure of alginate and description of M and G blocks. 
Reprinted from Ref 117. (Page 43) 
Figure 1-18. Represented timescale of drug delivery and cell delivery via cell 
encapsulation. Reprinted from Ref 124. (Page 47) 
Figure 1-19. Molecular structures of (A) chitin and (B) chitosan. (Page 50) 
 
Figure 2-1. The 1H NMR spectrum of compound 2 as described in Scheme 2-1. (Page 
77) 
Figure 2-2. The 1H NMR spectrum of compound 3 as described in Scheme 2-1. (Page 
77) 
Figure 2-3. The 1H NMR spectrum of compound 4 as described in Scheme 2-1. (Page 
78) 
Figure 2-4. The 1H NMR spectrum of compound 5 as described in Scheme 2-2. (Page 
80) 
Figure 2-5. The 1H NMR spectrum of compound 6 as described in Scheme 2-2. (Page 
80) 
Figure 2-6. The UV-vis profiles of PDI solution in different solvents (acetone, 
cyclohexane, and dichloromethane (DCM)). The concentration is 0.05 mg/ml for all 
solutions. (Page 81) 
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Figure 2-7. The UV-Vis profiles of aqueous PDI nanoparticle suspensions prepared by 
solvent evaporation using PVA and DEAMA50DEGDMA2OEGMA80 as stabilizers. 
The concentration of the PDI was 0.17 mg/mL for all the suspensions. (Page 83) 
Figure 2-8. (a) The DLS graph of aqueous PDI nanosuspensions prepared by solvent 
evaporation with PVA as stabilizer; (b) the relevant zeta potential graph. (Page 84) 
Figure 2-9. (a) The molecular structure of DEAMA50DEGDMA2OEGMA80. (b) The 
schematic representation of the core-shell nanoparticle formed by the block copolymer 
DEAMA50DEGDMA2OEGMA80. (Page 85) 
Figure 2-10. Characterization of aqueous PDI nanoparticle suspension prepared with 
different concentrations of block copolymer DEAMA50DEGDMA2OEGMA80. (a) The 
DLS graph shows the particle size distribution. (b) The zeta potential data measured for 
aqueous PDI nanosuspensions. (Page 86) 
Figure 2-11 Photo (A) of freeze-dried PDI monolith and SEM images (B-D) of PDI 
nanoparticles with different magnification. Yellow circles indicate a lot of PDI 
nanoparticles together. Red arrows indicate the pore structures. (Page 88) 
Figure 2-12. The UV-vis profiles of aqueous PDI nanoparticle by dissolving the 
freeze-dried materials in water, giving a raw concentration of 0.36 mg/mL PDI in the 
suspension. The suspensions were filtered before analysis using a 0.22 µm syringe 
filter. (Page 90) 
Figure 2-13. The DLS profiles of aqueous PDI nanoparticle by dissolving the freeze-
dried materials in water, after filtering with a 0.22 µm syringe filter. (Page 91) 
 
Figure 3-1. Representative optical images of MSCs cultured with medium containing 
PDI nanoparticles for 24 hours. The PDI nanoparticles were prepared by emulsion 
freeze-drying with different surfactants (a) TPEG, (b) PVA, and (c) TPEG + PVA. (d) 
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Shows the result with PDI-free medium. All the images have the same magnification. 
(Page 105) 
Figure 3-2. The effect of PDI nanoparticles prepared using PVA as stabilizer on MSC 
viability. Cells were cultured with PDI-containing medium for 24 h and analysed using 
an ATP assay. Error bars show standard division (SD) of three technical replicates. 
(Page 106) 
Figure 3-3. The effect of PDI nanoparticles prepared using block copolymer 
DEAMA50DEGDMA2OEGMA80 as stabilizer on MSC viability. Cells were cultured in 
PDI-containing medium for 24 h and analysed using an ATP assay. Error bars show 
SD of three technical replicates. (Page 107) 
Figure 3-4. Proliferation of MSCs cultured in the presence of 25 µg/mL PDI 
nanoparticles with the ratio of PDI: block copolymer at 1:1 w/w. Error bars are 
standard deviation (SD) of three technical replicates. (Page 108) 
Figure 3-5. The UV-vis profiles of the MSC cell suspensions in PBS after culturing 
with PDI nanoparticles 24 hours at different concentrations with different stabilisers: a) 
PVA as stabiliser, b) the block copolymer as stabilizer. (Page 109) 
Figure 3-6. The effect of PDI concentrations on the intensity of the PDI-labelled 
MSCs as measured by flow cytometry.  MSCs were cultured in medium containing 
PDI nanoparticles (with the block copolymer as stabilizer) at the defined conditions. 
(Page 110) 
Figure 3-7. Confocal images showing MSCs after co-culturing PDI-containing MSCs 
(mitomycin-c treated) and ZsGreen+ MSCs in PDI-free medium for 5 days. The PDI 
nanoparticles were prepared with block copolymer as stabilizer. (a: ZsGreen, b: PDI, c: 
compsite of a and b), the yellow stars are PDI labelled cells, the white stars are 
ZsGreen+ cells. (Page 111) 
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Figure 3-8. Flow cytometry analysis shows the intensity change of mitomycin C-
treated non-proliferating PDI-containing MSCs cultured in PDI-free medium for 14 
days with the control being non-labelled MSCs. The PDI nanoparticles were prepared 
with block copolymer as stabilizer. (Page 112) 
Figure 3-9. Flow cytometry analysis shows the signal intensity of the MSCs cultured 
in PDI-containing medium for 1 day (the ‘labelled’ sample), then in a fresh PDI-free 
medium for a further 24 h (sample ‘day 2’) or 72 h (sample ‘day 4’), with the control 
being non-labelled MSCs. The PDI nanoparticles were prepared with block copolymer 
as stabilizer. (Page 113) 
Figure 3-10. MSOT imaging of the MSCs in the phantom: PDI-labelled MSCs (left, 
red spot) and non-labelled MSCs (right, white circle). (Page 114) 
Figure 3-11. Day 1 MSOT imaging of the mouse just after injection with non-labelled 
MSCs and PDI-labelled MSCs. The white arrow indicates the position where 1 x 106 
non-labelled MSCs were injected while the circles for the PDI-labelled MSCs are as 
follows: red: 1 x 106 cells, yellow: 0.5 x 106 cells, green: 0.25 x 106 cells. (Page 117) 
Figure 3-12. Enlarged MSOT images for day 1, red circle, indicate 1 x 106 PDI 
labelled cells, yellow circle indicates 0.5 x 106 PDI labelled cells and green circle 
indicates 0.25 x 106 PDI labelled cells. (Page 118) 
Figure 3-13. Day 11 MSOT imaging of  mouse after injection with non-labelled MSCs 
and PDI-labelled MSCs. The white arrow indicates the position where 1 x 106 non-
labelled MSCs were injected while the circles for the PDI-labelled MSCs are as 
follows: red, 1 x 106 MSCs;  yellow, 0.5 x 106 MSCs;  green, 0.25 x 106 MSCs. (Page 
119) 
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Figure 3-14. Enlarged MSOT images for day 11, red circle, indicate 1 x 106 PDI 
labelled cells; yellow circle indicates 0.5 x 106 PDI labelled cells; and green circle 
indicate 0.25 x 106 PDI labelled cells. (Page 120) 
Figure 3-15. MSOT 3D view of  mouse after injection with MSCs on: a) day 1, b) day 
7 and c) day 11. Each panel shows the three cross-section views, transverse plane/ top 
left, sagittal plane/top right and coronal plane/bottom left. Red circles indicate 1 x 106 
PDI labelled cells, yellow circles indicate 0.5 x 106 PDI labelled cells; and green 
circles indicate 0.25 x 106 PDI labelled cells. (Page 121) 
Figure 3-16. Bioluminescence imaging (a-c) and fluorescence imaging (d-f) of the 
mouse subcutaneously injected with MSCs; day 1 (a,d), day 7 (b,e), and day 11 (c,f). 
Top left: unlabelled MSCs, Top right: PDI-labelled MSCs, 1 x 106 cells/150 µl; Bottom 
left, PDI-labelled MSCs, 0.5 x 106 cells /75 µl; Bottom right, PDI-labelled MSCs, 0.25 
x 106 cells /37.5 µl. The three bioluminescence images share same colour scale bar 
while the three fluorescence images share same colour scale bar. (Page 124) 
Figure 3-17. Images of the four dissected MSC masses at day 11, following culling. 
The original positions of the MSC masses in the mice are described in the image. (Page 
125) 
Figure 3-18. Confocal microscope images of frozen sections of dissected MSC masses 
co-stained with the nuclear stain, DAPI (blue). Green indicates ZsGreen-expressing 
MSCs and red indicates PDI-labelled MSCs.  (a) top left MSC mass comprising 
unlabelled ZsGreen-expressing MSCs; (b) top right MSC mass comprising PDI-
labelled ZsGreen-expressing cells. In each panel, image (i) is the composite images of 
(ii – iv); image (ii), DAPi staining; image (iii), ZsGreen fluorescence; image (iv), PDI 
fluorescence. (Page 126) 
		 170	
Figure 3-19 Histology of the MSC masses stained with alizarin red for the detection of 
calcium. (a) non-labelled MSCs (top left MSC mass); (b) PDI-labelled MSCs (top right 
MSC mass). (Page 127) 
Figure 3-20 Histology of the MSC masses stained with alcian blue for the detection of 
cartilage. (a) non-labelled MSCs (top left MSC mass); (b) PDI-labelled MSCs in the 
position of top right.  (Page 128) 
 
Figure 4-1. Photos show (a) chitosan solution with green PDI nanoparticle and (b) the 
hydrogel formed after incubation at 37 °C for 30 min. The numbers on the glass bottles 
indicate the amount of GP solution (1 g/ml) added, i.e., (1) 200 µl, (2) 300 µl, (3) 400 
µl, (4) 500 µl, and (5) 600 µl. (Page 141) 
Figure 4-2. MSOT image shows 3 D view of chitosan-GP-PDI hydrogel in a phantom 
with solution state and gel state (after gelation). Red circles indicate gels and yellow 
circles indicate solutions. There are three different cross section images: top left/xy, 
/top right/xz and bottom left/xy. (Page 142) 
Figure 4-3. Optical property of chitosan-GP-PDI hydrogel with MSOT. (Page 143) 
Figure 4-4. The release profile of PDI nanoparticles from chitosan-GP hydrogel, 
measured by UV-vis at 698 nm. (Page 144) 
Figure 4-5. The representive ZsGreen images of incubated mouse MSCs after 24 h 
culture in thermo-setting chitosan-GP-hydrogel, as imaged by Cell IQ, without PDI 
nanoparticles (a for day 1, c for day 3) and with PDI nanoparticles (b for day 1, d for 
day 3). (Page 145) 
Figure 4-6. The integrated ZsGreen density changes over 3 days imaging time. The 
controls are for chitosan hydrogel without PDI nanoparticles. The error bars represent 
SD of 3 technical replicates. (Page 146) 
		 171	
Figure 4-7.	The images of incubated mouse MSCs after 24 h culture in thermo-setting 
chitosan-GP-hydrogel, as imaged by Cell IQ, without PDI nanoparticles (a for 
ZsGreen, b for PDI) and with PDI nanoparticles (c for ZsGreen, d for PDI). Yellow 
arrows indicate ZsGreen-expressing cells that appear to have uptaken PDI 
nanoparticles. Blue arrows indicate bright spots of PDI fluorescence that are not 
positive for ZsGreen. (Page 147) 
Figure 4-8. The photo of mouse MSCs in chitosan hydrogel after incubating for 2 
months. Top row: chitosan hydrogel without PDI nanoparticles; bottom row: chitosan 
hydrogel with PDI nanoparticles. (Page 148) 
 
Figure 5-1. (A) The photo shows the hydrogels formed with Compound C in Scheme 
5-1 and (B) the dry structure of the hydrogel 1. (Page 160) 
 
A-2 List of tables 
 
Table 1-1. Surface markers used to characterise MSCs. (Adapted from refs 9 and 18). 
(Page 5) 
Table 1-2. Characteristics of different imaging modalities (adapted from ref 32). (Page 
12) 
Table 1-3. Comparison of ultrasound and PAI imaging parameters (adapted from ref 
43). (Page 18) 
Table 1-4. Common small molecular NIR fluorescent dyes (adapted from ref 5). (Page 
24) 
Table 1-5. Different cell sources used for cell encapsulation (adapted from ref 112). 
(Page 46) 
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A-3: List of schemes 
 
Scheme 2-1. Synthesis of brominated perylene-3,4,9,10-tetracarboxylic dianhydride 
(PTCDA). This synthesis method was adopted from ref 3. (Page 75) 
Scheme 2-2. Synthesis of perylene diimide derivatives with NIR absorbance from 
brominated PTCDA. This synthesis method was adapted from ref 2. (Page 79) 
 
Scheme 5-1. Proposed routes for the synthesis of perylene diimide derivatives. (Page 
159) 
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Chitosan hydrogels crosslinked with benzene tricarboxylic 
acid and some applications 
Yonghong Yang,†,‡ Patricia Murray, ‡ Haifei Zhang*,† 
† Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD, UK 
‡ Department of Cellular and Molecular Physiology, Institute of Translational 
Medicine, University of Liverpool, Liverpool, L69 3GE, UK 
 
ABSTRACT: Chitosan hydrogels crosslinked by 1,3,5-benzene tricarboxylic acid 
(BTC) in the form of beads can be readily prepared at room temperature by adding 
aqueous chitosan solution dropwise into BTC-ethanol solution. L929 cells could 
survive for at least 24 h during culturing with the chitosan hydrogel although the cells 
did not attach to the hydrogel. Both hydrophobic and hydrophilic compounds, as 
demonstrated with model dyes, could be easily encapsulated within the chitosan gel 
beads, and the sustainable release of hydrophilic dyes could be achieved. Due to the 
use of BTC as crosslinker, the chitosan gel beads were used as scaffolds to prepare 
chitosan-based composite beads by reaction with copper acetate. The composite beads 
showed the presence of crystalline phase which, however, is not consistent with the 
powder x-ray diffraction pattern of the targeted metal-organic framework HKUST-1. 
This may be attributed to the lack of free BTC molecules in the hydrogel and hence it 
is difficult to form the linkage between Cu2+ and BTC as in HKUST-1.  
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INTRODUCTION 
Hydrogels have been extensively used as scaffolds for tissue engineering and as 
carriers for drug delivery.1,2 Hydrogels can be formed from both synthetic and natural 
polymers.1 The basic requirements include biocompatibility, biodegradability, mild 
processing conditions, and the ease for further modification. Chitosan, the only cationic 
natural polymer, has been extensively used as scaffolds for tissue engineering,3,4 cell 
culture,5 and drug delivery.6,7 Chitosan is the deacetylation product of chitin, which is a 
natural polysaccharide, poly(β-(1→4)-N-acetyl-D-glucosamine), and is the second 
most abundant polymer after cellulose.8 The common sources of chitin are crab and 
shrimp shells. There are two forms of chitin, α-chitin and β-chitin, with α-chitin being 
the most common. It is difficult to dissolve chitin in conventional solvents, which 
limits its applications. Chitin can be deacetylated under heating in concentrated NaOH 
to produce chitosan.9  
Chitosan is usually present as a copolymer, defined by the degree of 
deacetylation. When the degree of deacetylation is greater than 50%, it is called 
‘chitosan’ and can be dissolved in acidic water. The structure of chitosan (considering 
it is 100 % deacetylated) is very similar to cellulose, with –NH2 group replacing one of 
the –OH groups on cellulose. The presence of the –NH2 groups on chitosan is 
significant as it can be protonated to be soluble in water (providing positive charges) 
and facilitates chemical modifications.8 One of the most common methods to modify 
chitosan is by carboxylation at the –O or –N position.8 Carboxymethyl chitosan is 
soluble in neutral water and has found unique applications in drug delivery and tissue 
engineering.10 There are also other chemical modifications,8 including, amino acid-
modified chitosan for biomedical applications.11 Chitosan can also be blended with 
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other polymers to produce hybrid hydrogels; for example, chitosan-alginate hydrogel 
for tumour treatment,12 collagen-chitosan for endothelial differentiation and 
angiogenesis.13 
Chitosan hydrogels are formed by chemical crosslinking, physical crosslinking, 
or electrostatic interaction.14 Due to the positive charge of chitosan in solution, 
multivalent cations or negatively charged polymers (e.g., certain proteins, nucleic 
acids) can be used to form hydrogels via ionic interaction. Another way to produce 
physically crosslinked hydrogels is by adding base into a chitosan solution. The 
increase of pH leads to deprotonation of chitosan, reduced solubility, and self-
assembled gels by H bonding, hydrophobic interaction, and Van der Waals forces. This 
can be simply achieved by adding NaOH or Na2CO3. However, these hydrogels are 
heterogeneous due to the dramatic change of local pH. Chitosan hydrogels for cell 
culture are usually produced by crosslinking chitosan with calcium phosphate,5 
triphosphate,15 and β-glycerol phosphate.16-18 Chitosan is often chemically crosslinked 
with glutaraldehyde.8,19 However, due to its toxicity, glutaraldehyde can be replaced 
with biocompatible crosslinkers such as heparin20 and genipin.21 Chitosan hydrogels 
may be prepared as bulky gels (by simple gelation of chitosan solution), injectable 
gels,16-18 microparticles,22 nanoparticles,9,22,23 or nanofibers.24  
Chitosan is usually dissolved in water with the aid of monocarboxylic acid such 
as acetic acid or formic acid. Dicarboxylic acids such as oxalic acid, succinic acid, 
malic acid, and adipic acid have been used to dissolve chitosan and also act as 
crosslinkers. The chitosan solutions with dicarboxylic acid were either freeze dried25 or 
air dried.26 The resulting dry materials could take up water to form hydrogels with 
improved mechanical strength.25 However, to form hydrogels without the drying step, a 
mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-
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dimethylaminopropyl)carbodiimide (EDC) was required to facilitate the gelation 
process.27,28  
Here, we describe a new method to prepare chitosan hydrogels using 1,3,5-
benzyl tricarboxylic acid (BTC) as a crosslinker by dropping aqueous chitosan solution 
into BTC-ethanol solution. The chitosan gel beads or films can be readily formed at 
room temperature. To the best of our knowledge, this is the first study to use BTC as a 
crosslinker to produce chitosan gel, although there has been a report to form 
supramolecular hydrogels from BTC and hydroxyl pyridines, via the interaction 
between the –COOH group and –N containing group.29 The chitosan-BTC hydrogels 
were evaluated for their cytotoxicity and their potential for encapsulation of 
hydrophilic and hydrophobic compounds and sustainable release. BTC is a common 
ligand to synthesize one of the most widely investigated metal-organic framework 
(MOF) HKUST-1 under mild conditions30-32 and MOFs are extensively used for a 
range of applications including biomedical applications such as drug delivery.33 We 
have therefore also attempted to synthesize chitosan/HKUST-1 composite beads using 
the chitosan-BTC hydrogel beads as scaffolds. 
 
RESULTS AND DISCUSSION 
Morphological characterization of chitosan hydrogel. Typically the chitosan 
(medium molecular weight) solution was prepared with 0.6 v/v% acetic acid in water. 
BTC was dissolved in ethanol and used as the crosslinking agent. The low density of 
the ethanol solution allows the drops of aqueous solution to sink through. When 
dropping chitosan solution using a syringe, the droplets gelled rapidly in the BTC 
solution before hitting the bottom. The gelation process produced the gel beads with 
sufficient mechanical stability so that no deformation of the beads occurred at the 
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bottom of the glass beaker. The gel beads were kept in the BTC solution for 1 h at 
room temperature, to allow for full gelation. The formation of the chitosan gel beads 
was significantly influenced by the concentrations of both chitosan and BTC. It was 
noted that a BTC concentration of  > 2 mM and chitosan concentration of > 5 mM 
were required to form the gel beads in a glass vial.  
The chitosan gel beads formed were mechanically quite strong and could be 
handled easily. This was supported by observation of a dense porous structure of the 
dry bead. The chitosan gel beads were both air dried (Figure 1a-b) and freeze dried 
(Figure 1 c-d). Freeze-drying is a process that can be used to produce highly porous 
materials with minimal shrinkage with or without ice crystals as templates.34 Surface 
wrinkles were observed in both cases. The higher magnifications of the surface 
morphology by scanning electron microscopy (SEM) showed no macroporous 
structures, although some macropores observed on the freeze-dried sample (Figure 1d).  
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Figure 1. SEM images of dry BTC-chitosan beads prepared by adding 1 wt% chitosan 
solution into 50 mM BTC-ethanol solution. (a) the air-dried beads and (b) the bead 
surface at a higher magnification; (c) the freeze-dried bead and (b) its surface structure 
at higher magnification. 
 
Chitosan beads were also prepared using the conventional crosslinkers sodium 
triphosphate (NaTPP) and NaOH. In the preparation, aqueous chitosan solution was 
added dropwise in the aqueous solution containing NaTPP or NaOH. Under similar 
preparation conditions, the gel beads formed from NaOH and NaTPP were much 
weaker. Due to the poor mechanical stability, the chitosan gel beads formed from 
NaOH solution were further chemically crosslinked using the biocompatible 
crosslinker genipin. Figure 2 shows the photograph and the microscopic image of three 
types of chitosan beads. As can be seen, the NaTPP-chitosan bead is transparent. The 
genipin-crosslinked chitosan bead is very stable and shows a dark greenish colour. The 
BTC-chitosan bead is transparent in ethanol. However, it turns translucent after 
washing with water. 
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Figure 2. The photograph (a) and the optical microscopic image (b) of chitosan beads 
(~ 2 mm) prepared using BTC, NaTPP, NaOH/genipin as crosslinkers. 
 
The porous structure of the BTC-chitosan bead was very different from the 
chitosan beads prepared by the conventional NaTPP and genipin crosslinking methods, 
where the interconnected macroporous structures could be both observed (Figure 3).  
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Figure 3. The interconnected macroporous structures of the freeze-dried chitosan gel 
beads prepared using NaOH/genipin and NaTPP. (a-b) Chitosan beads were firstly 
formed in dilute NaOH solution and then crosslinked by genipin; (c-d) Chitosan beads 
were formed directly by dropping chitosan solution into the aqueous NaTPP solution. 
 
Ice-templating and freeze-drying can be used to produce layered porous 
materials, interconnected porous structures, or nanofibrous structures.34-36 The freeze-
dried BTC-chitosan bead was crushed to reveal the internal structure. Some layered 
structures were observed, a result of ice templating (Figure 4). No macropores were 
observed within the layer. This may restrict its use as a 3D scaffold for cell growth. 
However, this issue may be addressed or improved by preparing chitosan hydrogels 
with dilute solutions. For example, although the chitosan beads discussed above were 
formed by dropping 1 wt% chitosan solution in 50 mM BTC-ethanol solution, the 
decreased concentration of BTC solutions was still able to form chitosan beads. It was 
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found that chitosan beads could be formed in the concentration range of 20 mM – 0.5 
mM. With the lower concentrations, the beads became bigger and softer. When the 
BTC concentration was lower than 0.5 mM, gel pieces instead of gel beads were 
formed. Thus, a lower concentration of BTC and/or chitosan may be able to produce 
chitosan beads with higher porosity. 
 
 
Figure 4. The internal structure of a freeze-dried chitosan gel bead with BTC as 
revealed by imaging the cross-sectioned bead.  
 
The BTC gelation method is simple and convenient because the gelation occurs 
at room temperature. Compounds containing two carboxylic groups (e.g., glutamic acid 
and succinic acid) were used to crosslink chitosan or enhance chitosan gel properties. 
However, either heating the solution (e.g., to 70 oC)27 or an additional room 
temperature crosslinking mechanism is required.28 Due to the simplicity of our method, 
chitosan gel beads, dots, films, or 3D gels could be readily prepared. For example, 
chitosan gel film could be prepared by evenly spreading on a coverslip and then soaked 
into BTC solution. Hydrogel dots on coverslip were prepared by placing chitosan 
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solution droplets on the coverslip instead of evenly spreading the chitosan solution and 
then immersing into the BTC solution. 
Cytotoxicity evaluation of chitosan hydrogel. Chitosan-based hydrogels have 
been widely used to support cell growth. The chitosan hydrogel dots on the coverslip 
were evaluated by culturing L929 cells on them. As shown in Figure 5, L929 cells 
grew well on the glass substrate but did not attach to the gel bead with BTC 
crosslinking. 
 
Figure 5. Culturing L929 cells on various substrates. (a) A BTC-crosslinked chitosan 
bead on glass. The cells grew well on the glass away from the chitosan bead; (b) The 
chitosan bead formed by genipin crosslinking; (c) The chitosan gel bead formed by 
NaTPP crosslinking. (d) The control with glass substrate. The scale bar is the same for 
all images. 
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For the chitosan dots crosslinked with genipin, the material was too thick to be 
viewed clearly, but there were cell aggregates on the NaTPP-crosslinked chitosan; the 
cells on this substrate appeared rounded, and were not elongated like the cells on the 
glass substrate.  Cells cultured on BTC-crosslinked chitosan dots did not survive 
beyond 24 h. It is speculated that the poor biocompatibility and scaffolding property 
may be attributed to the presence of trace amounts of ethanol and the BTC in the 
hydrogel. Developing procedures to completely remove ethanol and BTC may be able 
to improve the gel’s biocompatibility. 
Encapsulation of hydrophilic/hydrophobic dyes and sustainable release of 
hydrophilic dye. To achieve encapsulation, hydrophilic compounds may be dissolved 
in aqueous chitosan solution and encapsulated in situ within the formed chitosan 
hydrogel. For hydrophobic compounds (e.g., poorly water-soluble drug compounds), 
the low solubility in water can be a significant issue.37 Although powders of 
hydrophobic compounds may be directly encapsulated within chitosan gels, that does 
not improve water solubility as a result of encapsulation. It is however possible to 
prepare hydrophobic drug nanoparticles to enhance water solubility 37 and encapsulate 
them thereafter. It should be pointed out that many of these hydrophobic drug 
compounds are soluble in polar organic solvents such as ethanol. However, these 
compounds can be encapsulated into the BTC-chitosan hydrogel, by firstly dissolving 
them in the ethanol solution with BTC. When dropping chitosan solution into the BTC-
ethanol solution to form gel beads, the target compounds may be encapsulated into the 
gel beads.  
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Figure 6. Photo of the chitosan-BTC gel beads with encapsulated Oil Red O in 1 wt% 
acetic acid solution.  
 
This concept was demonstrated by encapsulating two model dyes, the polar 
Rhodamine 6G (soluble in both water and ethanol) and the hydrophobic Oil Red O 
(OR, very low solubility in water but good solubility in ethanol) in the BTC-chitosan 
beads. In both cases, the formed chitosan gel beads were red, indicating that OR and 
Rhodamine 6G were successfully encapsulated into the beads. Figure 6 shows the OR-
encapsulated chitosan beads suspended in 1 wt% acetic acid aqueous solution, 
demonstrating the encapsulation of the hydrophobic dye and the stability in acidic 
water. Due to the presence of ethanol in the gel bead and the fact that ethanol is a 
solvent for OR, the hydrophobic red dye could be released during washing using water. 
The presence of ethanol in the gel bead may not be ideal for drug release. Because of 
the difference in vapor pressure for water and ethanol, it is possible to remove ethanol 
from the gel bead by evaporation or vacuum drying. There will be loss of water during 
the processing, but the beads can be re-hydrated and used as carriers for release. 
The release of the hydrophilic dye, Rhodamine 6G, into aqueous medium from 
chitosan gel beads was successfully performed. The beads were prepared by adding 2 
mL chitosan 1 wt% solution containing 1mg/1mL Rhodamine 6G dropwise into 20 mL 
50mM BTC ethanol solution, aged for 10 minutes. After this, the chitosan beads 
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encapsulated with Rhodamine 6G were taken out from the BTC solution and then 
immersed in 20 mL freshly prepared phosphate buffer solution (PBS). This was to 
minimize the release of Rhodamine 6G into ethanol while still maintaining sufficient 
gelation. As shown in Figure 7a, a near-linear release profile is obtained in the first 20 
minutes. There is no burst release as observed previously with the freeze-dried 
chitosan.38 The release then slowed down and the releasing profile flattened at about 60 
minutes with the absorbance recorded as 0.774. This sustained release profile may be 
potentially very useful for drug delivery.39 At this stage, the beads were still red and the 
red intensity of the release medium was quite similar. The beads were left in the 
solution for a total of 24 hours, with the absorbance reading 0.819. It is thus clear that 
there was minimal release in the last 23 hours. This suggests that the release of 
Rhodamine 6G has reached equilibrium in the first 60 minutes. In order to further 
release the encapsulated Rhodamine 6G, the still-red chitosan beads were taken out and 
placed in another 20 mL of freshly prepared PBS solution (Figure 7b). Further release 
can be clearly seen until about 40 minutes and then slowed down and reached 
equilibrium at around 60 minutes. The release may be continuous if there is a 
mechanism that consumes the released compound. 
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Figure 7. The release of Rhodamine 6G in the PBS at room temperature. (a) As-
prepared chitosan bead with encapsulated Rhodamine 6G; (b) The beads from (a) were 
replaced in fresh PBS. 
 
Chitosan-based composite beads. The reactions of metal ions and organic 
ligands can produce crystalline microporous MOFs33 or metal-organic gels (MOGs, 
usually amorphous porous materials).40 One of the earliest and most widely 
investigated MOFs is HKUST-1, which is formed from copper salts (usually copper 
acetate) and BTC. Although MOFs are commonly synthesized under solvothermal 
conditions, HKUST-1 can be prepared under mild conditions. For example, BTC and 
copper acetate powders were mixed and then packed into a column, which was soaked 
with a suitable amount of solvent. A HKUST-1 monolith was formed after heating in 
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an oven at 80 oC.30 In another study, the DMSO (dimethyl sulfoxide) solution of BTC 
and copper acetate was freeze-dried and a subsequent thermal treatment in the presence 
of ethanol vapor was carried out to ensure the formation of highly crystalline and 
hierarchically porous HKUST-1 monolith.31 Ameloot et al pumped aqueous solution of 
copper acetate as droplets into the continuous flow of 1-octanol containing BTC. The 
reaction at the interface of oil and water phases at room temperature resulted in the 
production of HKUST-1 hollow capsules.32 Based on these studies, it was proposed to 
use the BTC-chitosan gel beads as scaffolds to prepare chitosan-HKUST-1 beads, via 
the reaction with copper ions in a solution. 
The BTC-chitosan gels were soaked in both aqueous and ethanolic solutions of 
copper acetate with the same concentrations (3.6 g copper acetate in 50 mL distilled 
water or ethanol). After the reaction, blue beads were obtained in both cases, indicating 
the incorporation of Cu ions into the gel bead. When the beads were cut into halves, the 
blue colour was found to be distributed across the whole bead (Figure 8a). The only 
difference was that a relatively hard blue shell was formed when beads were placed in 
the aqueous copper acetate solution, while blue translucent jelly beads were formed in 
the ethanolic solution. The rapid evaporation of ethanol during imaging led to 
shrinking and roughening of the surface (Figure 8b). 
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Figure 8. Optical microscopic images show the blue bead produced by immersing the 
BTC-chitosan gel bead in the ethanol solution of copper acetate. (a) The bead was cut 
in half and immediately imaged. (b) The rough surface of the bead is the result of rapid 
evaporation of ethanol during imaging. The beads are around 2 mm in diameter. 
 
When chitosan gel beads were dried in air or under vacuum at room 
temperature or elevated temperature, the beads shrank considerably and it was very 
difficult to rehydrate them in water. However, there was no such problem when air 
drying the blue composite beads. Figure 9a & b show the beads after drying. This was 
attributed to the reaction of Cu ions with BTC that enhanced the mechanical stability of 
the beads. Although the surface looked rough by optical microscopic imaging, the 
completely dry beads exhibited a rather smooth surface at high magnifications. The 
surface of the beads was very dense and it was difficult to see any pores by SEM 
imaging even at a relatively high magnification of 60K. The bead was crushed to reveal 
the internal structure, showing a more porous layer structure with a rough surface 
(Figure 9c and d). 
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Figure 9. SEM characterization of air-dried BTC-chitosan gel beads after reaction with 
copper acetate. (a) Bead produced from aqueous copper acetate solution; (b) Bead 
produced from ethanol copper acetate solution. (c & d) The internal structure of the 
bead shown in (b) after being crushed. 
 
The crushed bead powders were further examined using powder x-ray 
diffraction (PXRD) analysis. Similar PXRD patterns were obtained for the beads 
produced from aqueous and ethanol solution of copper acetate. Figure 10 shows the 
PXRD pattern for the dry bead prepared from the reaction with ethanol copper acetate 
solution. A number of sharp peaks can be observed, indicating a crystalline material or 
a material with high crystalline content. However, this pattern is not consistent with the 
pattern obtained for standard HKUST-1, indicating that HKUST-1 is not formed.30-31 
We have not identified what the crystalline material is at this stage although it is likely 
to be copper oxides, copper hydroxides, or another type of MOF structure. The 
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structure cannot be identified via single crystal x-ray diffraction because the beads are 
still a type of composite materials and it is not possible to grow a single crystal for 
analysis. The structure may be determined by comparing with the patterns of 
crystalline materials in the database. It is possible that a mixture of crystalline materials 
has been formed. 
 
Figure 10. The power x-ray diffraction (PXRD) pattern shows the presence of 
crystalline phase in the composite beads after reaction in the ethanolic copper acetate 
solution.  
 
The dry beads were also characterized by N2 sorption in order to obtain surface 
area and porosity. This characterization is particularly important if the materials have 
high surface areas or contain micropores and/or mesopores. Figure 11 shows the 
isothermal curves and the pore size distribution of the dry bead prepared by the 
reaction in copper acetate ethanol solution. The adsorption curve and the desorption 
curve do not coincide with each other. The desorption of N2 is clearly delayed, 
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indicating a possible strong interaction of N2 molecules with the material. This material 
exhibited a BET surface area of 12.80 m2/g (possible multiple layer of adsorbed N2 
molecules) and a Langmuir surface area of 18.23 m2/g (monolayer adsorption of N2 
molecules). The maximum uptake of N2 was 0.41 mmol/g.  
 
 
Figure 11. The characterization data of the dry BTC-chitosan gel beads reacted in 
ethanol copper acetate solution by N2 sorption at 77 K. (a) The isothermal plot; (b) The 
pore size distribution obtained by the BJH method from the adsorption data. 
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Based on Figure 11b, a high proportion of the pores are in the range of < 5 nm. 
Polymer gels usually show very low surface area and a lack of micropores and 
mesopores. Thus, the data here indicate that some new structures may be formed in the 
composite beads. Although the total surface area is not high, there is a possibility that 
the newly-formed structure has high surface area but the micropores/mesopores may be 
blocked. In this case, a probe molecule with smaller size, e.g., H2, may be useful for 
better examining the porosity. 
 
Figure 12. The characterization data of the dry BTC-chitosan gel beads reacted in 
aqueous copper acetate solution by N2 sorption at 77 K. (a) The isothermal plot; (b) 
The pore size distribution obtained by the BJH method from the adsorption data. 
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Figure 12 shows the isothermal curves and the pore size distribution for the 
composite bead made from the reaction with aqueous copper acetate solution. There is 
also a discrepancy between the adsorption and desorption branches, similarly 
indicating a strong interaction between N2 molecules and the material. The N2 uptake 
was a bit lower, at 0.293 mmol/g. This is reflected by lower BET surface area of 9.15 
m2/g and Langmuir surface area of 13.48 m2/g. As shown in Figure 12b, the pore size 
distribution is quite different from that of the beads made from ethanolic copper acetate 
solution. In addition to the pores < 5 nm, there is a peak across 5-20 nm. It should be 
pointed out the pore size is associated with the possible intrinsic metal-organic 
structure and the aggregation/assembly of the nanoparticles as seen in Figure 9d. 
 
CONCLUSION 
A new method of preparing chitosan hydrogel using 1,3,5-benzene tricarboxylic 
acid (BTC) has been reported. The hydrogels can be readily formed at room 
temperature simply by dropping aqueous chitosan solution into the ethanol-BTC 
solution. The gel beads are formed instantly but are usually kept in the ethanol-BTC 
solution for an additional 10 minutes to complete the gelation. Chitosan hydrogel dots 
or films can be similarly formed by spreading or dotting the chitosan solution on a 
glass slide which is then immersed in the ethanol-BTC solution. 
Some of the useful properties of this method and the chitosan hydrogels have 
been shown. The chitosan hydrogel is not cytotoxic at least for 24 hours, as 
demonstrated by culturing with L929 cells. However, the cells did not attach to the 
hydrogel and tended to aggregate. This has been attributed to the presence of BTC and 
ethanol in the chitosan hydrogels. It is proposed that a thorough washing procedure 
may be able to address this issue. However, this new preparation method has found to 
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be effective for encapsulating hydrophilic or hydrophobic compounds into the chitosan 
gel, as evidenced by the encapsulation of hydrophobic dye Oil Red O and hydrophilic 
dye Rhodamine 6G. The sustainable release of Rhodamine 6G has also been shown. 
Furthermore, the chitosan hydrogel beads have been used as scaffolds to prepare the 
chitosan-based composite beads via the reactions with copper acetate. Strong blue 
beads with surface areas in the region of 10 m2/g and micropores/mesopores have been 
prepared.  
 
EXPERIMENTAL SECTION 
Chemicals and Reagents. Sodium triphosphate pentabasic (NaTPP), NaOH, chitosan 
(medium molecular weight), acetic acid, Rhodamine 6G, Oil Red O, glutaraldehyde 
solution, 1,3,5-benzyl tricarboxylic acid (BTC) were purchased from Sigma Aldrich. 
Genipin was purchased from Alpha Laboratories Ltd. Distilled water was used for all 
the water solutions. All chemicals were used without further treatment. 
The biological reagents: phosphate buffer solution (PBS), high glucose DMEM 
(Dulbecco's Modified Eagle's Medium) base medium, non-essential aminio acid, L-
glutamine, trypsin- EDTA (Ethylenediaminetetraacetic acid) and methylene blue were 
obtained from Sigma-Aldrich. The L929 cell line (mouse fibroblast cells) was obtained 
commercially from ATCC. 
Preparation of chitosan hydrogels. Aqueous chitosan solution (1 wt%) was 
prepared by dissolving 2 g chitosan in 200 mL water containing 0.6 v/v% acetic acid 
by stirring overnight. 50 mM BTC ethanol solution was prepared by dissolving 2.10 g 
BTC powder in 200 mL ethanol. 10 % TPP aqueous solution was prepared by 
dissolving 10 g NaTPP in 100 mL deionized water. 0.1 N sodium hydroxide (NaOH) 
aqueous solution was prepared by dissolving 0.2 g NaOH  in 50 mL deionized water. 
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0.5 wt% genipin solution was prepared by dissolving 0.1 g genipin in 20 ml 50 v/v% 
ethanol water solution. 
 Chitosan hydrogel formed in BTC ethanol solution: A syringe with 26 gauge 
needle was used to inject chitosan solution into BTC ethanol solution drop by drop. Gel 
beads were instantly formed as chitosan drops were sinking into BTC solution. The gel 
beads were kept the bottom of the solution for 1 hour before filtration. For chitosan gel 
film on coverslip, 50 uL 1 wt% chitosan was pipetted on a 13 mm coverslip and evenly 
spread and then soaked into BTC solution. Gel dots on coverslip were prepared by 
placing chitosan solution droplets on coverslip instead of evenly spreading chitosan 
solution. Chitosan hydrogels were always allowed to age for at least 1 hour in the 
BTC-ethanol solution before collection by filtration.  
The same procedure was followed to chitosan hydrogels with 10 wt% aqueous 
NaTPP solution. 
Chitosan hydrogel further crosslinked by genipin: The chitosan gel beads 
prepared from 0.1 N NaOH solution and the chitosan gel on coverslip formed by 
soaking in 0.1 N NaOH solution were transferred and soaked in 0.5% genipin solution 
at room temperature for 1 h.  
Cell culture with chitosan hydrogel. Chitosan hydrogel dots on coverslips 
were used for cell culture experiments. Glass coverslip were used as controls. After 
gelation, the gel dots were washed with ethanol three times before washing with 
deionized water three times, and then soaked in full culture medium (10% FBS in high 
glucose DMEM with supplements: L- glutamine, non-essential amino acid) overnight 
before seeding cells. The coverslips were carefully put into the 24 well culture plate 
and the seeding density was 5000 cells per coverslip. Images were taken after culturing 
for 48 hours using Leica DM 2500 microscope. 
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Encapsulation and release of hydrophilic/hydrophobic compounds 
(Rhodamine 6G and Oil Red O). Oil Red O is a hydrophobic dye. It was dissolved in 
the ethanol solution of BTC (50 mM) with a concentration of around 0.05 w/v%. This 
results in a clear red solution. The aqueous chitosan solution (1 wt%) was injected into 
the red BTC solution dropwise. The red gel beads remained in the ethanol solution for 
1 hour to complete the gelation process. 
Rhodamine 6G is soluble in both water and ethanol. In this study, Rhodamine 
6G was dissolved in 1 wt% aqueous chitosan solution with a concentration of 0.1 wt %. 
The similar preparation procedure was applied to produce the gel beads. Initially, the 
beads were red. With time, Rhodamine 6G was released into the surrounding ethanol 
solution.  
Preparation of chitosan-based composite beads with copper acetate. 
Chitosan gel beads prepared with the above procedure were washed with pure ethanol 
3 times. The washed gel beads were then immersed in copper acetate solution in water 
(3.6 g copper acetate dissolved in 50 mL water) for 24 hours. The same experiment 
was also performed in copper acetate-ethanol solution with the same w/v % 
concentration for 24 hours. This was because both water and ethanol have been used as 
solvents to prepare the metal-organic framework HKUST-1 from BTC and copper 
acetate. After the reaction, the colourless transparent chitosan gel beads turned blue. 
The blue beads were washed with ethanol, air dried or freeze-dried, crushed as 
necessary for further characterization. 
Characterizations. The morphology of the materials was observed by a 
Hitachi-S4800 scanning electron microscope (SEM). A small piece of the material was 
adhered to a stud using double-sided carbon tape. The non-conductive samples were 
coated with gold using a sputter-coater (EMITECH K550X) for 2 minutes at 25 mA 
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before SEM imaging. Powder X-ray diffraction (PXRD) patterns were collected on a 
Panalytical X’ Pert Pro Multi-Purpose Diffractometer in high-throughput transmission 
geometry. Cu anode was operated at 40 kV and 40 mA. Samples were pressed into the 
well of aluminium plate. XRD patterns were measured over 5-50°2θ with a scan time 
of 60 min. Brunauer-Emmette-Teller (BET) speciﬁc surface areas and Barrette-
Joynere-Halenda (BJH) pore size distributions were obtained by N2 sorption at 77 K 
using a Micromeritics ASAP 2420 volumetric adsorption analyser. The samples were 
degassed for 48 h at 120 °C before N2 sorption analysis. An Olympus CX41 
microscope with Plan magnifying lenses was used for imaging hydrogel beads. 
CellSens entry imaging software by Olympus was used for size measurements. The 
Leica DM 2500 microscope was used to observe the cell growth. 
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